test1

1000 abstracts

Abstract HER2 expression in ovarian cancer: Its relationship with HRD status, and other biomarkers Congress:ESMO 2024, Search all connections
Abstract Her2-low/HRR proficient early triple negative breast cancer is characterized by good prognosis Congress:ESMO 2024, Search all connections
Abstract HER2 testing in multiple solid tumors: Concordance between 3 scoring algorithms Congress:ESMO 2024, Search all connections
Abstract HER2 expression across solid tumors and real-world implications for use of fam-trastuzumab deruxtecan-nxki (T-Dxd) Congress:ESMO 2024, Search all connections
Abstract HER2 targeted therapy and outcome in HER2-equivocal cases after 2018 ASCO/CAP HER2 guideline modification. Congress:ASCO 2019, Search all connections
Abstract HER2 testing: Insights from pathologists’ perspective on challenging HER2 cases. Congress:ASCO 2019, Search all connections
Abstract HER2 cluster amplification as a factor of an especial sensitivity for anti-HER2 neoadjuvant therapy with biosimilar of trastuzumab in Russian women with breast cancer stage II-III. Congress:ASCO 2019, Search all connections
Abstract HER2-positive breast cancer: Combined 18F-FDG PET and CGFL/Curie nomogram to predict pathologic complete response after preoperative chemotherapy with trastuzumab. Congress:ASCO 2019, Search all connections
Abstract HER2 heterogeneity as a predictor of response to neoadjuvant T-DM1 plus pertuzumab: Results from a prospective clinical trial. Congress:ASCO 2019, Search all connections
Abstract HER2-low and gastric cancer: A prognostic biomarker? Congress:ASCO 2021, Search all connections
Abstract HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy. Congress:ASCO 2021, Search all connections
Abstract HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress). Congress:ASCO 2021, Search all connections
Abstract HER2 in uterine carcinosarcoma: Testing platforms and implications for targeted therapy. Congress:ASCO 2022, Search all connections
Abstract HER2 in endometrioid endometrial adenocarcinoma (E-EMCA): Defining incidence, molecular profiles, and outcomes. Congress:ASCO 2022, Search all connections
Abstract HER2 expression and extensive molecular characterization of resected brain metastases from colorectal cancer: The HEROES study. Congress:ASCO 2022, Search all connections
Abstract HER2 alterations and prognostic implications in all subtypes of breast cancer. Congress:ASCO 2022, Search all connections
Abstract HER2-targeted immunoconjugates for breast cancer: Ancestry and dose adjustment for thrombocytopenia. Congress:ASCO 2022, Search all connections
Abstract HER2 in situ hybridization testing in breast cancer: Applying algorithm-assisted assessment to reduce interobserver variability in difficult cases. Organization:Mater Health Service...,Mater Research Insti...,Centre for the Busin...,Drug:HER2 CAR-T, Search all connections
Abstract HER2-low expression as a prognostic factor in patients treated with CDK4/6 inhibitors: A retrospective analysis. Organization:Virgen del Rocio Hos...,Institute of Biomedi...,CSIC,Drug:abemaciclib,palbociclib,ribociclib, Search all connections
Abstract HER2 testing in the MOUNTAINEER trial: Analysis of treatment response based on central HER2 assessment using IHC/ISH and NGS. Clinical trial:SGNTUC-017,Organization:Duke University Medi...,Division of Solid Tu...,Memorial Sloan Kette..., Search all connections
Abstract HER2-low breast cancer brain metastases: Incidence and treatment implications. Organization:University of Toront...,Sunnybrook Hospital,Toronto, ON, Canada,Drug:trastuzumab deruxtec..., Search all connections
Abstract HER2CLIMB-05: Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer. Clinical trial:SGNTUC-028,Organization:Sarah Cannon Researc...,Hospital General Uni...,Mayo Clinic, Search all connections
Abstract HER2 persistence after treatment with T-DXd in breast and gastrointestinal cancers. Organization:Memorial Sloan Kette...,Memorial Sloan Kette...,Lombardi Comprehensi...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2023, Search all connections
Abstract HER2/neu in head and neck cancers: A worthy target or not? Organization:Agilus Diagnostics,Congress:ASCO 2024, Search all connections
Abstract HER2 expression-independent antitumor effect of trastuzumab deruxtecan (T-DXd) on pediatric solid tumors. Drug:trastuzumab deruxtec...,DXd,Organization:Division of Cancer I...,Children's Cancer Ce...,National Center for ...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract HER2 low hormone positive breast cancer: Unveiling the driver. Drug:trastuzumab deruxtec...,Organization:Medical Research Ins...,University of Alexan...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract HER2 expression in a molecularly characterized cohort of patients with endometrial cancer (EC): SPECTRUM study. Organization:Clinical Biostatisti...,Congress:ASCO 2024, Search all connections
Abstract HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort. Organization:Fudan University Sha...,China National Biote...,West China Hospital, Search all connections
Abstract MRG002-HER2 ADC combined with pucotenlimab (a PD-1 inhibitor), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase I/II study Congress:ESMO 2024, Search all connections
Abstract A randomized phase II study of disitamab vedotin (DV) plus toripalimab and chemotherapy versus DV plus toripalimab versus chemotherapy as perioperative treatment for HER2-expressing locally advanced gastric or gastroesophageal junction adenocarcinoma (GC/GEJ) Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Data update from a phase II single-arm study Congress:ESMO 2024, Search all connections
Abstract Potential impact of APC mutation on survival via immune evasion through WNT signaling activation in HER2-positive gastric cancer treated with trastuzumab (tmab), nivolumab (nivo), and chemotherapy Congress:ESMO 2024, Search all connections
Abstract Pembrolizumab and olaparib in advanced HER2 negative esophagogastric adenocarcinoma (EGA): Biomarker results of the phase II AIO IKF-038/POLESTAR trial Congress:ESMO 2024, Search all connections
Abstract Correlation between intratumor HER2 heterogeneity and circulating tumor DNA in HER2 positive advanced gastric cancer: A phase Ib trial of HER2 and PD-1 dual targeted therapy (Ni-High) substudy Congress:ESMO 2024, Search all connections
Abstract First-line (1L) zolbetuximab + chemotherapy in patients (pts) with claudin 18.2 (CLDN18.2) +, HER2-, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma: A pooled final analysis of SPOTLIGHT + GLOW Congress:ESMO 2024, Search all connections
Abstract Tislelizumab (TIS) + chemotherapy (CT) vs placebo (PBO) + CT in HER2-negative advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GC/GEJC): RATIONALE-305 study minimum 3-year survival follow-up Congress:ESMO 2024, Search all connections
Abstract A phase I/II study of FG-M108 plus capecitabine and oxaliplatin (CAPOX) as first-line (1L) treatment for patients with CLDN18.2+/HER2- advanced gastric or gastroesophageal junction (G/GEJ) adenocarcinoma Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of KN026 in combination with chemotherapy in patients (pts) with unresectable or metastatic HER2 positive gastric or gastroesophageal cancers (GC/GEJC) after first-line treatment with a trastuzumab-containing regimen Congress:ESMO 2024, Search all connections
Abstract Zanidatamab + chemotherapy for first-line (1L) treatment of HER2+ advanced or metastatic gastro-oesophageal adenocarcinoma (mGEA): New and updated data from a phase II trial Congress:ESMO 2024, Search all connections
Abstract First-line rilvegostomig (rilve) + chemotherapy (CTx) in patients (pts) with HER2-negative (HER2â€“) locally advanced unresectable or metastatic gastric cancers: First report of GEMINI-Gastric sub study 2 Congress:ESMO 2024, Search all connections
Abstract Final results of the phase II trial of HER-Vaxx, a B-cell peptide-based vaccine plus standard care of chemotherapy in patients with HER2-overexpressing advanced gastric cancer Congress:ESMO 2024, Search all connections
Abstract A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02) Congress:ESMO 2024, Search all connections
Abstract Epidemiological and genomic features of patients (pts) with advanced/metastatic (a/m) non-small cell lung cancer (NSCLC) with HER2/ERBB2 mutations within and outside the tyrosine kinase domain (TKD) Congress:ESMO 2024, Search all connections
Abstract A phase II study to evaluate the efficacy and safety of BB-1701 in advanced or metastatic NSCLC patients with HER2 mutation/amplification Congress:ESMO 2024, Search all connections
Abstract The landscape of human epidermal growth factor receptor 2 (HER2) expression in gynecologic tumors (GTs) Congress:ESMO 2024, Search all connections
Abstract JSKN003, a HER2-targeting antibody-drug conjugate, in patients with platinum-resistant ovarian cancer: A pooled analysis of two studies Congress:ESMO 2024, Search all connections
Abstract Comparison of breast and gastric HER2 immunohistochemistry (IHC) scoring criteria in the assessment of endometrial endometrioid adenocarcinoma (EEA) Congress:ESMO 2024, Search all connections
Abstract Evaluation of the safety and efficacy of JSKN003 in patients with advanced HER2-positive (IHC 3+) solid tumors (excluding breast cancer) Congress:ESMO 2024, Search all connections
Abstract Phase I/Ib open-label study of an HER2-targeted T cell engager (TCE)â€’SAR443216 in patients (pts) with advanced solid tumors: Intravenous (IV) dose-escalation results Congress:ESMO 2024, Search all connections
Abstract Persistence and resistance of HER2 amplification after T-DM1 in a basket trial for patients with solid tumors Congress:ESMO 2024, Search all connections
Abstract Preliminary results of GQ1005 in metastatic HER2-low expressing breast cancer and HER2 positive gastric cancer Congress:ESMO 2024, Search all connections
Abstract Tucatinib and trastuzumab in advanced cancers with HER2 mutations or amplification: A molecular screening and therapeutics (MoST) program substudy Congress:ESMO 2024, Search all connections
Abstract Safety and efficacy of IBI354 (anti-HER2 ADC) in patients (pts) with advanced gastrointestinal (GI) cancers: Results from a phase I study Congress:ESMO 2024, Search all connections
Abstract Trastuzumab deruxtecan with pyrotinib in first-line HER2-positive unresectable or metastatic breast cancer: An exploratory, multi-center, single-arm, phase II study (TROPHY, trial in progress) Congress:ESMO 2024, Search all connections
Abstract An open-label, multicenter, phase II study to evaluate the safety and efficacy of BB-1701, a novel antibody drug conjugate (ADC) targeting HER2, in previously treated patients (pts) with HER2+ or HER2-low unresectable or metastatic (M) breast cancer (BC) Congress:ESMO 2024, Search all connections
Abstract DYNASTY-Breast02: A phase III trial of BNT323/DB-1303 vs investigator's choice chemotherapy in HER2-low, hormone receptor positive, metastatic breast cancer Congress:ESMO 2024, Search all connections
Abstract ALTER-BC-Ib-01: A prospective phase Ib study of anlotinib with trastuzumab deruxtecan (T-DXd) for HER2-low unresectable (u)/metastatic (m) breast cancer (BC) Congress:ESMO 2024, Search all connections
Abstract Phase III, randomized, open-label TroFuse-010 Study of sacituzumab tirumotecan (sac-TMT) alone and with pembrolizumab vs treatment of physicianâ€™s choice chemotherapy (TPC) in patients with HR+/HER2- unresectable locally advanced or metastatic breast cancer (mBC) Congress:ESMO 2024, Search all connections
Abstract Exploratory biomarker analysis of trastuzumab deruxtecan versus treatment of physicianâ€™s choice in HER2-low, hormone receptorâ€“positive metastatic breast cancer in DESTINY-Breast04 Congress:ESMO 2024, Search all connections
Abstract Exposure-adjusted incidence rates (EAIRs) of adverse events (AEs) from the TROPION-Breast01 study of datopotamab deruxtecan (Dato-DXd) vs investigatorâ€™s choice of chemotherapy (ICC) in patients (pts) with pretreated, inoperable/metastatic HR+/HER2â€“ breast cancer (BC) Congress:ESMO 2024, Search all connections
Abstract Impact of novel agents in patients with stage IV denovo HR+ve/Her2-ve breast cancer: Results from a real-world dataset Congress:ESMO 2024, Search all connections
Abstract Longitudinal circulating tumor DNA (ctDNA) dynamics in phase I/IIa study of the first-in-class CDK4-selective inhibitor, PF-07220060, in combination with endocrine therapy in patients with HR+/HER2âˆ’ metastatic breast cancer (mBC) who progressed on prior CDK4/6 inhibitors Congress:ESMO 2024, Search all connections
Abstract Exploratory circulating tumor DNA (ctDNA) analysis in HR+/HER2- metastatic breast cancer (mBC) and impact on clinical efficacy with sacituzumab govitecan (SG) in TROPiCS-02 Congress:ESMO 2024, Search all connections
Abstract Genomic profiling and prediction role of the molecular tumor burden index in advanced HR+HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract Evaluation of HER2 scoring in breast carcinoma-stained whole slide images Congress:ESMO 2024, Search all connections
Abstract Treatment patterns and outcomes in HER2-low, HR+ metastatic breast cancer patients previously treated with endocrine therapy in the United States Congress:ESMO 2024, Search all connections
Abstract Quantitative standardized high sensitivity (HS)-HER2 testing predicts outcomes with trastuzumab deruxtecan (T-DXd) for metastatic breast cancer (MBC) Congress:ESMO 2024, Search all connections
Abstract Disitamab vedotin (RC48) for previously treated HER2-expressing metastatic breast cancer with abnormal activation of PAM pathway: Results from a single-arm, prospective phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract Pyrotinib combined with metronomic oral etoposide (VP-16) in heavily pretreated HER2-positive metastatic breast cancer: A single-arm, phase II study Congress:ESMO 2024, Search all connections
Abstract Updated data on real-world efficacy and safety of inetetamab-based therapy in HER2-positive metastatic breast cancer patients with prior exposure to trastuzumab Congress:ESMO 2024, Search all connections
Abstract Phase II study of trifluridine/tipiracil in pre-treated patients with ER-positive, HER2-negative metastatic breast cancer: A Dutch BOOG (2019-01 TIBET) study Congress:ESMO 2024, Search all connections
Abstract Real-world (Rw) outcomes in patients (pts) with hormone receptor-positive and human epidermal growth factor receptor-2 negative (HR+/HER2-) metastatic breast cancer (mBC) treated with chemotherapy (CT) in France and Germany Congress:ESMO 2024, Search all connections
Abstract Quality-of-life outcomes in patients with HER2-positive, locally advanced or metastatic breast cancer treated with eribulin mesylate in combination with trastuzumab and pertuzumab in the phase III JBCRG-M06/EMERALD study Congress:ESMO 2024, Search all connections
Abstract Is capecitabine (CAPE) the best treatment (trt) option for estrogen receptor-positive (ER+) HER2-negative (HER2-) metastatic breast cancer (MBC) after progression on endocrine treatment (ET): An analysis of the ESME real-world database Congress:ESMO 2024, Search all connections
Abstract Efficacy of metronomic capecitabine plus aromatase inhibitor as initial therapy in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: The phase III MECCA trial Congress:ESMO 2024, Search all connections
Abstract A phase Ib study to evaluate the efficacy and safety of afuresertib plus fulvestrant in subjects with locally advanced or metastatic HR+/HER2- breast cancer who failed standard of care therapies: A subgroup analysis of efficacy in PIK3CA/AKT1/PTEN-altered subjects Congress:ESMO 2024, Search all connections
Abstract Elacestrant combinations in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) locally advanced or metastatic breast cancer (mBC): Preliminary data from ELEVATE, a phase Ib/II, open-label, umbrella study Congress:ESMO 2024, Search all connections
Abstract Tucidinostat and metronomic capecitabine plus endocrine therapy for patients with HR+/HER2- advanced breast cancer after CDK4/6 inhibitors: Preliminary findings of a multi-center, phase II study Congress:ESMO 2024, Search all connections
Abstract Interim analysis (IA) of the giredestrant (G) + samuraciclib (SAMURA) arm in MORPHEUS breast cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with oestrogen receptor-positive (ER+), HER2-negative, locally advanced/metastatic BC (LA/mBC) Congress:ESMO 2024, Search all connections
Abstract Elacestrant in combination with abemaciclib in patients (pts) with brain metastasis (mets) from estrogen receptor-positive (ER+), HER2-negative (HER2-) breast cancer: Preliminary data from ELECTRA, an open-label, multicenter, phase Ib/II study Congress:ESMO 2024, Search all connections
Abstract Overall survival of palbociclib (PAL) + endocrine therapy (ET) in Japanese patients with hormone receptor-positive (HR+)/ human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC) in the 1st line (1L) or 2nd line (2L) setting: A multicenter observational study Congress:ESMO 2024, Search all connections
Abstract Everolimus or ribociclib in patients with HER2-negative, hormone-receptor positive metastatic breast cancer and circulating tumor cells: Results from DETECT IVa Congress:ESMO 2024, Search all connections
Abstract Bridging the gap between real-world studies (RWSs) and randomized controlled trials (RCTs) of 1st-line palbociclib+aromatase inhibitors (P+AI) in hormone receptor-positive (HR+)/HER2-negative(-) metastatic breast cancer (mBC) Congress:ESMO 2024, Search all connections
Abstract Real-world effectiveness in subgroups of palbociclib + endocrine therapy in HR+/HER2- ABC patients: Interim results of the PERFORM study Congress:ESMO 2024, Search all connections
Abstract EVERolimus effectiveness after proGREssion on CDK4/6 inhibitors for ENdocrine receptor-positive/HER2-negative, advanced breast cancer: EVERGREEN quasi-experimental study Congress:ESMO 2024, Search all connections
Abstract Synergistic preclinical efficacy through combination of the CDK4 and CDK2 selective inhibitors, PF-07220060 and PF-07104091, respectively, in HR+ HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract Abemaciclib plus fulvestrant for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Subgroup analyses from the phase III postMONARCH trial Congress:ESMO 2024, Search all connections
Abstract A randomized trial of trastuzumab deruxtecan and biology-driven selection of neoadjuvant treatment for HER2-positive breast cancer (ARIADNE) Congress:ESMO 2024, Search all connections
Abstract EORTC-2129-BCG: Elacestrant for treating ER+/HER2- breast cancer patients with ctDNA relapse (TREAT ctDNA) Congress:ESMO 2024, Search all connections
Abstract First-in-human phase I/IIa clinical trial of ZV0203, a novel pertuzumab-based antibody-drug conjugate (ADC), in patients (pts) with Her2 positive advanced solid tumors Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant intetamab in combination with standard chemotherapy for locally advanced HER2-positive breast cancer Congress:ESMO 2024, Search all connections
Abstract Randomized phase II study of neoadjuvant chemotherapy with denosumab compared to chemotherapy alone in hormonal receptor-positive, HER2-negative premenopausal breast cancer patients Congress:ESMO 2024, Search all connections
Abstract RANK/RANKL, ERBB-2: A putative dual targeting strategy in RANK+/Her2+ breast carcinomas patients Congress:ESMO 2024, Search all connections
Abstract Real-world evidence (RWE) of effectiveness and safety of TCHP regimen: INSIGHT-HER2BC trial interim results Congress:ESMO 2024, Search all connections
Abstract Neoadjuvant trastuzumab, pertuzumab and tucatinib without chemotherapy in stage II-III HER2-positive breast cancer: The TRAIN-4 study Congress:ESMO 2024, Search all connections
Abstract A randomized, multicenter, open-label phase II neoadjuvant study to evaluate the safety and efficacy of HER2-ADC disitamab vedotin in combination toripalimab or sequence chemotherapy in participants with HR-negative, HER2 low-expressing breast cancer Congress:ESMO 2024, Search all connections
Abstract Identification of racial disparities across MammaPrint and BluePrint subtypes in HR+HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract A multicenter, prospective, non-interventional study to investigate the treatment patterns of neratinib in human epidermal growth factor receptor 2 positive (HER2+) early breast cancer (EBC) in China: Interim analysis of the NER-Tree study Congress:ESMO 2024, Search all connections
Abstract Perceptions of women with HER2+ breast cancer on the risk of recurrence and disease management: Results from the ASKHER survey Congress:ESMO 2024, Search all connections
Abstract Characterization and clinical outcomes of low hormonal receptor positive / HER2 negative early breast cancer Congress:ESMO 2024, Search all connections
Abstract Survival outcomes according to tumor-infiltrating lymphocytes and 21-gene recurrence score in ER+HER2- breast cancer Congress:ESMO 2024, Search all connections
Abstract Real-world evidence on risk of recurrence (ROR) in patients (pts) with node-negative (N0) and node-positive HR+/HER2â€“ early breast cancer (EBC) from US electronic health records (EHR) Congress:ESMO 2024, Search all connections
Abstract Prevalence of HER2-low breast cancer in the GEICAM/2011-06 trial: Agreement in HER2-low classification between standardized immunohistochemistry assays Congress:ESMO 2024, Search all connections
Abstract Personalized treatment approaches with HER2DX in early HER2-positive breast cancer: A precision tool for treatment decision-making Congress:ESMO 2024, Search all connections
Abstract Prognostic and biologic significance of HER2-low early-stage breast cancer with long-term follow-up Congress:ESMO 2024, Search all connections
Abstract Long term follow-up of neoadjuvant chemotherapy with or without anthracyclines in the presence of trastuzumab in patients with HER2-positive breast cancer Congress:ESMO 2024, Search all connections
Abstract SHR-A1811 in combination with pyrotinib as neoadjuvant treatment for HER2-positive breast cancer (HER2+ BC): Preliminary results from MUKDEN 07 Congress:ESMO 2024, Search all connections
Abstract Phase II study of pyrotinib plus albumin-bound paclitaxel and trastuzumab (HLX02) as neoadjuvant treatment in HER2-positive, stage II-III breast cancer Congress:ESMO 2024, Search all connections
Abstract Association of RAD51 and efficacy outcomes in patients with HER2-negative breast cancer (BC) and homologous recombination deficiency (HRD): Post-hoc analysis of the GeparOla trial Congress:ESMO 2024, Search all connections
Abstract Impact of HER2-low status on clinicopathological characteristics and pathological complete response in luminal and triple-negative early breast cancer Congress:ESMO 2024, Search all connections
Abstract Correlation between pathological complete response (pCR) following neoadjuvant docetaxel, carboplatin and trastuzumab (TCH) with or without pertuzumab (TCHP) and PAM50 subtypes in HER2(+) early breast cancer (eBC) Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of dalpiciclib, exemestane, and goserelin as neoadjuvant therapy in premenopausal HR-positive, HER2-negative breast cancer patients: A phase II clinical trial Congress:ESMO 2024, Search all connections
Abstract Prognosis of patients with hormone receptor-positive/HER2-negative early breast cancer according to monarchE and NATALEE trials risk categories: Patient-level analysis of Mammella InterGruppo (MIG) and Gruppo Italiano Mammella (GIM) randomised trials Congress:ESMO 2024, Search all connections
Abstract Clinical outcomes in patients (pts) with HR+/HER2âˆ’ early breast cancer (EBC) by prior systemic treatment (tx): A subgroup analysis of the NATALEE trial Congress:ESMO 2024, Search all connections
Abstract Overall survival and updated invasive disease free survival results from the Penelope-B trial investigating palbociclib vs placebo for patients with high-risk HR+/HER2- breast cancer and residual disease after NACT Congress:ESMO 2024, Search all connections
Abstract Efficacy and safety of ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) in older patients (pts) with HR+/HER2âˆ’ early breast cancer (EBC) in NATALEE Congress:ESMO 2024, Search all connections
Abstract Preclinical efficacy of the trastuzumab duocarmazine SYD985 as monotherapy or in combination with the PARP inhibitor niraparib in HER2-expressing endometrial cancer Congress:ESMO 2024, Search all connections
Abstract From breast and gastric to beyond: Expanding HER2 detection in solid tumors using quantitative RNA and protein analysis Congress:ESMO 2024, Search all connections
Abstract Clinical presentations and prognosis of HER2-low breast cancer in Taiwan Congress:ESMO 2024, Search all connections
Abstract Genomic landscape and prognostic impact of HER2 low-expressing tumors Congress:ESMO 2024, Search all connections
Abstract Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial Congress:ESMO 2024, Search all connections
Abstract Predicting tumor ER and HER2 status using a cell-free RNA liquid biopsy assay Congress:ESMO 2024, Search all connections
Abstract Circulating tumor DNA as a biomarker for neratinib and trastuzumab efficacy in HER2-mutated advanced solid tumors: Insights from KCSG AL20-17/KM23 phase II trial Congress:ESMO 2024, Search all connections
Abstract Ultra-sensitive ctDNA NGS assay enhances genomic profiling for advanced HR-positive, HER2-negative breast cancer on endocrine therapy Congress:ESMO 2024, Search all connections
Abstract HERIZON-BTC-302: A phase III study of zanidatamab with standard-of-care (SOC) therapy vs SOC alone for first-line (1L) treatment of human epidermal growth factor receptor 2 (HER2)-positive advanced/metastatic biliary tract cancer (BTC) Congress:ESMO 2024, Search all connections
Abstract Branched-chain amino acids metabolism reprogramming in trastuzumab primary resistant HER2 positive breast cancer Congress:ESMO 2024, Search all connections
Abstract Efficacy and cost-effectiveness of HER2+ early breast cancer therapies. Congress:ASCO 2019, Search all connections
Abstract Impact of dual anti-HER2 therapy on pathologic complete response rate in breast cancer in a minority-enriched population. Congress:ASCO 2019, Search all connections
Abstract Disparities in HER2 testing in breast cancer. Congress:ASCO 2019, Search all connections
Abstract Evaluation of next generation sequencing for detecting HER2 copy number in breast and gastric cancers. Congress:ASCO 2019, Search all connections
Abstract Radiomics features on CT scans to predict response to HER2-targeted therapy of hepatic metastases from colorectal cancer. Congress:ASCO 2019, Search all connections
Abstract Changes of estrogen receptor, progesterone receptor and HER2 expression in breast cancer with/without neoadjuvant chemotherapy or endocrine therapy. Congress:ASCO 2019, Search all connections
Abstract Breast MRI as a radiomic biomarker of immune enrichment in HER2+ breast cancer. Congress:ASCO 2019, Search all connections
Abstract Anti-HER2/Neu antibody therapy can reduce the immunosuppressive activity of MDSCs in breast tumor model. Congress:ASCO 2019, Search all connections
Abstract Influence of agomelatine and trastuzumab on the HER2/neu(+), MT1 (+) and MT2 (+) chemo and immunoresistant breast cancer cells lines from the previously treated patients by targeted therapy with trastuzumab. Congress:ASCO 2019, Search all connections
Abstract Comparison of in vitro antitumor activity between SB3 (trastuzumab biosimilar, Ontruzant) and Herceptin combined with an antibody for subdomain II of HER2 in HER2-positive cancer cells. Congress:ASCO 2019, Search all connections
Abstract Indirect treatment comparison of the efficacy and safety of olaparib 300 mg tablets BID and talazoparib 1 mg once daily in the treatment of patients with germline BRCA-mutated (gBRCA) HER2-negative metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract Searching for a link between Ki-67 values and HER2 absence in 297 patients with triple-negative breast cancer. Congress:ASCO 2019, Search all connections
Abstract CDK4/6 inhibitors in advanced hormone receptor-positive/HER2-negative breast cancer: A network meta-analysis (NMA) of randomized controlled trials (RCTs). Congress:ASCO 2019, Search all connections
Abstract Abemaciclib with or without fulvestrant for the treatment of hormone receptor-positive and HER2-negative metastatic breast cancer with disease progression following prior treatment with palbociclib. Congress:ASCO 2019, Search all connections
Abstract Selected reaction monitoring mass spectrometry (SRM-MS) evaluation of HER2 equivocal breast cancer. Congress:ASCO 2019, Search all connections
Abstract Real-world effectiveness of ribociclib + aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: Baseline data from the RIBANNA study. Congress:ASCO 2019, Search all connections
Abstract Risk stratification based on a prognostic factor index among patients with HR+, HER2- MBC. Congress:ASCO 2019, Search all connections
Abstract REACHAUT: First-line (1L) ribociclib (RIB) + endocrine therapy (ET) in HR+, HER2- metastatic breast cancer (MBC) in the real-world setting. Congress:ASCO 2019, Search all connections
Abstract Progression-free survival (PFS) and overall survival (OS) in HER2-ve advanced breast cancer (ABC) patients (pts) according to the molecular subtype in the era of modern agents: Results from the GIM-13 AMBRA study. Congress:ASCO 2019, Search all connections
Abstract Acquired NF2 mutations confer resistance to HER2 targeted therapy in HER2-mutant breast cancer. Congress:ASCO 2019, Search all connections
Abstract Impact of mastectomy in women with stage IV HER2+ breast cancer. Congress:ASCO 2019, Search all connections
Abstract Tumor pathological and immunological changes in HER2+ metastatic breast cancer (MBC) following trastuzumab combined with expanded and activated autologous natural killer (NK) cell infusion. Congress:ASCO 2019, Search all connections
Abstract Biological behavior of HER2+ breast cancer: Differences based in hormone receptor expression. Congress:ASCO 2019, Search all connections
Abstract Phase II trial of metronomic capecitabine and cyclophosphamide with lapatinib and trastuzumab in patients with HER2-positive metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract Combining denosumab (D) and trastuzumab (T) as a novel treatment strategy in HER2-positive (+) breast carcinomas (BC). Congress:ASCO 2019, Search all connections
Abstract Effect of additional administration of pertuzumab for the post-treatment in patients with HER2-positive locally advanced/metastatic breast cancer who were previously treated with pertuzumab. Congress:ASCO 2019, Search all connections
Abstract Estrogen receptor (ER) status and survival outcomes in HER2 positive (+) metastatic breast cancer (mBC). Congress:ASCO 2019, Search all connections
Abstract Real-world evidence regarding the efficacy and toxicity of neoadjuvant trastuzumab and pertuzumab in the management of HER2-positive early-breast cancer. Congress:ASCO 2019, Search all connections
Abstract Phase II study of preoperative chemotherapy versus standard postoperative chemotherapy in HR-negative HER2-positive breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract Retrospective single-center outcome analysis of neoadjuvant and palliative treatment with dual trastuzumab and pertuzumab in HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract The diagnostic accuracy of 12-point core biopsy of a tumor bed compared to the study of surgically obtained breast tissue in patients with locally advanced triple-negative or HER2-positive breast cancer after neoadjuvant systemic and targeted therapy. Congress:ASCO 2019, Search all connections
Abstract Investigating the utility of breast cancer (BC) molecular signatures and immune signature profiling (ISP) as predictors of pathological complete response (pCR) to neoadjuvant chemotherapy + trastuzumab (NAC+T) in HER2+ BC. Congress:ASCO 2019, Search all connections
Abstract Sequence of anthracyclines and taxanes in the neoadjuvant chemotherapy of HER2-negative breast cancer: Experience of a Brazilian oncological center. Congress:ASCO 2019, Search all connections
Abstract Biomarkers involved in the neoadjuvant therapy response in triple-negative and Her2+ subtypes breast cancer. Congress:ASCO 2019, Search all connections
Abstract Clinical utility of SERUM extracelullar domain of HER2 receptor (ECD) in HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract Neoadjuvant chemotherapy with docetaxel, carboplatin and biosimilar trastuzumab in Her2-positive early breast cancer. Congress:ASCO 2019, Search all connections
Abstract Correlation between TopIIα and ki-67 expression in tumors of luminal, primary operable breast cancer without HER2/neu overexpression in postmenopausal women as a prognostic factor. Congress:ASCO 2019, Search all connections
Abstract Clinical relevance of 21-gene recurrence score with lymph node involvement in HR+HER2- early breast cancer: A tumor size-match paired cohort study. Congress:ASCO 2019, Search all connections
Abstract Short versus long duration of adjuvant trastuzumab (T) in HER2+ breast cancer: A systematic review and meta-analysis of randomized controlled trials (RCTs). Congress:ASCO 2019, Search all connections
Abstract Survival outcomes by hormone receptor expression in early-stage HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract Oncotype DX score in hormone receptor-positive/HER2-positive breast cancer: A SEER analysis. Congress:ASCO 2019, Search all connections
Abstract Performance of Oncotype Dx test in patients with T1bN0, grade 1, hormone receptor-positive, HER2-negative breast cancer. Congress:ASCO 2019, Search all connections
Abstract Cumulative benefit of multiple agents and drug classes for adjuvant therapy (adj rx) of HER2+ early breast cancer (EBC). Congress:ASCO 2019, Search all connections
Abstract Impact of delaying initiation of adjuvant chemotherapy and trastuzumab in patients with early-stage HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract Modeling the consequences of recurrences after trastuzumab treatment of HER2+ early-stage breast cancer. Congress:ASCO 2019, Search all connections
Abstract The Neat-HER Virtual Registry: A novel registry following HER2+ ESBC patients receiving neratinib in the extended adjuvant setting. Congress:ASCO 2019, Search all connections
Abstract Effect of cyclin E overexpression on resistance to trastuzumab and phosphorylation of SMAD3 in HER2+ breast cancer. Congress:ASCO 2019, Search all connections
Abstract Is neratinib following trastuzumab in early-stage HER2-positive breast cancer cost-effective? Congress:ASCO 2019, Search all connections
Abstract Omega-3 fatty acids and ERPR(-) and HER2/neu(+/-) breast cancer prevention. Congress:ASCO 2019, Search all connections
Abstract Clinicopathologic profile and treatment outcomes of non-sensitizing EGFR and HER2 (ERBB2) activating mutations in NSCLC: Results from a single-center retrospective study. Congress:ASCO 2019, Search all connections
Abstract Single-arm, phase II study of pyrotinib in advanced non-small cell lung cancer (NSCLC) patients with HER2 exon 20 mutation. Congress:ASCO 2019, Search all connections
Abstract Characterization of 648 non-small cell lung cancer (NSCLC) cases with 28 unique HER2 exon 20 insertions. Congress:ASCO 2019, Search all connections
Abstract Impact of HER2 aberrations on EGFR-TKI treatment outcomes in lung tumors harboring EGFR mutations: A HER2-CS STUDY subset analysis. Congress:ASCO 2019, Search all connections
Abstract KEYNOTE-811 pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction cancer (mG/GEJC): A double-blind, randomized, placebo-controlled phase 3 study. Congress:ASCO 2019, Search all connections
Abstract A phase Ib study of IMU-131 HER2/neu peptide vaccine plus chemotherapy in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Congress:ASCO 2019, Search all connections
Abstract Treatment patterns and outcomes in Chinese gastric cancer by HER2 status: A non-interventional registry study (EVIDENCE). Congress:ASCO 2019, Search all connections
Abstract Tumor mutation burden and immunogenicity in gastric cancer with HER2 alterations. Congress:ASCO 2019, Search all connections
Abstract Comparison of HER2 overexpression with total Her2 mutation on resistance of EGFR-targeted therapy in Ras wild-type mCRC patients. Congress:ASCO 2019, Search all connections
Abstract Reassignment of HER2 status for subgroups of breast cancer according to the 2018 updated American Society of Clinical Oncology and College of American Pathologists guidelines: The impact of combined immunohistochemistry (IHC) and fluorescence in situ hybridization (FISH) reflex testing in a large national reference laboratory. Congress:ASCO 2019, Search all connections
Abstract HER family protein expression and activation predicts response to combination T-DM1/pertuzumab in HER2+ patients in the I-SPY 2 TRIAL. Congress:ASCO 2019, Search all connections
Abstract Genomic somatic alterations of human epidermal growth factor-2 (HER2) gene: A pan-cancer analysis. Congress:ASCO 2019, Search all connections
Abstract A randomized phase 0 trial of the mitochondrial inhibitor ME344 or placebo added to the antiangiogenic (Aa) bevacizumab in early HER2-negative breast cancer (E-HERNEBC). Congress:ASCO 2019, Search all connections
Abstract Preliminary results of a phase I clinical trial using an autologous dendritic cell cancer vaccine targeting HER2 in patients with metastatic cancer or operated high-risk bladder cancer (NCT01730118). Congress:ASCO 2019, Search all connections
Abstract Balixafortide (a CXCR4 antagonist) + eribulin in HER2-negative metastatic breast cancer (MBC): Survival outcomes of the phase I trial. Congress:ASCO 2019, Search all connections
Abstract KEYNOTE-756: Randomized, double-blind, phase 3 study of pembrolizumab vs placebo combined with neoadjuvant chemotherapy and adjuvant endocrine therapy for high-risk, early-stage estrogen receptor–positive, human epidermal growth factor receptor 2–negative (ER+/HER2−) breast cancer. Congress:ASCO 2019, Search all connections
Abstract ADAPTcycle: Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer. Congress:ASCO 2019, Search all connections
Abstract NATALEE: Phase III study of ribociclib (RIBO) + endocrine therapy (ET) as adjuvant treatment in hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) early breast cancer (EBC). Congress:ASCO 2019, Search all connections
Abstract Nimbus: A phase II study of nivolumab plus ipilimumab in metastatic hypermutated HER2-negative breast cancer. Congress:ASCO 2019, Search all connections
Abstract CONTESSA: A multinational, multicenter, randomized, phase III registration study of tesetaxel plus a reduced dose of capecitabine in patients (pts) with HER2-, hormone receptor + (HR+) locally advanced or metastatic breast cancer (LA/MBC) who have previously received a taxane. Congress:ASCO 2019, Search all connections
Abstract Randomized phase II trial of venetoclax + fulvestrant versus fulvestrant in estrogen receptor+, HER2– locally advanced or metastatic breast cancer following recurrence or progression during or after a CDK4/6 inhibitor: VERONICA. Congress:ASCO 2019, Search all connections
Abstract A phase III study comparing trastuzumab emtansine with trastuzumab, pertuzumab, and docetaxel in elderly patients with advanced stage HER2-positive breast cancer: (JCOG1607 HERB TEA study). Congress:ASCO 2019, Search all connections
Abstract EMERALD: A randomized, open label, phase III trial to evaluate the efficacy and safety of elacestrant (RAD1901) versus investigator’s choice (IC) of endocrine therapy (ET) for ER+/HER2- advanced breast cancer (BC) following CDK4/6 inhibitor (CDK4/6i) therapy. Congress:ASCO 2019, Search all connections
Abstract Phase 1/2 dose-escalation and expansion study investigating SAR439859 +/- palbociclib in postmenopausal women with estrogen receptor-positive (ER+)/HER2- metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract XENERA-1: A phase II trial of xentuzumab (Xe) in combination with everolimus (Ev) and exemestane (Ex) in patients with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC) and non-visceral involvement. Congress:ASCO 2019, Search all connections
Abstract B-PRECISE-01 Study: A phase Ib trial of MEN1611, a PI3K Inhibitor, combined with trastuzumab ± fulvestrant for the treatment of HER2-positive advanced or metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract A phase III, multicenter, randomized, open label trial of [fam-] trastuzumab deruxtecan (DS-8201a) versus investigator’s choice in HER2-low breast cancer. Congress:ASCO 2019, Search all connections
Abstract Development and external validation of a deep learning model for predicting response to HER2-targeted neoadjuvant therapy from pretreatment breast MRI. Congress:ASCO 2019, Search all connections
Abstract A neutrophil to lymphocyte ratio is predictive of response to neoadjuvant HER2-targeted therapies in the patients with HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract Health-related quality of life in the Swedish PREDIX HER2 trial, evaluating docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract Open label, phase II trial of neoadjuvant TAK-228 plus tamoxifen in patients with estrogen receptor (ER)-positive, human epidermal growth factor receptor type 2 (HER2)-negative breast cancer-ANETT. Congress:ASCO 2019, Search all connections
Abstract Genomic-based predictive biomarkers to anti-HER2 therapies: A combined analysis of CALGB 40601 (Alliance) and PAMELA clinical trials. Congress:ASCO 2019, Search all connections
Abstract Evaluation of survival by ADCC status: Subgroup analysis of SB3 (Trastuzumab Biosimilar) and reference trastuzumab in patients with HER2-positive early breast cancer at three-year follow-up. Congress:ASCO 2019, Search all connections
Abstract Correlation between mutation landscape and clinical outcomes of neoadjuvant therapy in HER2-positive breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract On-treatment changes in tumor-infiltrating lymphocytes (TIL) during neoadjuvant HER2 therapy (NAT) and clinical outcome. Congress:ASCO 2019, Search all connections
Abstract Role of anthracyclines in neoadjuvant anti-HER2 regimens for HER2+ breast cancer (BC): A network meta-analysis (NMA). Congress:ASCO 2019, Search all connections
Abstract Cardiac safety of the trastuzumab biosimilar ABP 980 in women with HER2-positive early breast cancer in the LILAC study. Congress:ASCO 2019, Search all connections
Abstract Genomics of HER2+ breast cancer in young women before and after exposure to chemotherapy (chemo) plus trastuzumab (H). Congress:ASCO 2019, Search all connections
Abstract Tailored dose-dense chemotherapy in combination with trastuzumab as adjuvant therapy for HER2-positive breast cancer: A secondary analysis of the phase III PANTHER trial. Congress:ASCO 2019, Search all connections
Abstract Effect of prophylaxis on neratinib-associated diarrhea and tolerability in patients with HER2+ early-stage breast cancer: Phase II CONTROL trial. Congress:ASCO 2019, Search all connections
Abstract Prognostic value of PD-L1 gene expression with Recurrence Score and 70-gene signature in patients with ER+/HER2- early breast cancer. Congress:ASCO 2019, Search all connections
Abstract Patterns of systemic treatment utilization in ER+/PgR+/HER2+, early-stage breast cancer (BC): An analysis of the National Cancer Database. Congress:ASCO 2019, Search all connections
Abstract PAM50 HER2-enriched subtype as an independent prognostic factor in early-stage HER2+ breast cancer following adjuvant chemotherapy plus trastuzumab in the ShortHER trial. Congress:ASCO 2019, Search all connections
Abstract Distinct mutational landscape between HR+ and HR- HER2+ early-stage breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract Additional prognostic value of OncoMasTR multigene prognostic signature to clinicopathological information in patients with HR-positive, HER2-negative, lymph node-negative breast cancer from the TAILORx Tissue Bank, Ireland. Congress:ASCO 2019, Search all connections
Abstract A novel 95-gene signature (Curebest 95GC Breast) that predicts recurrence-risk in patients with ER-positive, HER2-negative, node-negative, early-stage primary invasive breast cancer with an intermediate Oncotype DX Recurrence Score. Congress:ASCO 2019, Search all connections
Abstract Ki67 during and after neoadjuvant trastuzumab, pertuzumab and palbociclib plus or minus fulvestrant in HER2 and ER-positive breast cancer: The NA-PHER2 Michelangelo study. Congress:ASCO 2019, Search all connections
Abstract De-escalating adjuvant trastuzumab in human epidermal growth factor receptor 2 (HER2)-positive early-stage breast cancer: A systemic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract Do all patients with HER2-positive breast cancer require one year of adjuvant trastuzumab?: A systematic review and meta-analysis. Congress:ASCO 2019, Search all connections
Abstract A phase II study of pembrolizumab and capecitabine for triple-negative (TN) and hormone receptor-positive, HER2-negative endocrine-refractory metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract TAKTIC: A prospective, multicenter, uncontrolled, phase IB/II study of LY2780301 (LY) in combination with weekly paclitaxel (wP) in HER2-negative locally advanced (LA) or metastatic breast cancer (MBC) patients. Congress:ASCO 2019, Search all connections
Abstract Evaluation of oral S-1 as a first-line chemotherapy for metastatic HER2-negative breast cancer: An analysis of two randomized phase III studies (SELECT BC-CONFIRM and SELECT BC). Congress:ASCO 2019, Search all connections
Abstract Phase II clinical trial using anti-CD3 x anti-HER2 bispecific antibody armed activated T cells (HER2 BATs) for HER2-negative (0-2+) metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract First-line (1L) ribociclib (RIB) plus letrozole (LET) for postmenopausal women with hormone receptor-positive (HR+), HER2- advanced breast cancer (ABC): MONALEESA-2 long-term safety results. Congress:ASCO 2019, Search all connections
Abstract A phase II, single-arm study of apatinib and oral etoposide in pretreated metastatic HER2-negative breast cancer. Congress:ASCO 2019, Search all connections
Abstract Phase I dose escalation of H3B-6545, a first-in-class highly Selective ERα Covalent Antagonist (SERCA), in women with ER-positive, HER2-negative breast cancer (HR+ BC). Congress:ASCO 2019, Search all connections
Abstract A multicenter analysis of abemaciclib after progression on palbociclib in patients (pts) with hormone receptor-positive (HR+)/HER2- metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract Dose-escalation study of SAR439859, an oral selective estrogen receptor (ER) degrader (SERD), in postmenopausal women with ER+/HER2- metastatic breast cancer (mBC). Congress:ASCO 2019, Search all connections
Abstract Exploratory analysis of the effect of taselisib on downstream pathway modulation and correlation with tumor response in ER-positive/HER2-negative early-stage breast cancer from the LORELEI trial. Congress:ASCO 2019, Search all connections
Abstract Germline BRCA1and BRCA2 mutations in patients with HER2-negative metastatic breast cancer (mBC) treated with first-line chemotherapy: Data from the German PRAEGNANT registry. Congress:ASCO 2019, Search all connections
Abstract Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor-2-negative (HER2-) advanced breast cancer (ABC): First interim BYLieve study results. Congress:ASCO 2019, Search all connections
Abstract Alpelisib (ALP) with fulvestrant (FUL) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancer (ABC): Primary or secondary resistance to prior endocrine therapy (ET) in the SOLAR-1 trial. Congress:ASCO 2019, Search all connections
Abstract Patient-reported outcomes (PROs) in patients (pts) with PIK3CA-mutated hormone receptor-positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC) from SOLAR-1. Congress:ASCO 2019, Search all connections
Abstract Safety, efficacy, and biomarker analysis of pyrotinib in combination with capecitabine in HER2-positive metastatic breast cancer patients: A phase I clinical trial. Congress:ASCO 2019, Search all connections
Abstract Tucatinib, palbociclib, and letrozole in HR+/HER2+ metastatic breast cancer: Report of phase IB safety cohort. Congress:ASCO 2019, Search all connections
Abstract Disparities in treatment patterns and overall survival (OS) in hormone receptor-positive HER2+ metastatic breast cancer (MBC): A National Cancer Database Analysis. Congress:ASCO 2019, Search all connections
Abstract Elevated serum activin A and PD-L1 and survival in the CCTG MA.31 phase III trial (trastuzumab vs. lapatinib) in first-line HER2+ metastatic breast cancer. Congress:ASCO 2019, Search all connections
Abstract Comparison of outcomes in a population-based cohort of women with metastatic breast cancer receiving anti-HER2 therapy with clinical trial outcomes. Congress:ASCO 2019, Search all connections
Abstract Real-world treatment patterns and outcomes in ER+/PR+/HER2+ metastatic breast cancer (MBC) patients: A National Cancer Database analysis. Congress:ASCO 2019, Search all connections
Abstract Efficacy and safety of talazoparib (TALA) or physician's choice of therapy (PCT) in United States patients (pts) with HER2- germline BRCA1/2-mutated (gBRCAm) locally advanced/metastatic breast cancer (LA/MBC) in the EMBRACA study. Congress:ASCO 2019, Search all connections
Abstract Effect of HER2/neu 655 polymorphism on trastuzumab-induced cardiotoxicity in HER2-positive breast cancer patients. Congress:ASCO 2019, Search all connections
Abstract A phase III, randomized, double-blind, placebo (Pla)-controlled study of pertuzumab (P) + trastuzumab (H) + docetaxel (D) versus Pla + H+ D in previously untreated HER2-positive locally recurrent/metastatic breast cancer (LR/MBC) (PUFFIN). Congress:ASCO 2019, Search all connections
Abstract High frequency of HER2-specific immunity observed in patients (pts) with HER2+ cancers treated with margetuximab (M), an Fc-enhanced anti-HER2 monoclonal antibody (mAb). Congress:ASCO 2019, Search all connections
Abstract Interim results from the full population of the phase 3b CompLEEment-1 study of ribociclib (RIBO) plus letrozole (LET) in the treatment of HR+/HER2– advanced breast cancer (ABC). Congress:ASCO 2019, Search all connections
Abstract Next-generation sequencing (NGS) results among hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC) patients treated with a CDK4 & 6 inhibitor: A retrospective observational study based on real‑world data. Congress:ASCO 2019, Search all connections
Abstract Association of HER2 alterations and ESR1 mutations in cell-free DNA (cfDNA) with circulating tumor cells (CTCs), multiple metastasis, and prognosis in stage III/IV breast cancer (BCa). Congress:ASCO 2019, Search all connections
Abstract Clinical characteristics of patients with no evidence of disease (NED) versus residual disease (RES) to anti-HER2 therapy in metastatic breast cancer (MBC): A multi-institutional analysis. Congress:ASCO 2019, Search all connections
Abstract Trastuzumab emtansine (T-DM1) and ribociclib, an oral inhibitor of cyclin dependent kinase 4 and 6 (CDK 4/6), for patients with metastatic HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract First-line pembrolizumab (P), trastuzumab (T), capecitabine (C) and oxaliplatin (O) in HER2-positive metastatic esophagogastric adenocarcinoma. Congress:ASCO 2019, Search all connections
Abstract A phase II study of RC48-ADC in HER2-positive patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2019, Search all connections
Abstract Multimodality liquid biopsy for early monitoring and outcome prediction in first-line metastatic HER2-negative breast cancer: Final results of the prospective cohort from the French Breast Cancer InterGroup Unicancer (UCBG)— COMET study. Congress:ASCO 2019, Search all connections
Abstract Patient-reported outcomes (PROs) from KATHERINE: A phase III study of adjuvant trastuzumab emtansine (T-DM1) versus trastuzumab (H) in patients (pts) with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer. Congress:ASCO 2019, Search all connections
Abstract End-of-study analysis from the phase III, randomized, double-blind, placebo (Pla)-controlled CLEOPATRA study of first-line (1L) pertuzumab (P), trastuzumab (H), and docetaxel (D) in patients (pts) with HER2-positive metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract A phase II study of abemaciclib in patients (pts) with brain metastases (BM) secondary to HR+, HER2- metastatic breast cancer (MBC). Congress:ASCO 2019, Search all connections
Abstract Event-free survival analysis of the prospectively randomized phase III ETNA study with neoadjuvant nab-paclitaxel (nab-P) versus paclitaxel (P) followed by anthracycline regimens in women with HER2-negative high-risk breast cancer. Congress:ASCO 2019, Search all connections
Abstract Triplet therapy (continuous ribociclib, everolimus, exemestane) in HR+/HER2− advanced breast cancer postprogression on a CDK4/6 inhibitor (TRINITI-1): Efficacy, safety, and biomarker results. Congress:ASCO 2019, Search all connections
Abstract In-depth gene expression analysis of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with ribociclib-containing therapy in the Phase III MONALEESA-7 trial. Congress:ASCO 2019, Search all connections
Abstract Genomic correlates of response to adjuvant trastuzumab (H) and pertuzumab (P) in HER2+ breast cancer (BC): Biomarker analysis of the APHINITY trial. Congress:ASCO 2019, Search all connections
Abstract Ado-trastuzumab emtansine in patients with HER2 amplified salivary gland cancers (SGCs): Results from a phase II basket trial. Congress:ASCO 2019, Search all connections
Abstract Talazoparib beyond BRCA: A phase II trial of talazoparib monotherapy in BRCA1 and BRCA2 wild-type patients with advanced HER2-negative breast cancer or other solid tumors with a mutation in homologous recombination (HR) pathway genes. Congress:ASCO 2019, Search all connections
Abstract GeparOLA: A randomized phase II trial to assess the efficacy of paclitaxel and olaparib in comparison to paclitaxel/carboplatin followed by epirubicin/cyclophosphamide as neoadjuvant chemotherapy in patients (pts) with HER2-negative early breast cancer (BC) and homologous recombination deficiency (HRD). Congress:ASCO 2019, Search all connections
Abstract Phase III MONALEESA-7 trial of premenopausal patients with HR+/HER2− advanced breast cancer (ABC) treated with endocrine therapy ± ribociclib: Overall survival (OS) results. Congress:ASCO 2019, Search all connections
Abstract Docetaxel, trastuzumab, pertuzumab versus trastuzumab emtansine as neoadjuvant treatment of HER2-positive breast cancer: Results from the Swedish PREDIX HER2 trial identifying a new potential de-escalation standard? Congress:ASCO 2019, Search all connections
Abstract Neoadjuvant trastuzumab (H), pertuzumab (P), and chemotherapy versus trastuzumab emtansine (T-DM1) and P in human epidermal growth factor receptor 2 (HER2)-positive breast cancer (BC): Final outcome results from the phase III KRISTINE study. Congress:ASCO 2019, Search all connections
Abstract Pyrotinib combined with capecitabine in women with HER2+ metastatic breast cancer previously treated with trastuzumab and taxanes: A randomized phase III study. Congress:ASCO 2019, Search all connections
Abstract SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C) versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). Congress:ASCO 2019, Search all connections
Abstract Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. Congress:ASCO 2019, Search all connections
Abstract Cost-effectiveness of subcutaneous pertuzumab, trastuzumab, and hyaluronidase-zzxf for the treatment of high-risk HER2+ early breast cancer. Congress:ASCO 2021, Search all connections
Abstract Real-world outcomes of neoadjuvant treatment for HER2 positive early-stage breast cancer. Congress:ASCO 2021, Search all connections
Abstract Treatment patterns following first-line pertuzumab + trastuzumab in patients with HER2+ metastatic breast cancer in the United States. Congress:ASCO 2021, Search all connections
Abstract Real-world treatment patterns among advanced HR+/HER2- breast cancer patients in the post-CDK4/6 inhibitor era: An analysis of administrative claims data. Congress:ASCO 2021, Search all connections
Abstract Clinical outcomes in HER2-positive and triple-negative breast cancer: Assessing racial disparities. Congress:ASCO 2021, Search all connections
Abstract Patient and provider education on HER2-positive metastatic breast cancer: Defining gaps in clinician practice, patient behaviors, patient-provider alignment, and clinical knowledge. Congress:ASCO 2021, Search all connections
Abstract Clinicopathological characteristics of patients with HER2-positive gastric and gastroesophageal junction cancer in a single tertiary hospital. Congress:ASCO 2021, Search all connections
Abstract A noninvasive gastric cancer Her2 test using surrogate methylation markers. Congress:ASCO 2021, Search all connections
Abstract HERIZON: A phase 1B/2 open-label study of imu-131 HER2/neu peptide vaccine PLUS standard of care chemotherapy with randomization in phase 2 in patients with HER2/neu overexpressing metastatic or advanced adenocarcinoma of the stomach or gastroesophageal junction. Congress:ASCO 2021, Search all connections
Abstract A phase 1 multicenter, dose expansion study of ARX788 as monotherapy in patients with HER2-positive advanced gastric and gastroesophageal junction adenocarcinoma (ACE-Gastric-01). Congress:ASCO 2021, Search all connections
Abstract Association between timely targeted therapy initiation and clinical outcomes in patients with advanced HER2+ gastroesophageal adenocarcinoma. Congress:ASCO 2021, Search all connections
Abstract Clinical features, treatments and survival of HER2 positive gastric cancer with elevated alpha-fetoprotein: An analysis of 16 cases. Congress:ASCO 2021, Search all connections
Abstract The preliminary efficacy of KN026 (Anti-HER2 BsAb) in advanced gastric and gastroesophageal junction cancer patients with HER2 expression. Congress:ASCO 2021, Search all connections
Abstract Pyrotinib combined with SHR6390 in the treatment of refractory advanced HER2 positive gastric cancer or solid tumors: Safety and efficacy results from a phase Id trial. Congress:ASCO 2021, Search all connections
Abstract Dual-targeted therapy with pyrotinib and trastuzumab for HER2-positive advanced colorectal cancer: Preliminary results from a multicenter phase 2 trial. Congress:ASCO 2021, Search all connections
Abstract Pretreatment 18F-FDG uptake heterogeneity predicts response to pyrotinib in patients with metastatic HER2-positive breast cancer. Congress:ASCO 2021, Search all connections
Abstract Phase Ib/II study of capecitabine 7/7 schedule with neratinib in patients with HER2-positive metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Outcomes of ER, PR, HER2, and triple-negative mutated breast cancer with brain metastasis. Congress:ASCO 2021, Search all connections
Abstract Effect of type and timing of systemic therapy on risk of radiation necrosis in patients with HER2+ breast cancer brain metastases. Congress:ASCO 2021, Search all connections
Abstract Efficacy of everolimus-containing chemotherapy in HER2 negative metastatic breast cancer patients with PI3K/AKT/mTOR mutations: A retrospective study. Congress:ASCO 2021, Search all connections
Abstract Treatment and prognosis of advanced triple-negative breast cancer patients with HER2-low expression: A 15-year retrospective study. Congress:ASCO 2021, Search all connections
Abstract The effectiveness and safety of eribulin therapy in HR-positive HER2-negative metastatic breast cancer post-CDK4/6 inhibitor therapy in Russian clinical practice. Congress:ASCO 2021, Search all connections
Abstract Effect of cyclin-dependent kinase 4 and 6 inhibitors (CDKIs) on body composition (BC) in patients (pts) with hormone receptor-positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Real-world outcomes from the systemic use of CDK 4/6 inhibitors (CDKIs) in the management of ER positive (+) HER2 negative (-) metastatic breast cancer (mBC). Congress:ASCO 2021, Search all connections
Abstract Real-world analysis of disease progression after CDK 4/6 inhibitor (CDKi) therapy in patients with hormone receptor positive (HR+)/HER2- metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Phase 1b study of H3B-6545 in combination with palbociclib in women with metastatic estrogen receptor–positive (ER+), human epidermal growth factor receptor 2 (HER2)-negative breast cancer. Congress:ASCO 2021, Search all connections
Abstract Everolimus combined with endocrine therapy in advanced HR-positive, HER2-negative Chinese breast cancer patients: A retrospective study. Congress:ASCO 2021, Search all connections
Abstract Australian real-world outcomes of ribociclib and aromatase inhibitor in hormone receptor (HR) positive, HER2 negative metastatic breast cancer (MBC): Results from Kisqali Access Registry for Metastatic breast cancer in Australia (KARMA) collected alongside a medicine access program. Congress:ASCO 2021, Search all connections
Abstract Cardiac function in patients receiving dual anti-Her2 antibodies (trastuzumab and pertuzumab) combined with chemotherapy for breast cancer in routine practice. Congress:ASCO 2021, Search all connections
Abstract TDM-1 efficacy in trastuzumab-pertuzumab pre-treated HER2 positive metastatic breast cancer patients: A meta-analysis. Congress:ASCO 2021, Search all connections
Abstract Pyrotinib in the treatment of women with advanced HER2 positive breast cancer: A multicenter, prospective, real-world study. Congress:ASCO 2021, Search all connections
Abstract Liquid biopsy for baseline evaluation of tumor burden in patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A proof of principle study. Congress:ASCO 2021, Search all connections
Abstract Baseline neutrophil-to-lymphocyte ratio and absolute lymphocyte count in patients with HER2-negative breast cancer treated with eribulin may predict overall survival. Congress:ASCO 2021, Search all connections
Abstract Predictive factors associated with a pathologic complete response in a Mexican HER2+ breast cancer population. Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety of neoadjuvant docetaxel, carboplatin, trastuzumab, and pertuzumab (TCH-P) in HER2-positive breast cancer: An Indian experience. Congress:ASCO 2021, Search all connections
Abstract Change in HER2 status after neoadjuvant chemotherapy (NAC) with trastuzumab and pertuzumab (HP) in patients with HER2-positive early-stage breast cancer. Congress:ASCO 2021, Search all connections
Abstract A prognostic miRNA based signature in early-stage HER2-positive breast cancer patients. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab-dkst versus trastuzumab: Real-world pCR rates in patients with HER2+ breast cancer treated with neoadjuvant chemotherapy plus trastuzumab from Alberta, Canada. Congress:ASCO 2021, Search all connections
Abstract Heterogeneity between core needle biopsy and synchronous axillary lymph node metastases in early breast cancer patients: Comparison of HER2, estrogen and progesterone receptor expression profiles during primary treatment regime. Congress:ASCO 2021, Search all connections
Abstract Impact of updated 2013 human epidermal growth factor receptor-2 testing guidelines on HER2 positive invasive breast cancer diagnosis: A three year retrospective study. Congress:ASCO 2021, Search all connections
Abstract The intra-tumor heterogeneity of ER and HER2 expression in patients with ER-positive and HER2-positive breast cancer. Congress:ASCO 2021, Search all connections
Abstract Prediction of long-term prognosis over ten years in ER-positive HER2-negative early-stage breast cancer using 18F-FDG PET/CT before treatment. Congress:ASCO 2021, Search all connections
Abstract Recurrence rate according to Oncotype Dx recurrence score (RS) in women with estrogen receptor (ER) positive, Her2 negative and 1 to 3 positive nodes: Real-world data in a Mexican private institution. Congress:ASCO 2021, Search all connections
Abstract Clinical significance of crown-like structures to trastuzumab response in patients with primary invasive HER2+ breast cancer. Congress:ASCO 2021, Search all connections
Abstract Retrospective analysis of HER2-low in young breast cancer patients. Congress:ASCO 2021, Search all connections
Abstract Racial disparities in second-line (2L) treatment and overall survival among patients (pts) with hormone receptor positive HER2 negative (HR+HER2-) metastatic breast cancer (mBC) treated in routine practice. Congress:ASCO 2021, Search all connections
Abstract Impact of race on biomarker testing among HER2- advanced breast cancer (ABC) patients (pts) in the United States: Results from a real-world study. Congress:ASCO 2021, Search all connections
Abstract Breast cancer ER, PR, and HER2 expression variance by germline cancer predisposition genes. Congress:ASCO 2021, Search all connections
Abstract Incorporating HER2/HER3 targeted therapies across solid tumors: Assessing the impact of digital education on clinician practice patterns. Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies. Congress:ASCO 2021, Search all connections
Abstract An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009). Congress:ASCO 2021, Search all connections
Abstract A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14). Congress:ASCO 2021, Search all connections
Abstract Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study). Congress:ASCO 2021, Search all connections
Abstract Imaging HER2-positive metastatic esophagogastric cancer with 89Zr-trastuzumab PET and 18F-FDG PET. Congress:ASCO 2021, Search all connections
Abstract Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01). Congress:ASCO 2021, Search all connections
Abstract ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA). Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02). Congress:ASCO 2021, Search all connections
Abstract Assessment of HER2 (ERBB2) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC). Congress:ASCO 2021, Search all connections
Abstract Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with HER2 (ERBB2) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602). Congress:ASCO 2021, Search all connections
Abstract Association of HER2 expression with pathologic features and prognosis in stage II and III colon cancer. Congress:ASCO 2021, Search all connections
Abstract A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01). Congress:ASCO 2021, Search all connections
Abstract SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress). Congress:ASCO 2021, Search all connections
Abstract A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial). Congress:ASCO 2021, Search all connections
Abstract Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types. Congress:ASCO 2021, Search all connections
Abstract Correlation between different levels of HER2 expression in circulating tumor cells (cHER2 ratio) and metastatic behavior in stageIVaggressive breast cancer. Congress:ASCO 2021, Search all connections
Abstract Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials. Congress:ASCO 2021, Search all connections
Abstract A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors. Congress:ASCO 2021, Search all connections
Abstract Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress. Congress:ASCO 2021, Search all connections
Abstract Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer. Congress:ASCO 2021, Search all connections
Abstract Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors. Congress:ASCO 2021, Search all connections
Abstract Heterogeneity of HER2 expression in circulating tumor cells of patients with breast cancer brain metastases and impact on brain disease control. Congress:ASCO 2021, Search all connections
Abstract A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer. Congress:ASCO 2021, Search all connections
Abstract TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer. Congress:ASCO 2021, Search all connections
Abstract ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer. Congress:ASCO 2021, Search all connections
Abstract A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy (JCOG1806: AMATERAS-BC study). Congress:ASCO 2021, Search all connections
Abstract A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer. Congress:ASCO 2021, Search all connections
Abstract Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA. Congress:ASCO 2021, Search all connections
Abstract eMonarcHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer. Congress:ASCO 2021, Search all connections
Abstract SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease. Congress:ASCO 2021, Search all connections
Abstract AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer. Congress:ASCO 2021, Search all connections
Abstract persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2– LA/mBC). Congress:ASCO 2021, Search all connections
Abstract Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician’s choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC). Congress:ASCO 2021, Search all connections
Abstract Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050). Congress:ASCO 2021, Search all connections
Abstract Automated, IHC/FISH-free, H&E histopathology image-based HER2 amplification, tumor infiltrating lymphocyte (TIL) and tumor heterogeneity profiling in breast cancer. Congress:ASCO 2021, Search all connections
Abstract Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07). Congress:ASCO 2021, Search all connections
Abstract Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2–) operable breast cancer (BC). Congress:ASCO 2021, Search all connections
Abstract MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology. Congress:ASCO 2021, Search all connections
Abstract Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial. Congress:ASCO 2021, Search all connections
Abstract Role of 21- gene recurrence score in patients age ≥70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy. Congress:ASCO 2021, Search all connections
Abstract Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients < 50 years and >50 years. Congress:ASCO 2021, Search all connections
Abstract Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature. Congress:ASCO 2021, Search all connections
Abstract ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial. Congress:ASCO 2021, Search all connections
Abstract Neoadjuvant talazoparib (TALA) in patients (pts) with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor BRCA mutational status and zygosity and overall mutational landscape in a phase 2 study. Congress:ASCO 2021, Search all connections
Abstract Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States. Congress:ASCO 2021, Search all connections
Abstract Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer. Congress:ASCO 2021, Search all connections
Abstract Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial. Congress:ASCO 2021, Search all connections
Abstract Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer. Congress:ASCO 2021, Search all connections
Abstract Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial. Congress:ASCO 2021, Search all connections
Abstract The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC). Congress:ASCO 2021, Search all connections
Abstract Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer. Congress:ASCO 2021, Search all connections
Abstract A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline BRCA mutation. Congress:ASCO 2021, Search all connections
Abstract Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): A subgroup analysis from POLARIS. Congress:ASCO 2021, Search all connections
Abstract Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial. Congress:ASCO 2021, Search all connections
Abstract Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC). Congress:ASCO 2021, Search all connections
Abstract Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Alpelisib and fulvestrant efficacy in HR-positive HER2-negative PIK3CA-mutant advanced breast cancer: Data from the French early access program. Congress:ASCO 2021, Search all connections
Abstract Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2– advanced breast cancer: Phase 1 results. Congress:ASCO 2021, Search all connections
Abstract Endocrine therapy-based strategies with different endocrine sensitivity statuses for hormone receptor positive/HER2 negative metastatic breast cancer: A network meta-analysis. Congress:ASCO 2021, Search all connections
Abstract Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–), PIK3CA-mutated advanced breast cancer (ABC) from BYLieve. Congress:ASCO 2021, Search all connections
Abstract Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane. Congress:ASCO 2021, Search all connections
Abstract Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials. Congress:ASCO 2021, Search all connections
Abstract A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease. Congress:ASCO 2021, Search all connections
Abstract AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC). Congress:ASCO 2021, Search all connections
Abstract Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC). Congress:ASCO 2021, Search all connections
Abstract The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer. Congress:ASCO 2021, Search all connections
Abstract 68Ga-HER2 affibody PET/CT imaging as an option in patients whose HER2 status of any tumor in the body needs to be deciphered. Congress:ASCO 2021, Search all connections
Abstract Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer. Congress:ASCO 2021, Search all connections
Abstract Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB). Congress:ASCO 2021, Search all connections
Abstract Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer. Congress:ASCO 2021, Search all connections
Abstract Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpresing solid tumors: Results from two phase 1 clinical trials. Congress:ASCO 2021, Search all connections
Abstract Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM). Congress:ASCO 2021, Search all connections
Abstract Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive. Congress:ASCO 2021, Search all connections
Abstract Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia). Congress:ASCO 2021, Search all connections
Abstract Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study. Congress:ASCO 2021, Search all connections
Abstract Concordance of HER2+ status by IHC/ISH and ERBB2 status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC). Congress:ASCO 2021, Search all connections
Abstract Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results. Congress:ASCO 2021, Search all connections
Abstract Chemoprotective effect of metformin against HR+/HER2- breast cancer among women with type-2 diabetes. Congress:ASCO 2021, Search all connections
Abstract Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial. Congress:ASCO 2021, Search all connections
Abstract Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study. Congress:ASCO 2021, Search all connections
Abstract RC48-ADC, a HER2-targeting antibody-drug conjugate, in patients with HER2-positive and HER2-low expressing advanced or metastatic breast cancer: A pooled analysis of two studies. Congress:ASCO 2021, Search all connections
Abstract Prevalence of HER2 low in breast cancer subtypes using the VENTANA anti-HER2/neu (4B5) assay. Congress:ASCO 2021, Search all connections
Abstract Inflammatory cytokines and distant recurrence in HER2-negative early breast cancer in the ECOG-ACRIN 5103 trial. Congress:ASCO 2021, Search all connections
Abstract Subgroup of post-neoadjuvant luminal-B tumors assessed by HTG in PENELOPE-B investigating palbociclib in high risk HER2-/HR+ breast cancer with residual disease. Congress:ASCO 2021, Search all connections
Abstract Safety and activity of single-agent giredestrant (GDC-9545) from a phase Ia/b study in patients (pts) with estrogen receptor-positive (ER+), HER2-negative locally advanced/metastatic breast cancer (LA/mBC). Congress:ASCO 2021, Search all connections
Abstract Characterizing demographics, clinical, and genomic characteristics for U.S. patients with HR+, HER2- metastatic breast cancer following progression on a CDK4 and 6 inhibitor. Congress:ASCO 2021, Search all connections
Abstract Phase I/II study of H3B-6545, a novel selective estrogen receptor covalent antagonist (SERCA), in estrogen receptor positive (ER+), human epidermal growth factor receptor 2 negative (HER2-) advanced breast cancer. Congress:ASCO 2021, Search all connections
Abstract Prospective longitudinal multi-omics study of palbociclib resistance in hormone receptor+/HER2- metastatic breast cancer. Congress:ASCO 2021, Search all connections
Abstract Lisinopril or carvedilol in prevention of trastuzumab-induced cardiotoxicity in patients with HER2-positive early stage breast cancer: Longitudinal changes of left ventricular ejection fraction below normal levels (LVEF <50%). Congress:ASCO 2021, Search all connections
Abstract Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. Congress:ASCO 2021, Search all connections
Abstract Phase I study of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. Congress:ASCO 2021, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01). Congress:ASCO 2021, Search all connections
Abstract MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors. Congress:ASCO 2021, Search all connections
Abstract Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial. Congress:ASCO 2021, Search all connections
Abstract De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results. Congress:ASCO 2021, Search all connections
Abstract Neoadjuvant talazoparib in patients with germline BRCA1/2 (gBRCA1/2) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study. Congress:ASCO 2021, Search all connections
Abstract Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial. Congress:ASCO 2021, Search all connections
Abstract Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC). Congress:ASCO 2021, Search all connections
Abstract Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC). Congress:ASCO 2021, Search all connections
Abstract Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB). Congress:ASCO 2021, Search all connections
Abstract Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial. Congress:ASCO 2021, Search all connections
Abstract Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study. Congress:ASCO 2021, Search all connections
Abstract Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2–) advanced breast cancer (ABC): Updated analyses from PALOMA-3. Congress:ASCO 2021, Search all connections
Abstract OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline BRCA1/2 mutations and high-risk HER2-negative early breast cancer. Congress:ASCO 2021, Search all connections
Abstract Updated FDA pooled analysis of pain medication use in trial participants with HR+, HER2-negative metastatic breast cancer treated with endocrine therapy and a CDK 4/6 inhibitor. Congress:ASCO 2022, Search all connections
Abstract Effect of traditional Chinese medicine on pyrotinib-associated diarrhea in patients with HER2-positive breast cancer. Congress:ASCO 2022, Search all connections
Abstract The analgesic compound palmitoylethanolamide reduces inflammation in human cardiomyocytes and vascular endothelial cells exposed to doxorubicin and anti-HER2 monoclonal antibody through PPAR-α and NLRP3-related pathways. Congress:ASCO 2022, Search all connections
Abstract Clinical outcomes of immune checkpoint inhibitors in HER2-amplified non-small cell lung cancers. Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Preliminary results from a phase Ib study. Congress:ASCO 2022, Search all connections
Abstract Retrospective study on the safety and efficacy of pyrotinib in the treatment of HER2-positive non-breast advanced solid tumors. Congress:ASCO 2022, Search all connections
Abstract Assessment of tumour infiltrating subpopulations and pathological complete response using multiplex immunohistochemistry and digital pathology in early HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract An open-label, multicenter, phase II study of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor sequential GM-CSF and IL-2 for salvage therapy in patients with HER2-expressing advanced solid tumors(PRaG3.0). Congress:ASCO 2022, Search all connections
Abstract Outcomes and prognostic factors in patients with HER2-positive metastatic breast cancer with brain metastasis. Congress:ASCO 2022, Search all connections
Abstract Characteristics of disease course in patients with locally advanced primarily inoperable HER2-negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Results of the safety run-in of gedatolisib plus talazoparib in advanced triple negative or BRCA 1/2 positive HER2 negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Translational relevance of HER2-low expression in triple-negative breast cancer: A retrospective single-center study. Congress:ASCO 2022, Search all connections
Abstract Treatment sequence for hormone receptor-positive HER2-negative advanced breast cancer: Results of a retrospective analysis of Russian patients diagnosed with aBC in 2014-2021. Congress:ASCO 2022,ASCO 2021, Search all connections
Abstract Liquidscan mediated HER2 amplification detection in patient samples study. Congress:ASCO 2022, Search all connections
Abstract Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive advanced breast cancer: A single-arm, multicenter, phase 2 study. Congress:ASCO 2022, Search all connections
Abstract Clinical characteristics and real-world progression-free survival (rwPFS) of patients with HER2-positive and hormone receptor (HR)-positive metastatic breast cancer (MBC) initiating endocrine therapy (ET) in combination with the first line of treatment: An analysis of electronic health records in the United States. Congress:ASCO 2022, Search all connections
Abstract Prognostic factors influencing progression-free survival in HER2 positive metastatic breast cancer patients who treated with lapatinib and capecitabine combination. Congress:ASCO 2022, Search all connections
Abstract Platelet-to-Lymphocyte ratio (PLR) as a predictive marker in HER2 positive metastatic breast cancer patients treated with first-line trastuzumab therapy. Congress:ASCO 2022, Search all connections
Abstract Maintenance endocrine therapy prolonged progression-free survival of first-line chemotherapy with trastuzumab in advanced HR-positive, HER2-positive breast cancer patients. Congress:ASCO 2022, Search all connections
Abstract Real-world survival outcomes associated with use of pertuzumab and trastuzumab emtansine (T-DM1) for HER2-positive (HER2+) metastatic breast cancer (MBC) in Brazilian private healthcare setting. Congress:ASCO 2022, Search all connections
Abstract HERibuline: Eribulin mesylate and Trastuzumab in pretreated HER2-positive advanced breast cancer—A report of region’s practice. Congress:ASCO 2022, Search all connections
Abstract Whole genome sequencing of HER2+ metastatic breast cancer and CNA comparison between long term survivor and short-term survivor. Congress:ASCO 2022, Search all connections
Abstract Safety, efficacy and survival outcome of Ado-trastuzumab emtansine (T-DM1) in patients with metastatic HER2-positive breast cancer: An Indian experience. Congress:ASCO 2022, Search all connections
Abstract Neoadjuvant therapy with concurrent anthracyclines and taxanes in Her2-negative breast cancer (HNBC): TAC legacy. Congress:ASCO 2022, Search all connections
Abstract Real-world data on outcomes using taxane, trastuzumab, and pertuzumab (THP) in patients with early stage HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Importance of accurate clinical staging in patients with early stage HER2+ and triple negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Short-term preoperative endocrine therapy allows to estimate and revert patient prognosis with further treatment plan correction in HR+ HER2- early breast cancer patients. Congress:ASCO 2022, Search all connections
Abstract The ratio of PD1+CD8+T cells in stromal area of tumor tissue is associated with the effect of neoadjuvant chemotherapy in HER2 negative breast cancer patients. Congress:ASCO 2022, Search all connections
Abstract Neoadjuvant pegylated liposomal doxorubicin (PLD) plus cyclophosphamide followed by nab-paclitaxel (Nab-P) as primary chemotherapy continuously combined with dual HER2 blockage for HER2-positive breast cancer: A single-arm phase 2 trial (Brecan Trial). Congress:ASCO 2022, Search all connections
Abstract Real-life analysis of pathologic complete response with neoadjuvant trastuzumab plus taxane with or without pertuzumab therapy in HER2 positive locally-advanced breast cancer (HER2PATH Study). Congress:ASCO 2022, Search all connections
Abstract Serum thymidine kinase 1 and its kinetics in HER2-positive breast cancer: Results from the Swedish phase II PREDIX HER2 trial. Congress:ASCO 2022, Search all connections
Abstract Pyrotinib combined with EC-TH neoadjuvant therapy for patients with HER2-positive breast cancer: A multicenter, randomized, phase II, open-label trial. Congress:ASCO 2022, Search all connections
Abstract Outcomes of neoadjuvant combination chemotherapy with and without targeted therapy in HER2-positive breast cancer: A real-world experience from tertiary care center in North India. Congress:ASCO 2022, Search all connections
Abstract Fragement C Gamma receptor IIIa polymorphism is predictive of trastuzumab efficacy in the neoadjuvant setting of HER2-positive breast cancer patients. Congress:ASCO 2022, Search all connections
Abstract Influencing factors of the recurrence after neoadjuvant therapy in HER2-positive breast cancer. Congress:ASCO 2022, Search all connections
Abstract A nomogram to predict pathological complete response of neoadjuvant systemic therapy in HER2-positive breast cancer based on clinicopathologic characteristics and pretreatment systemic inflammation response index: A dual-center study. Congress:ASCO 2022, Search all connections
Abstract Serial genomic analysis of circulating tumor cells and circulating tumor DNA in triple-negative and HER2-positive advanced, metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract Differences in tumor microenvironment between HER2-positive and HER2-negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Correlation of the oncotype DX breast recurrence score and the ki-67 IHC MIB-1 pharmDX score in HR+, HER2-, node-positive early breast cancer. Congress:ASCO 2022, Search all connections
Abstract Artificial intelligence-powered human epidermal growth factor receptor 2 (HER2) analyzer in breast cancer as an assistance tool for pathologists to reduce interobserver variation. Congress:ASCO 2022, Search all connections
Abstract CD45-positive tumor infiltrating lymphocytes in early-stage hormone-positive, HER2-negative (ER+/HER2-) breast cancer: Correlation with proliferation and prognostic signature scores. Congress:ASCO 2022, Search all connections
Abstract A prospective real-world study to assess the effectiveness and safety of trastuzumab biosimilar in the adjuvant treatment of HER2-positive breast cancer: Preliminary safety results. Congress:ASCO 2022, Search all connections
Abstract The correlation analysis of 21-gene assay use in uninsured and underrepresented minorities with estrogen receptor (ER) positive HER2 negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Analysis of prognostic factors and survival outcomes for patients with T1N0 HER2-positive infiltrating ductal carcinoma of the breast: A real-world study with long-term follow-up. Congress:ASCO 2022, Search all connections
Abstract Prognostic role of the stromal tumor-infiltrating lymphocytes (TILs) in women with early ER+/HER2+ breast cancer (BC) in whom adjuvant chemotherapy (ChT) was omitted. Congress:ASCO 2022, Search all connections
Abstract Automated H&E image-based detection and prognostic evaluation of HER2 heterogeneity in ER+ breast cancers. Congress:ASCO 2022, Search all connections
Abstract Adjuvant trastuzumab and vinorelbine (TV) for early-stage HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Baseline GP2 immune response as an independent prognostic factor in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus. GM-CSF alone after adjuvant trastuzumab in HER2-positive women with breast cancer. Congress:ASCO 2022, Search all connections
Abstract Adherence to different adjuvant endocrine therapies in HR+ HER2-breast cancer and its relation to real-world progression rates. Congress:ASCO 2022, Search all connections
Abstract The effect of breast radiotherapy parameters (XRT), chemotherapy regimens (CT) and dual anti-HER2 monoclonal antibodies (MoAb) on the development of cardiac dysfunction (CD) among patients with HER2-positive breast cancer from Saudi Arabia. Congress:ASCO 2022, Search all connections
Abstract A real-world experience of TCH (docetaxel/carboplatin/trastuzumab) regimen in early, locally advanced and oligometastatic HER2 positive breast cancer from tertiary care center in North India. Congress:ASCO 2022, Search all connections
Abstract Diversity, inclusion, and patient (pt)-centricity in the randomized, double-blind, phase III ASTEFANIA study of ado-trastuzumab emtansine (T-DM1) ± atezolizumab in pts with HER2-positive early breast cancer (EBC) with residual invasive disease after preoperative chemotherapy and anti-HER2 therapy. Congress:ASCO 2022, Search all connections
Abstract Impact of anti-HER2 therapy alone and in association with weekly paclitaxel on the ovarian reserve of young women with HER2-positive early breast cancer: Biomarker analysis of the NeoALTTO trial. Congress:ASCO 2022, Search all connections
Abstract Generating meaningful peer-to-peer engagement through a mentor-led, small group social learning experience on the evolving standards of care for advanced HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Open-label, randomized, multicenter, phase 3 study evaluating trastuzumab deruxtecan (T-DXd) as first-line treatment in patients with unresectable, locally advanced, or metastatic non–small cell lung cancer (NSCLC) harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04). Congress:ASCO 2022, Search all connections
Abstract A phase I, open-label, dose escalation, confirmation, and expansion trial of BI 1810631 as monotherapy in patients with advanced/metastatic solid tumors with HER2 aberrations. Congress:ASCO 2022, Search all connections
Abstract Clinicopathologic and molecular features associated with response to anti-HER2 therapy in endometrial cancer. Congress:ASCO 2022, Search all connections
Abstract Assessment of a HER-2 scoring system and its correlation of HER2-targeting antibody-drug conjugate therapy in urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract Phase 2 study of trastuzumab deruxtecan in the neoadjuvant treatment for patients with HER2-positive gastric and gastroesophageal junction adenocarcinoma (EPOC2003). Congress:ASCO 2022, Search all connections
Abstract EA2183: A phase III study of consolidative radiotherapy in patients with oligometastatic HER2-negative esophageal and gastric adenocarcinoma. Congress:ASCO 2022, Search all connections
Abstract Trastuzumab plus FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer: A multi-institutional phase II trial of the Korean Cancer Study Group (KCSG-HB19-14). Congress:ASCO 2022, Search all connections
Abstract Targeting HER2 mutation–positive advanced biliary tract cancers with neratinib: Final results from the phase 2 SUMMIT basket trial. Congress:ASCO 2022, Search all connections
Abstract A phase II study evaluating KN026 monotherapy in patients (pts) with previously treated, advanced HER2-expressing gastric or gastroesophageal junction cancers (GC/GEJC). Congress:ASCO 2022, Search all connections
Abstract Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with chemotherapy (chemo) and tislelizumab (TIS) as first-line (1L) therapy for patients (pts) with advanced HER2-positive gastric/gastroesophageal junction adenocarcinoma (G/GEJC): Preliminary results from a phase 1b/2 study. Congress:ASCO 2022, Search all connections
Abstract NSABP FC-11: A phase II study of neratinib (N) plus trastuzumab (T) or N plus cetuximab (C) in patients (pts) with "quadruple wild-type" metastatic colorectal cancer (mCRC) based on HER2 status. Congress:ASCO 2022, Search all connections
Abstract Primary results from JUPITER, a phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with HER2-amplified solid tumors. Congress:ASCO 2022, Search all connections
Abstract Theranostic pairing: ABY-025/251 targeting HER2 with 68Ga and 188Re—Minimized radioligands using Affibody peptide scaffold technology. Congress:ASCO 2022, Search all connections
Abstract 64Cu-SAR-Bombesin PET-CT imaging in the staging of ER+/PR+/HER2- metastatic breast cancer: Safety, dosimetry, and feasibility in a phase I trial. Congress:ASCO 2022, Search all connections
Abstract The HERPET study: Imaging HER2 expression in breast cancer with the novel PET tracer [18F]GE-226, a first-in-patient study. Congress:ASCO 2022, Search all connections
Abstract Defining resistance mechanisms to CDK4/6 inhibition in hormone receptor-positive HER2-negative metastatic breast cancer (MBC) through a machine learning approach applied to circulating tumor DNA (ctDNA). Congress:ASCO 2022, Search all connections
Abstract Circulating tumor DNA (ctDNA) in HER2 exon 20 insertion mutations and responses in NSCLC HER2 exon 20 insertion treated with poziotinib. Congress:ASCO 2022, Search all connections
Abstract Dose-finding and -expansion studies of trastuzumab deruxtecan in combination with other anti-cancer agents in patients (pts) with advanced/metastatic HER2+ (DESTINY-Breast07 [DB-07]) and HER2-low (DESTINY-Breast08 [DB-08]) breast cancer (BC). Congress:ASCO 2022, Search all connections
Abstract A phase 1, first-in-human (FIH) study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2 overexpressing solid tumors. Congress:ASCO 2022, Search all connections
Abstract A phase 1 study of the novel immunotoxin MT-5111 in patients with HER2+ tumors: Interim results. Congress:ASCO 2022, Search all connections
Abstract A phase 1, first-in-human (FIH) study of the anti-HER2 CAR macrophage CT-0508 in subjects with HER2 overexpressing solid tumors. Congress:ASCO 2022, Search all connections
Abstract Assessing response to neoadjuvant docetaxel and trastuzumab in Nigerian women with HER2-positive breast cancer (ARETTA). Congress:ASCO 2022, Search all connections
Abstract DECRESCENDO: De-escalation of adjuvant chemotherapy in patients with HER2+/HR-/node-negative early breast cancer who achieve pCR after neoadjuvant taxane and subcutaneous dual anti-HER2 blockade. Congress:ASCO 2022, Search all connections
Abstract TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early-stage breast cancer. Congress:ASCO 2022, Search all connections
Abstract Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open-label randomized phase II trial. Congress:ASCO 2022, Search all connections
Abstract A single-arm, phase 2 study of perioperative ipilimumab, nivolumab, and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer. Congress:ASCO 2022, Search all connections
Abstract Phase II neoadjuvant pyrotinib combined with epirubicin and cyclophosphamide followed by docetaxel in HER2-low–expressing and HR-positive early or locally advanced breast cancer (PILHLE-001): A single-arm trial. Congress:ASCO 2022, Search all connections
Abstract NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, hormone receptor+, HER2-, RS ≤18 breast cancer. Congress:ASCO 2022, Search all connections
Abstract Phase II trial to evaluate immune-related biomarkers for pathological response in stage II-III HER2-positive breast cancer receiving neoadjuvant chemotherapy with subsequent randomization to multi-epitope HER2 vaccine versus placebo in patients with residual disease post-neoadjuvant chemotherapy. Congress:ASCO 2022, Search all connections
Abstract Adjuvant dynamic marker-adjusted personalized therapy comparing endocrine therapy plus ribociclib versus chemotherapy in intermediate-risk HR+/HER2- early breast cancer: ADAPTcycle. Congress:ASCO 2022, Search all connections
Abstract A phase 3, single arm, open-label study evaluating ovarian suppression following 3-month leuprolide acetate for injectable suspension in combination with endocrine therapy in premenopausal subjects with HR+, HER2-negative breast cancer (OVELIA). Congress:ASCO 2022, Search all connections
Abstract TWT-203: Phase 1b/2 dose-confirming study of CFI-402257 as a single agent in advanced solid tumors and in combination with fulvestrant in patients with ER+/HER2- advanced breast cancer after disease progression on prior CDK4/6 and endocrine therapy. Congress:ASCO 2022, Search all connections
Abstract Phase 3 ENABLAR-2 study to evaluate enobosarm and abemaciclib combination compared to estrogen-blocking agent for the second-line treatment of AR+, ER+, HER2- metastatic breast cancer in patients who previously received palbociclib and estrogen-blocking agent combination therapy. Congress:ASCO 2022, Search all connections
Abstract DOLAF: An international multicenter phase II trial of durvalumab (MEDI4736) plus olaparib plus fulvestrant in patients with metastatic or locally advanced ER-positive, HER2-negative breast cancer selected using criteria that predict sensitivity to olaparib. Congress:ASCO 2022, Search all connections
Abstract ARV-471, an estrogen receptor (ER) PROTAC degrader, combined with palbociclib in advanced ER+/human epidermal growth factor receptor 2–negative (HER2-) breast cancer: Phase 1b cohort (part C) of a phase 1/2 study. Congress:ASCO 2022, Search all connections
Abstract postMONARCH: A phase 3 study of abemaciclib plus fulvestrant versus placebo plus fulvestrant in patients with HR+, HER2-, metastatic breast cancer following progression on a CDK4 & 6 inhibitor and endocrine therapy. Congress:ASCO 2022, Search all connections
Abstract KEYNOTE-B49: A phase 3, randomized, double-blind, placebo-controlled study of pembrolizumab plus chemotherapy in patients with HR+/HER2- locally recurrent inoperable or metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract A randomized, multicenter, placebo-controlled, phase III study to evaluate the efficacy and safety of HER2/neu peptide GLSI-100 (GP2 + GM-CSF) in patients with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy, Flamingo-01. Congress:ASCO 2022, Search all connections
Abstract Phase 2 trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ locally advanced or metastatic breast cancer with and without brain metastases (HER2CLIMB-04, trial in progress). Congress:ASCO 2022, Search all connections
Abstract A phase II, single-arm, non-randomized study of alpelisib (BYL719) in combination with continued endocrine therapy following progression on endocrine therapy in hormone receptor–positive, HER2-negative, PIK3CA-mutant metastatic breast cancer: A Big Ten Cancer Research Consortium Study (btcrc-BRE19-409). Congress:ASCO 2022, Search all connections
Abstract EPIK-B5: A phase III, randomized study of alpelisib (ALP) plus fulvestrant (FUL) in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated advanced breast cancer (ABC) progressing on/after an aromatase inhibitor (AI) with a cyclin-dependent kinase 4/6 inhibitor (CDK4/6i). Congress:ASCO 2022, Search all connections
Abstract Phase 3 study of tucatinib or placebo in combination with trastuzumab and pertuzumab as maintenance therapy for HER2+ metastatic breast cancer (HER2CLIMB-05, trial in progress). Congress:ASCO 2022, Search all connections
Abstract Targeting HER2-positive metastatic breast cancer with ARX788, a novel anti-HER2 antibody-drug conjugate in patients whose disease is resistant or refractory to T-DM1, and/or T-DXd, and/or tucatinib-containing regimens. Congress:ASCO 2022, Search all connections
Abstract EPIK-B4: A phase 2, randomized study of metformin (MET) extended release (XR) +/- dapagliflozin (DAPA) to prevent hyperglycemia (HG) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-), PIK3CA-mutated (mut) advanced breast cancer (ABC) treated with alpelisib (ALP) and fulvestrant (FUL). Congress:ASCO 2022, Search all connections
Abstract Evaluation of booster injections in maintaining peak immunity in a phase IIb study evaluating HER2/neu peptide GP2 (GLSI-100) versus GM-CSF alone after adjuvant trastuzumab in women with HER2-positive breast cancer. Congress:ASCO 2022, Search all connections
Abstract Combined assessment of metabolic response and tumor infiltrating lymphocytes as a predictor of outcomes following neoadjuvant therapy for HER2-positive breast cancer: Results from the randomized PREDIX HER2 trial. Congress:ASCO 2022, Search all connections
Abstract Dapagliflozin associated to sacubitril/valsartan and relationship with cardioprotection in human cardiac cells exposed to doxorubicin and HER2-blocking agents through MyD88, NLRP3 mediated pathways. Congress:ASCO 2022, Search all connections
Abstract Real-world outcomes of patients with human epidermal growth factor 2 (HER2)–positive breast cancer receiving neoadjuvant therapy without adjuvant ado-trastuzumab emtansine (T-DM1). Congress:ASCO 2022, Search all connections
Abstract Neoadjuvant giredestrant (GDC-9545) plus palbociclib (P) versus anastrozole (A) plus P in postmenopausal women with estrogen receptor–positive, HER2-negative, untreated early breast cancer (ER+/HER2– eBC): Final analysis of the randomized, open-label, international phase 2 coopERA BC study. Congress:ASCO 2022, Search all connections
Abstract Three-year disease-free survival in randomized trials of chemotherapy and HER2-targeted therapy: A meta-analysis. Congress:ASCO 2022, Search all connections
Abstract Real-world clinical outcomes in patients with local/regional HER2-low breast cancer: An NCDB analysis. Congress:ASCO 2022, Search all connections
Abstract Predictive value of ectopic HORMAD1 tumor expression for high-dose platinum-based chemotherapy benefit in patients with high-risk HER2-negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Type of endocrine therapy and DFS in patients with early HER2+/HR+ BC: Analysis from the phase III randomized ShortHER trial. Congress:ASCO 2022, Search all connections
Abstract Comparison of predicted benefit using RS clin versus observed benefit in a U.S. registry of stage I ER-positive HER2-negative high oncotype DX RS breast cancer. Congress:ASCO 2022, Search all connections
Abstract Adjuvant chemotherapy is associated with an overall survival benefit regardless of age in patients with ER+/HER2-breast cancer with 1-3 positive nodes and Oncotype DX recurrence score 20 to 25: A National Cancer Database analysis. Congress:ASCO 2022, Search all connections
Abstract Concordance and clinical impact of ER, PR, HER2 expression by local and central immunohistochemistry versus RT-PCR in HR+/HER2- early breast cancer (EBC): Results from the ADAPT trial. Congress:ASCO 2022, Search all connections
Abstract Outcomes of patients with T1a,b N0 Her2-positive breast cancer treated with adjuvant trastuzumab in a prospective registry in Ontario, Canada. Congress:ASCO 2022, Search all connections
Abstract The survival benefit of anti-HER2 treatment in the management of small (T1mic, T1a, T1b, T1c), node-negative HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract A multiple center, open-label, single-arm, phase II clinical trial of MRG002, an HER2-targeted antibody-drug conjugate, in patients with HER2-low expressing advanced or metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract AMEERA-4: A preoperative window-of-opportunity (WOO) study to assess the pharmacodynamic (PD) activity of amcenestrant or letrozole in postmenopausal patients with ER+/HER2− primary breast cancer. Congress:ASCO 2022, Search all connections
Abstract Effect of mevalonate pathway inhibitors on outcomes of patients (pts) with HER2-positive early breast cancer (BC) in the ALTTO trial. Congress:ASCO 2022, Search all connections
Abstract Subgroup analysis of patients with no prior chemotherapy in EMERALD: A phase 3 trial evaluating elacestrant, an oral selective estrogen receptor degrader (SERD), versus investigator’s choice of endocrine monotherapy for ER+/HER2-advanced/metastatic breast cancer (mBC). Congress:ASCO 2022, Search all connections
Abstract A phase IB/II study of nivolumab in combination with eribulin in HER2-negative metastatic breast cancer (KCSG BR18-16). Congress:ASCO 2022, Search all connections
Abstract Retrospective study to estimate the prevalence of HER2-low breast cancer (BC) and describe its clinicopathological characteristics. Congress:ASCO 2022, Search all connections
Abstract Survival outcomes in metastatic HR-positive, HER2-negative invasive ductal carcinoma compared to invasive lobular carcinoma and mixed ductal/lobular treated with endocrine therapy in combination with CDK4/6 inhibitors, mTOR inhibitor, or PI3K inhibitor. Congress:ASCO 2022, Search all connections
Abstract Hormone therapy (HT) or capecitabine (CAP) as maintenance therapy following the first-line chemotherapy in HR+/HER2-ABC/MBC: Secondary endpoint adverse effects (AEs) and toxicity report of OVERSTEP Trial (ZJCH15001/CBCSG 035). Congress:ASCO 2022, Search all connections
Abstract Dalpiciclib in combination with letrozole/anastrozole or fulvestrant in HR+/HER2- advanced breast cancer: A phase Ib study. Congress:ASCO 2022, Search all connections
Abstract Real-world efficacy of ribociclib (RIB) plus aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fourth interim analysis (IA) from RIBANNA. Congress:ASCO 2022, Search all connections
Abstract Identifying genetic factors of response and resistance to CDK4/6 inhibitors in metastatic HR+/HER2-breast cancer using real-world data. Congress:ASCO 2022, Search all connections
Abstract Clinical value of next-generation sequencing in endocrine therapy for advanced hormone receptor–positive/HER2-negative breast cancer. Congress:ASCO 2022, Search all connections
Abstract Longitudinal circulating tumor DNA (ctDNA) whole-exome sequencing (WES) in the phase Ib/II trial of palbociclib and bazedoxifene reveals genomic dynamics and clonal evolution with the acquisition of treatment resistance in hormone receptor-positive, HER2-negative (HR+ HER2-), advanced breast cancer (ABC). Congress:ASCO 2022, Search all connections
Abstract CDK4/6 inhibitors outcomes in patients with advanced breast cancer based on HER2-low expression. Congress:ASCO 2022, Search all connections
Abstract Long-term safety of inavolisib (GDC-0077) in an ongoing phase 1/1b study evaluating monotherapy and in combination (combo) with palbociclib and/or endocrine therapy in patients (pts) with PIK3CA-mutated, hormone receptor-positive/HER2-negative (HR+/HER2-) metastatic breast cancer (BC). Congress:ASCO 2022, Search all connections
Abstract Prognostic implications of HER2Neu-low in metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract Brain metastasis as first and only metastatic relapse site portends poor outcomes in patients with advanced HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Treatment patterns and their impact on the outcome of patients with HR+/HER2+ metastatic breast cancer in a large real-world cohort. Congress:ASCO 2022, Search all connections
Abstract Survival of elderly patients with HER2+/HR- metastatic breast cancer in clinical practice: SEER-Medicare data 2012-2016. Congress:ASCO 2022, Search all connections
Abstract Factors associated with short- and long-term survival in metastatic HER2+ breast cancer. Congress:ASCO 2022, Search all connections
Abstract Pyrotinib-based therapy for patients with HER2-positive breast cancer: A multicenter, real-world study. Congress:ASCO 2022, Search all connections
Abstract Matched FES and FDG PET imaging in patients with hormone receptor-positive, HER2+ advanced breast cancer. Congress:ASCO 2022, Search all connections
Abstract Early clinical safety and pharmacokinetics data of DZD1516, an BBB-penetrant selective HER2 inhibitor for the treatment of HER2-positive metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract The mutational profile of ER-, PR+, HER2- metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract Updated results and biomarker analyses from the phase I trial of A166 in patients with HER2-expressing locally advanced or metastatic solid tumors. Congress:ASCO 2022, Search all connections
Abstract Pyrotinib plus nab-paclitaxel in patients with HER2-positive advanced or metastatic breast cancer: A multicenter, single-arm, open-label phase 2 trial. Congress:ASCO 2022, Search all connections
Abstract Pyrotinib monotherapy or pyrotinib in combination with capecitabine could significantly prolong progression-free survival and overall survival in patients with HER2-positive metastatic breast cancer. Congress:ASCO 2022, Search all connections
Abstract Pyrotinib in combination with metronomic oral vinorelbine in patients with HER2-positive advanced breast cancer who had failed prior trastuzumab-based therapy: A single-center, single-arm, prospective phase 2 study. Congress:ASCO 2022, Search all connections
Abstract A phase II, single-arm, open label, Simon two-stage study of pembrolizumab in patients with metastatic HER2-negative breast cancer: Evaluation of impact of germline variants in APOBEC3B (AUROR). Congress:ASCO 2022, Search all connections
Abstract Serena-1: Updated analyses from a phase 1 study (parts C/D) of the next-generation oral SERD camizestrant (AZD9833) in combination with palbociclib, in women with ER-positive, HER2-negative advanced breast cancer. Congress:ASCO 2022, Search all connections
Abstract Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line (1L) therapy for patients (pts) with advanced HER2-positive breast cancer: Preliminary results from a phase 1b/2 study. Congress:ASCO 2022, Search all connections
Abstract Neratinib plus fulvestrant plus trastuzumab (N+F+T) for hormone receptor-positive (HR+), HER2-negative, HER2-mutant metastatic breast cancer (MBC): Outcomes and biomarker analysis from the SUMMIT trial. Congress:ASCO 2022, Search all connections
Abstract Preliminary results of a phase Ib/II combination study of RC48-ADC, a novel humanized anti-HER2 antibody-drug conjugate (ADC) with toripalimab, a humanized IgG4 mAb against programmed death-1 (PD-1) in patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract A phase II study of RC48-ADC in HER2-negative patients with locally advanced or metastatic urothelial carcinoma. Congress:ASCO 2022, Search all connections
Abstract RC48-ADC for metastatic urothelial carcinoma with HER2-positive: Combined analysis of RC48-C005 and RC48-C009 trials. Congress:ASCO 2022, Search all connections
Abstract Preliminary analysis of an expanded access study of the fixed-dose combination of pertuzumab (P) and trastuzumab (H) for subcutaneous injection (PH FDC SC) for at-home administration (admin) in patients (pts) with HER2-positive (HER2+) breast cancer (BC) during the COVID-19 pandemic. Congress:ASCO 2022, Search all connections
Abstract Open-label, phase 2, multicenter study of lasofoxifene (LAS) combined with abemaciclib (Abema) for treating pre- and postmenopausal women with locally advanced or metastatic ER+/HER2− breast cancer and an ESR1 mutation after progression on prior therapies. Congress:ASCO 2022, Search all connections
Abstract Quality of life (QOL) with ribociclib (RIB) plus aromatase inhibitor (AI) versus abemaciclib (ABE) plus AI as first-line (1L) treatment (tx) of hormone receptor-positive/human epidermal growth factor receptor–negative (HR+/HER2−) advanced breast cancer (ABC), assessed via matching-adjusted indirect comparison (MAIC). Congress:ASCO 2022, Search all connections
Abstract TX05-03e: Adjuvant treatment following neoadjuvant treatment and surgical resection in TX05-03, a trial comparing the safety, efficacy, and immunogenicity of trastuzumab biosimilar candidate (TX05) with originator trastuzumab in HER2+ EBC. Congress:ASCO 2022, Search all connections
Abstract Molecular subtype to predict pathologic complete response in HER2-positive breast cancer in the I-SPY2 trial. Congress:ASCO 2022, Search all connections
Abstract Prognostic and predictive implications of the intrinsic subtypes and gene expression signatures in early-stage HER2+ breast cancer: A pooled analysis of CALGB 40601, NeoALTTO, and NSABP B-41 trials. Congress:ASCO 2022, Search all connections
Abstract Impact of ribociclib (RIB) dose modifications (mod) on overall survival (OS) in patients (pts) with HR+/HER2- advanced breast cancer (ABC) in MONALEESA(ML)-2. Congress:ASCO 2022, Search all connections
Abstract Alpelisib (ALP) + endocrine therapy (ET) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2–), PIK3CA-mutated (mut) advanced breast cancer (ABC): Baseline biomarker analysis and progression-free survival (PFS) by duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy in the BYLieve study. Congress:ASCO 2022, Search all connections
Abstract Circulating tumor DNA (ctDNA) and late recurrence in high-risk, hormone receptor–positive, HER2-negative breast cancer (CHiRP). Congress:ASCO 2022, Search all connections
Abstract Efficacy and safety of zenocutuzumab, a HER2 x HER3 bispecific antibody, across advanced NRG1 fusion (NRG1+) cancers. Congress:ASCO 2022, Search all connections
Abstract Circulating tumor DNA (ctDNA) and serum thymidine kinase 1 activity (TKa) matched dynamics in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor 2–negative (HER2-) advanced breast cancer (ABC) treated in first-line (1L) with ribociclib (RIB) and letrozole (LET) in the BioItaLEE trial. Congress:ASCO 2022, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing unresectable or recurrent biliary tract cancer (BTC): An investigator-initiated multicenter phase 2 study (HERB trial). Congress:ASCO 2022, Search all connections
Abstract Overall survival (OS) with first-line palbociclib plus letrozole (PAL+LET) versus placebo plus letrozole (PBO+LET) in women with estrogen receptor–positive/human epidermal growth factor receptor 2–negative advanced breast cancer (ER+/HER2− ABC): Analyses from PALOMA-2. Congress:ASCO 2022, Search all connections
Abstract A randomized, phase II trial of fulvestrant or exemestane with or without ribociclib after progression on anti-estrogen therapy plus cyclin-dependent kinase 4/6 inhibition (CDK 4/6i) in patients (pts) with unresectable or hormone receptor–positive (HR+), HER2-negative metastatic breast cancer (MBC): MAINTAIN trial. Congress:ASCO 2022, Search all connections
Abstract Primary results from TROPiCS-02: A randomized phase 3 study of sacituzumab govitecan (SG) versus treatment of physician’s choice (TPC) in patients (Pts) with hormone receptor–positive/HER2-negative (HR+/HER2-) advanced breast cancer. Congress:ASCO 2022, Search all connections
Abstract Final results from a phase III randomized clinical trial of adjuvant endocrine therapy ± chemotherapy in women ≥ 70 years old with ER+ HER2- breast cancer and a high genomic grade index: The Unicancer ASTER 70s trial. Congress:ASCO 2022, Search all connections
Abstract Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial. Congress:ASCO 2022, Search all connections
Abstract Alpelisib (ALP) + fulvestrant (FUL) in patients (pts) with hormone receptor–positive (HR+), human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC): Biomarker (BM) analyses by next-generation sequencing (NGS) from the SOLAR-1 study. Congress:ASCO 2022, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) versus trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive (HER2+) unresectable and/or metastatic breast cancer (mBC): Safety follow-up of the randomized, phase 3 study DESTINY-Breast03. Congress:ASCO 2022, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) versus treatment of physician’s choice (TPC) in patients (pts) with HER2-low unresectable and/or metastatic breast cancer (mBC): Results of DESTINY-Breast04, a randomized, phase 3 study. Congress:ASCO 2022, Search all connections
Abstract Phase II trial of rifaximin in patients with early-stage HER2 positive breast cancer with gastrointestinal toxicities related to pertuzumab-based therapy. Clinical trial:MC18C3,Organization:Mayo Clinic,H. Lee Moffitt Cance...,Mayo Clinic Florida,Drug:pertuzumab,rifaximin,docetaxel, Search all connections
Abstract Real-world clinical outcomes in patients (pts) with HR+/HER2- metastatic breast cancer (mBC) treated with chemotherapy (CT) in the United States (US). Organization:Dana-Farber Cancer I...,University Hospitals...,Stanford University ...,Drug:CAPOX, Search all connections
Abstract Adjuvant therapy for HR+/HER2– early-stage breast cancer (EBC): Changes in practice patterns among community oncologists in Brazil. Organization:Oncoclínicas&Co,Oncoclinicas Group,Grupo Oncoclinicas,Drug:Tamoxifen, Search all connections
Abstract Quality care of patients with HR+/HER2- breast cancer: Insights from an implementation science program. Organization:PRIME Education LLC,Baylor University Me...,Texas Oncology,Drug:Lilly,Novartis,Target:HR+/HER2- breast can...,HR+/HER2-, Search all connections
Abstract Real world evidence for continuing HER2-directed therapy for metastatic breast cancer. Organization:BC Cancer-Vancouver ...,B.C. Cancer Agency,University of Toront...,Drug:Trastuzumab,pertuzumab,TDM-1, Search all connections
Abstract Defining the patient population with HER2-low breast cancer in Hawaii. Organization:University of Hawaii...,John A Burns School ...,Kapiolani Medical Ce...,Drug:HER2-directed antibo...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Assessment of HER2 status in extramammary Paget disease and its implication for disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC) therapy. Organization:Key Laboratory of Ca...,National Cancer Cent...,Department of Medica...,Drug:Disitamab vedotin,Tiragolumab, Search all connections
Abstract Pyrotinib plus antiangiogenic agents for HER2-altered advanced non-small cell lung cancer: A retrospective real-world study. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:pyrotinib,apatinib,Anlotinib, Search all connections
Abstract Prognostic effects of TP53 variants co-occuring in patients with HER2-mutated non-small cell lung cancer (NSCLC). Organization:Princess Margaret Ca...,University Health Ne...,Toronto, ON, Canada, Search all connections
Abstract Assessing the Discordance Rate of HER2 expression by Immunohistochemistry between Primary and Secondary Prostate Cancer Biopsies. Organization:Washington DC Vetera...,Washington DC VA Med...,The George Washingto...,Drug:VENTANA anti-HER2/ne...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Efficacy and safety of perioperative chemotherapy combined with tislelizumab and trastuzumab for HER2-positive resectable gastric/gastroesophageal junction cancer (GC/EGJC): Preliminary results of a phase 2, single-arm trial. Clinical trial:TIS-HER2GC-PERIOPERA...,Organization:First Affiliated Hos...,Department of Medica...,Anyang Tumor Hospita...,Drug:tislelizumab,Trastuzumab,docetaxel, Search all connections
Abstract A retrospective cohort study examining the effects of anti–PD-1 antibody in combination with apatinib in patients previously treated for HER2-negative advanced gastric/gastroesophageal junction cancer. Organization:Affiliated Cancer Ho...,Henan Cancer Hospita...,Zhengzhou, China,Drug:apatinib,Camrelizumab + Rivoc...,sintilimab, Search all connections
Abstract Clinical and molecular characterization of HER2-low metastatic colorectal cancer. Organization:Hadassah-Hebrew Univ...,Dana-Farber Cancer I...,Drug:HER2-directed antibo...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Prognosis of patients with HER2-low breast cancer brain metastasis: A single-institution experience. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Preliminary results of a phase I, first-in-human, dose escalation study of IMM2902 in patients with HER2-expressing advanced solid tumors. Organization:Phase I Clinical Tri...,Fudan University Sha...,Shanghai, China, Gra..., Search all connections
Abstract Negative selection of patients (pts) with HER2-positive and RAS wild-type (wt) metastatic colorectal cancer (mCRC) receiving dual HER2 blockade. Organization:Department of Medica...,Department of Gastro...,Memorial Sloan Kette..., Search all connections
Abstract A novel anti-HER2 monoclonal antibody IAH0968 in HER2-positive, heavily pretreated solid tumors: Results from a phase Ⅰa/Ⅰb, first-in-human, open-label, single-center study. Clinical trial:IAH0968-I/IIa,Organization:The First Hospital o...,Shenyang Sunshine Ph...,China National Biote...,Drug:IAH0968,Trastuzumab,Target:HER2 (ERBB2), Search all connections
Abstract Preclinical antitumor activity of an anti-HER2/Trop-2 bispecific antibody-drug conjugate with a new DNA topoisomerase I inhibitor. Organization:BiOneCure Therapeuti...,BiOneCure Therapeuti...,Drug:Enhertu,Sacituzumab goviteca...,BIO-201,Target:HER2 (ERBB2),Trop-2, Search all connections
Abstract A multicenter, phase II trial of RC48-ADC combined with radiotherapy, PD-1/PD-L1 inhibitor, GM-CSF, and sequential IL-2 (PRaG3.0 regimen) for salvage therapy in patients with HER2-expressing advanced solid tumors. Organization:Second Affiliated Ho...,Institution of Radio...,Soochow University,Drug:PRaG therapy,RC48-ADC,PD-1/L1 inhibitors, Search all connections
Abstract T cell redirecting and TLR7/8 agonist encapsulated liposomes targeting HER2+ tumors: Preclinical efficacy, pharmacokinetics and safety evaluations. Organization:Hangzhou Highfield B...,Clinical Trial Cente...,National Cancer Cent..., Search all connections
Abstract Human epidermal growth factor receptor 2/3 (HER2/HER3) expression in higher-grade meningioma. Organization:Medical University o...,Institute of Patholo...,Ruprecht-Karls Unive...,Congress:ASCO 2023, Search all connections
Abstract Electronic health record (EHR) and genomics-based machine learning (ML) to predict therapeutic effectiveness among patients with hormone-receptor positive (HR)+/HER2- advanced breast cancer (aBC). Organization:ConcertAI,Perelman School of M...,University of Pennsy...,Congress:ASCO 2023, Search all connections
Abstract Characteristics and predictive modeling of HER2 mutation in patients with non-small cell lung cancer. Organization:Mayo Clinic,John Theurer Cancer ...,City of Hope Nationa...,Drug:KRAS,EGFR-tyrosine kinase...,Product:TMZ, Search all connections
Abstract Nine-weeks versus one-year trastuzumab for early-stage HER2+ breast cancer: 10-year update of the Short-HER phase III randomized trial. Organization:University of Padua ...,Veneto Institute of ...,Arcispedale Santa Ma..., Search all connections
Abstract Trastuzumab-deruxtecan in HER2-low metastatic/unresectable breast cancer: Real life data in two Parisian centers. Organization:Hôpital Tenon,Institut Universitai...,Sorbonne Université, Search all connections
Abstract Prognosis factors for long-term eribulin response in a cohort of patients with HER2-negative metastatic breast cancer. Organization:Department of Oncolo...,CHU Besançon,Besançon,Drug:eribulin,Target:MDM2, Search all connections
Abstract Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer: A multi-center, open-label, single-arm, phase II study. Organization:The Fifth Affiliated...,The First Affiliated...,Zhuhai Hospital of l..., Search all connections
Abstract Potential therapeutic implications of next generation sequencing (NGS)-based molecular profiling in HR+/HER2- metastatic breast cancer (mBC). Organization:Medical Oncology Gro...,Azienda Ospedaliera ...,Medical Surgeon, Search all connections
Abstract Clinical characteristics and outcome of PIK3CA mutated hormone receptor positive (HR+), human epidermal growth factor 2 negative (HER2-), advanced breast cancer (BC) treated with cyclin-dependent kinase 4/6 inhibitors (CDK4/6i): Real world data. Organization:University Hospital ...,Clinical Hospital Ce...,Drug:Alpelisib,fulvestrant,CDK4/6i,Target:CDK6,Estrogen Receptor (E...,PIK3CA, Search all connections
Abstract Sustained prognostic impact of primary tumor characteristics on long-term (overall) survival after distant metastasis in young ER+ HER2- breast cancer. Organization:Department of Surger...,Dongtan Sacred Heart...,Hallym University, Search all connections
Abstract The real-world modeling of benefits demonstrated in major clinical trials on 2 HR+/HER2− metastatic breast cancer treatment with CDK4/6 inhibitor in the US: PALOMA-2 and MONALEESA-3. Organization:University of Virgin...,Duke University Medi...,University of Virgin...,Drug:CDK4/6 inhibitors,letrozole,fulvestrant,Target:CDK6,Estrogen Receptor (E..., Search all connections
Abstract Treatment patterns and clinical outcomes following endocrine resistance among with HER2-low metastatic breast cancer: Retrospective observational study. Organization:Daiichi Sankyo Inc.,Basking Ridge, NJ,NJ, Search all connections
Abstract Incidence and outcomes among patients with HR+/HER2- metastatic breast cancer (mBC) with co-occurring ESR1 and PIK3CA mutations detected by ctDNA and treated with alpelisib: A retrospective review. Organization:Miami Cancer Institu...,Baptist Health South...,Flare Therapeutics, Search all connections
Abstract Clinicopathological characteristics, evolution, treatment patterns and outcomes of hormone-receptor-positive/HER2-low-positive metastatic breast cancer: A retrospective analysis. Organization:Department of Breast...,Fudan University Sha...,Drug:endocrine therapy,Cisplatin,Target:HER2 (ERBB2),Hormone receptors,Congress:ASCO 2023, Search all connections
Abstract Comparative effectiveness of palbociclib plus aromatase inhibitor versus fulvestrant alone as initial endocrine therapy for HR+/HER2- advanced breast cancer in Chinese clinical practice: A real-world study. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital, Chi..., Search all connections
Abstract The association between baseline patient characteristics and alpelisib-induced hyperglycaemia in patients with HR+, HER2-, PIK3CA-mutated metastatic breast cancer. Organization:Faculty of Health, M...,Maastricht Universit...,Institute of Oncolog...,Drug:Alpelisib,fulvestrant,Target:Estrogen Receptor (E...,PI3Kα, Search all connections
Abstract Efficacy of abemaciclib versus tucidinostat after progression on palbociclib in patients with HR+/HER2− MBC: A multicenter retrospective cohort study. Organization:Fudan University Sha...,Sun Yat-sen Universi...,The First Hospital o..., Search all connections
Abstract BPI-16350, a novel promising CDK4/6 inhibitor for HR+/HER2- metastatic breast cancer (MBC): Results from a phase I study. Organization:Phase I Clinical Tri...,Fudan University Sha...,Shanghai, China, Gra..., Search all connections
Abstract Open-label phase II study of everolimus plus endocrine therapy in postmenopausal women with ER+, HER2- metastatic breast cancer (Chloe trial). Organization:National Center for ...,Teine Keijinkai Hosp...,Kansai Medical Unive..., Search all connections
Abstract Real-world efficacy of ribociclib (RIB) + aromatase inhibitor (AI)/fulvestrant (FUL), or endocrine monotherapy (ET), or chemotherapy (CT) as first-line (1L) treatment (tx) in elderly patients (pts; > 75 years) with hormone receptor–positive (HR+), human epidermal growth factor receptor-2–negative (HER2–) advanced breast cancer (ABC): Results of fifth interim analysis (IA) from RIBANNA. Organization:Onkologie Ravensburg,University Women’s H...,Paracelsus Medical U..., Search all connections
Abstract Time to treatment failure (TTF) and overall survival (OS) with palbociclib (PAL) plus endocrine therapy (ET) versus ET in HR+/HER2- advanced breast cancer (ABC) patients: A real-world multicenter study from China. Organization:Department of Oncolo...,Breast Center, The A...,Department of Medica...,Drug:PAL plus ET, Search all connections
Abstract Impact of use of CDK4/6i and neratinib among patients with HER2 +ve MBC: Results from a real world dataset. Organization:Mediclinic City Hosp...,TriNetX Europe,Drug:CDK4/6i,neratinib,Trastuzumab, Search all connections
Abstract ERBB2 (HER2) gene amplification concordance analysis of circulating tumor cells and tumor tissue in patients with breast cancer. Organization:UC San Diego Moores ...,Biofluidica,Biomatrica, Inc.,Drug:HER2 monoclonal anti...,HER2 tyrosine kinase...,HER2 antibody drug c...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Use of PARPi among patients with HER2+ve MBC: Results from a real world dataset. Organization:Mediclinic City Hosp...,TriNetX Europe,Drug:PARPi,olaparib,Target:BRCA1,BRCA2,Congress:ASCO 2023, Search all connections
Abstract Comparing digital and glass slide methods for determining the HER2-low and negative categories in breast cancer. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C..., Search all connections
Abstract De novo metastatic Her2+ breast cancer in a diverse population of women under age 40. Organization:Ochsner Medical Cent...,Ochsner Health Syste...,Ochsner Health Cente...,Drug:Her2-directed therap...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Pyrotinib maleate for the treatment of brain metastases from HER2-positive solid tumours: A real-world study. Organization:Beijing Tian Tan Hos...,Capital Medical Univ...,Beijing InnoCare Pha...,Drug:pyrotinib,pyrrolizidine,Target:HER2 (ERBB2),HER1,HER4, Search all connections
Abstract A disease registry study to prospectively observe treatment patterns and outcomes in patients with HER2+ unresectable locally advanced or metastatic breast cancer (aBC): Interim results of the ESTHER study (NCT02393924). Organization:Roche Products Limit...,Cmed Clinical Resear...,Leeds Institute of M..., Search all connections
Abstract Real-world outcomes of long-term efficacy of T-DM1 after discontinuation due to limiting toxicity in patients with HER2-positive metastatic breast cancer. Organization:Hospital Beneficênci...,Drug:T-DM1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Safety and efficacy study of oral metronomic capecitabine in combination with pyrotinib for HER2‑positive metastatic breast cancer: A phase II trial. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:CAPOX,pyrotinib,Target:HER2 (ERBB2), Search all connections
Abstract ADC vs HP dual-antibody for HER2-positive advanced breast cancer after failed to TKI. Organization:Department of Oncolo...,The Fifth Medical Ce...,Fifth Medical Center...,Drug:TKI,ARX788, Search all connections
Abstract Real-life experience of trastuzumab deruxtecan (T-DXd) in patients with heavily pretreated HER2 positive advanced breast cancer: A retrospective single institution study. Organization:University of Califo...,UC Irvine Health,Chao Family Comprehe...,Drug:Tucatinib,Trastuzumab, Search all connections
Abstract Effect of suppressing the p38 pathway through upregulation of Wip1 on Her2 early dissemination of breast cancer. Organization:Wake Forest Baptist ...,Tianjin Medical Univ...,Drug:HER2 CAR-T,Wip1,Skp2,Target:Skp2,Wip1,MK2, Search all connections
Abstract Construction of a prognostic hierarchical model for patients with HER2 positive breast cancer with brain metastases. Organization:The Fifth Medical Ce...,Chinese PLA General ...,Fujian Provincial Ke...,Drug:Trastuzumab,pertuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Combination of eribulin with trastuzumab and pertuzumab for HER2 positive advanced or recurrent breast cancer: JBCRGM03. Organization:Kanagawa Cancer Cent...,Matsuyama Red Cross ...,Nagoya University Gr..., Search all connections
Abstract Retrospective registry of patients with locally advanced/metastatic HR+/HER2− breast cancer treated in clinical practice in Andalusia. Organization:Hospital de Jerez de...,Hospital Universitar...,H. Virgen de las Nie..., Search all connections
Abstract Preliminary analysis of pyrotinib and dalpiciclib-based therapy in HER2-positive advanced breast cancer (ABC). Organization:Shandong Cancer Hosp...,Shandong University ...,Jinan, China, Search all connections
Abstract Identifying the optimal therapeutics for patients with hormone receptor-positive, HER2-positive advanced breast cancer: A systematic review and network meta-analysis. Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital of C...,Drug:endocrine therapy,Trastuzumab,pertuzumab, Search all connections
Abstract Radiotherapy combined with pyrotinib plus capecitabine in patients with human epidermal growth factor receptor 2 (HER2)-positive breast cancer and brain metastases: A single-arm, exploratory trial. Organization:Department of Radiot...,Department of Breast...,Department of Breast...,Drug:pyrotinib,CAPOX,Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Circulating tumor cells in patients with hormone receptor-positive, HER2-negative metastatic breast cancer receiving palbociclib with fulvestrant after progression on palbociclib with an aromatase inhibitor. Clinical trial:J15212,Organization:Sidney Kimmel Compre...,Johns Hopkins Univer...,RPS Hematology Oncol..., Search all connections
Abstract De-escalating therapy dilemma in small HER2 positive node negative breast cancer. Organization:Centre Oscar Lambret,Drug:Trastuzumab,anthracyclines,taxanes,Target:HER2 (ERBB2),taxanes,Congress:ASCO 2023, Search all connections
Abstract Incidence of hypomagnesemia in patients with HER2+ breast cancer treated with pertuzumab. Organization:University of Florid...,University of Florid...,Drug:pertuzumab,Trastuzumab,cetuximab,Target:HER2 (ERBB2),EGFR-TKI sensitizing..., Search all connections
Abstract Decreased HER2 expression in residual disease following neoadjuvant therapy in patients with HER2-positive breast cancer. Organization:Yale-New Haven Healt...,Yale University Scho...,Drug:Trastuzumab,pertuzumab,ado trastuzumab emta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Neoadjuvant tucidinostat combined with chemotherapy for hormone receptor-positive, HER2-negative breast cancer. Organization:Department of Oncolo...,Shengjing Hospital o...,Department of Breast...,Drug:Tucidinostat,exemestane,epirubicin, Search all connections
Abstract Combined role of the neutrophil/lymphocyte ratio and Neo-Bioscore in neoadjuvant therapy in HER2-positive early breast cancer. Organization:Hospital Juan Ramón ...,Hospital Juan Ramon ...,Aodo Asociación Onub...,Drug:pertuzumab,Trastuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis. Organization:Universidade Estadua...,Princess Margaret Ho...,Division of Medical ...,Drug:veliparib,olaparib, Search all connections
Abstract Efficacy and safety of neoadjuvant double anti-Her2 blockade combined with anthracycline-free chemotherapy in locally advanced breast cancer. Organization:Hospital Juan Ramón ...,Hospital Juan Ramon ...,Juan Ramón Jiménez H...,Drug:TCHP,Filgrastim,pegfilgrastim, Search all connections
Abstract INSIGHT-HER2BC: Real-world evidence of TCHP regimen to describe the best patient profile and open up questions—The interim results. Organization:Moscow Clinical Scie...,Moscow Oncology City...,SBIH Municipal Clini...,Drug:docetaxel,carboplatin,Trastuzumab, Search all connections
Abstract Neoadjuvant stereotactic body radiotherapy plus dalpiciclib and exemestane for hormone receptor-positive, HER2-negative breast cancer. Clinical trial:BC-NEO-IIT-SHR1316-S...,Organization:Department of Oncolo...,Jiangsu Hengrui Phar...,Drug:dalpiciclib,exemestane,LHRH agonist,Target:CDK4/6,Gonadotropin-releasi..., Search all connections
Abstract Multi-omic subtyping and molecular determinants of neoadjuvant therapeutic regimen for locally advanced HER2-positive and triple-negative breast cancer: Implications of novel therapy. Organization:Department of Breast...,Guangdong Provincial...,Department of Breast...,Drug:Cisplatin, Search all connections
Abstract Racial disparity in the clinical outcomes of HER2-low and HER2-zero early-stage breast cancer. Organization:Roswell Park Compreh...,Buffalo, NY,Drug:neoadjuvant chemothe...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Neoadjuvant inetetamab combined with pertuzumab, paclitaxel, and carboplatin (TCbIP) for locally advanced HER2-positive breast cancer: Primary analysis of a phase II study. Clinical trial:IPNCb-01,Organization:National Cancer Cent...,National Clinical Re...,Cancer Hospital, Chi...,Drug:Inetetamab,pertuzumab, Search all connections
Abstract Phase II neoadjuvant trial of albumin-bound paclitaxel, trastuzumab and pertuzumab followed by anthracycline based regimens in patients with operable HER2 positive breast cancer (OMC-BC05). Organization:Department of Breast...,Osaka Medical and Ph...,Department of Rehabi..., Search all connections
Abstract Informative tools to optimize neoadjuvant therapy in ER positive, HER2 negative breast cancers. Organization:BC Cancer Vancouver,Vancouver General Ho...,BC Cancer-Vancouver ...,Drug:Oncotype DX, Search all connections
Abstract Methods for selection of neoadjuvant treatment with chemotherapy for patients with hormone receptor-positive and HER2-negative with early breast cancer. Organization:Hospital Universitar...,Hospital Universitar...,GEICAM Spanish Breas...,Congress:ASCO 2023, Search all connections
Abstract Role of plasma circulating HER2/EFTUD2 ratio in predicting pathological complete response (pCR) after neoadjuvant dual anti-HER2 therapy in HER2-positive breast cancer (HER2+ BC). Organization:Department of Clinic...,Department of Clinic...,Departments of Clini...,Drug:Trastuzumab,pertuzumab,taxane, Search all connections
Abstract Defendor special: Interim analysis of TCHP with primary empegfilgrastim prophylaxis (long-acting G-CSF) for treatment outcomes in early HER2+ breast cancer. Organization:Moscow Clinical Scie...,Russian Cancer Resea...,Drug:docetaxel,carboplatin,Trastuzumab, Search all connections
Abstract Clinical and biological heterogeneity in triple-negative breast cancer and HER2-low. Organization:Tangdu Hospital,Air Force Medical Un...,Xi'an, China,Congress:ASCO 2023, Search all connections
Abstract In search for new targets: Differences of HER2 receptor expression between CNB and synchronous axillary lymph node metastases in 205 patients. Organization:University of Leipzi...,Department of Gyneco...,Division of Breast S...,Drug:HER2 CAR-T,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Clinicopathologic features of early stage HER2-low breast cancer. Organization:Comprehensive Hemato...,St. Petersburg, FL,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Prevalence of low HER2 expression in breast cancer patients: An Indian experience. Organization:All India Institute ...,Department of Surgic...,Department of Radiat...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Clinical-pathological characterization of patients with HER2 negative breast cancer submitted to adjuvant docetaxel/cyclophosphamide (TC), TC4 versus TC6. Organization:A.C. Camargo Cancer ...,Drug:docetaxel,cyclophosphamide,Target:docetaxel,Congress:ASCO 2023, Search all connections
Abstract Lowering the bar for consideration of neoadjuvant chemotherapy in early-stage HER2-positive breast cancers. Organization:Henry Ford Cancer In...,Henry Ford Health Sy...,Drug:ado-trastuzumab emta...,TDM-1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Real world treatment patterns and survival by germline BRCA (gBRCA) mutation status in patients with HER2-negative early breast cancer (eBC) in the US community oncology setting: A retrospective observational study. Organization:Compass Oncology,Merck & Co., Inc.,Ontada,Drug:olaparib,Target:PARP,Congress:ASCO 2023, Search all connections
Abstract Nomograms for predicting survival in patients with HER2 negative breast cancer. Organization:Shandong Cancer Hosp...,Shandong First Medic...,Shandong Academy of ...,Congress:ASCO 2023, Search all connections
Abstract HR+/HER2- Breast cancer: The effect of online education on clinician knowledge, competence, and confidence in monitoring, mitigating toxicities, and developing patient-centric plans using a team-based approach. Organization:Medscape Oncology,Carrollton, TX,Medscape LLC,Drug:CDK4/6 inhibitors,Target:CDK6,CDK4 & 6,Congress:ASCO 2023, Search all connections
Abstract Exosome-based delivery of microRNAs to confer adriamycin-resistance to sensitive cells through modulating the immune- and metabolism-related gene PTEN in HER2-negative breast cancer. Organization:Department of Genera...,The First Affiliated...,Drug:anthracyclines,doxorubicin,Target:PTEN,Congress:ASCO 2023, Search all connections
Abstract Role of chemotherapy in early-stage hormone receptor positive HER2-negative (HR+) breast cancer patients with variant histology. Organization:Roswell Park Compreh...,University of Buffal...,University of Massac...,Drug:Cisplatin,Target:cancer cells,DNA,Congress:ASCO 2023, Search all connections
Abstract Side effects and impacts of extended adjuvant endocrine therapy: A qualitative study among women with HR+/HER2- breast cancer. Organization:RTI Health Solutions,Sanofi,University of North ...,Drug:endocrine therapy,Target:Hormone receptors,Congress:ASCO 2023, Search all connections
Abstract Cardiac safety of reduced surveillance for cancer therapy related cardiac dysfunction in patients with breast cancer treated with HER2-targeted therapy. Organization:Memorial Sloan Kette...,Hartford Healthcare ...,Hartford Healthcare ...,Drug:Tiragolumab,Trastuzumab,pertuzumab, Search all connections
Abstract PEPN1924, a phase 2 study of trastuzumab deruxtecan (DS-8201a, T-DXd) in adolescents and young adults with recurrent HER2+ osteosarcoma: A Children’s Oncology Group Pediatric Early-Phase Clinical Trial Network study. Clinical trial:NCI-2020-08428,Organization:H. Lee Moffitt Cance...,Dana-Farber Cancer I...,Institute for Clinic..., Search all connections
Abstract Association of Medicaid expansion with timely receipt of treatment and survival among patients with HER2-enriched breast cancer. Organization:American Cancer Soci...,Atlanta Cancer Care,Galderma R&D, Search all connections
Abstract Safety and efficacy of inetetamab in combination with pyrotinib in HER2 mutant patients with non-small cell lung cancer (NSCLC): An open-label, phase Ib trial. Organization:Department of Medica...,Sun Yat-sen Universi...,State Key Laboratory..., Search all connections
Abstract Prognostic and predictive implications of plasma ctDNA in guiding first-line targeted therapy for metastatic HER2-mutant non-small cell lung cancer (NSCLC). Organization:Memorial Sloan Kette...,Resolution Bioscienc...,Agilent,Drug:trastuzumab deruxtec...,pembrolizumab,trastuzumab-emtansin...,Target:HER2 (ERBB2),PD-1, Search all connections
Abstract Analytical and clinical validation of Oncomine Dx Target (ODxT) test and local testing for identifying patients with HER2 (ERBB2)-mutant (HER2m) non–small-cell lung cancer (NSCLC) for treatment with trastuzumab deruxtecan (T-DXd) in DESTINY-Lung01/02 (DL-01/02). Organization:Memorial Sloan Kette...,New York, NY,Netherlands Cancer I..., Search all connections
Abstract Phase I Beamion Lung 1 trial of BI 1810631, a HER2 tyrosine kinase inhibitor (TKI), as monotherapy in patients (pts) with advanced/metastatic solid tumors with HER2 aberrations: Updated data. Clinical trial:1479-0001,Organization:MD Anderson Cancer C...,Department of Clinic...,The Netherlands Canc..., Search all connections
Abstract Disitamab vedotin, a novel humanized anti-HER2 antibody-drug conjugate (ADC), combined with toripalimab in patients with locally advanced or metastatic urothelial carcinoma: An open-label phase 1b/2 study. Organization:Peking University Ca...,Peking University Fi...,Affiliated Drum Towe..., Search all connections
Abstract Alliance A022102: Randomized phase III trial of mFOLFIRINOX +/- nivolumab vs. FOLFOX +/- nivolumab for first-line treatment of metastatic HER2-negative gastroesophageal adenocarcinoma (GEA). Clinical trial:A022102,Organization:Dana-Farber Cancer I...,Alliance Statistics ...,Mayo Clinic, Search all connections
Abstract Phase 2 trial of zolbetuximab in combination with mFOLFOX6 and nivolumab in patients with advanced or metastatic claudin 18.2-positive, HER2-negative gastric or gastroesophageal junction adenocarcinomas. Clinical trial:8951-CL-0103,Organization:National Cancer Cent...,Society for Immunoth...,The Cancer Institute...,Drug:zolbetuximab, Search all connections
Abstract Trastuzumab (T) plus gemcitabine-cisplatin (GC) for treatment naïve HER2 positive biliary tract adenocarcinomas (BTC): A multicentre open-label, phase II study (TAB). Organization:Tata Memorial Hospit...,Tata Memorial Centre,Homi Bhabha cancer h...,Drug:FF-10832,Cisplatin,Trastuzumab,Target:TERT, Search all connections
Abstract Final survival results of ipilimumab or FOLFOX in combination with nivolumab and trastuzumab in previously untreated HER2 positive esophago gastric adenocarcinoma: The randomized AIO INTEGA trial. Organization:University Cancer Ce...,University Medical C...,Hämatologisch-Onkolo..., Search all connections
Abstract MOUNTAINEER-03: Phase 3 study of tucatinib, trastuzumab, and modified FOLFOX6 as first line treatment in HER2+ metastatic colorectal cancer. Clinical trial:SGNTUC-017,Organization:Mayo Clinic,University Hospitals...,KU Leuven, Search all connections
Abstract Efficacy and safety of KN026 in combination with KN046 in patients with locally advanced unresectable or metastatic HER2-positive other solid tumors. Organization:Beijing Cancer Hospi...,Cancer Hospital of S...,Central Hospital Aff..., Search all connections
Abstract Impact of HER2 assay sensitivity on the ability to detect tumors with low to ultra-low HER2 expression: A TMA study on more than 10,000 tumors from more than 100 tumor entities. Organization:University Medical C...,Institute of Patholo...,Academic Hospital Fu...,Drug:HercepTest,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Evolution of HER2 scores after neoadjuvant systemic therapy in breast cancer. Organization:Loma Linda Universit...,Loma Linda Universit...,Division of Medical ...,Drug:antibody-drug conjug...,Target:HER2 (ERBB2), Search all connections
Abstract Exploring expression levels of HER2, HER3, MET, Claudin18.2, and MUC16 across 16 cancer types using an artificial intelligence-powered immunohistochemistry analyzer. Organization:Oncology Therapeutic...,Lunit Inc.,Samsung Medical Cent...,Drug:Muc16CD,CLDN18.2, Search all connections
Abstract Trastuzumab emtansine (T-DM1) in advanced cancers with HER2 mutations or amplification: Results from the Molecular Screening and Therapeutics (MoST) Program substudy. Organization:NHMRC Clinical Trial...,The University of Sy...,Sydney, NSW, Austral..., Search all connections
Abstract Tolerability and preliminary activity of the potent, selective, oral CDK7 inhibitor SY-5609 in combination with fulvestrant in patients with advanced hormone receptor-positive (HR+), HER2- breast cancer (BC). Clinical trial:SY-5609-101,Organization:Massachusetts Genera...,Harvard Medical Scho...,Boston, MA, Search all connections
Abstract Liquid biopsy identification of ERBB2 amplified and HER2 expressing metastatic breast cancer: Comparison and combination of cell and cell-free platforms. Organization:Epic Sciences, Inc.,Renown Health-Pennin...,Congress:ASCO 2023, Search all connections
Abstract FS-1502 in HER2-positive advanced breast cancer: Results from an open-label, phase 1 study. Clinical trial:FS-CY1502-Ph1-01,Organization:Beijing Fosun Pharma...,Shanghai Fosun Pharm...,Fosun Pharma USA, In...,Drug:FS-1502,Trastuzumab,pertuzumab, Search all connections
Abstract A first-in-human, open label, multiple dose, dose escalation, and cohort expansion phase I study to investigate the safety, tolerability, pharmacokinetics and antitumor activity of BB-1701 in patients with locally advanced/metastatic HER2-expressing solid tumors. Clinical trial:BB-1701-101,Organization:Cancer Hospital of C...,Chinese Academy of M...,Beijing, China, Search all connections
Abstract Final analysis of multi-histology basket trial expansion of ado-trastuzumab emtansine in patients with HER2 amplified cancers. Clinical trial:15-335,Organization:Memorial Sloan Kette...,Weill Cornell Medica...,Drug:Ado-Trastuzumab emta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract A phase 1, first-in-human (FIH) study of autologous macrophages engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants (pts) with HER2-overexpressing solid tumors. Organization:City of Hope Compreh...,University of Texas ...,The Sarah Cannon Res..., Search all connections
Abstract Efficacy and safety of IBI110 in combination with sintilimab in first-line advanced HER2-negative gastric cancer or gastroesophageal junction cancer: Updated results from a phase Ib study. Organization:Innovent Biologics, ...,Drug:sintilimab,mFOLFOX6,CAPOX,Target:PD-1,LAG-3, Search all connections
Abstract A phase 1/2 study of a first-in-human immune-stimulating antibody conjugate (ISAC) BDC-1001 in patients with advanced HER2-expressing solid tumors. Clinical trial:BBI-20201001,Organization:Memorial Sloan Kette...,Stanford University ...,Seoul National Unive..., Search all connections
Abstract A systematic review and meta-analysis of intrathecal versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases. Organization:Université de Montré...,McGill University He...,Department of Medica..., Search all connections
Abstract Correlation between Oncotype DX, Predict, and Nottingham Prognostic Index on HR+, HER2- early breast cancer treatment: The current value of molecular testing. Organization:University of Miami ...,Ecua-american Labora...,Hospital de los Vall...,Drug:ODX,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Cost-effectiveness of trastuzumab deruxtecan in HER2 low metastatic breast cancer. Organization:Stanford Hospital & ...,Department of Manage...,Stanford University ...,Drug:trastuzumab deruxtec...,physician's choice c...,trastuzumab-deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Impact of geography on receipt of medical oncology consultation and neoadjuvant chemotherapy for triple negative and HER2 positive breast cancer. Organization:University of Toront...,Odette Cancer Centre,Sunnybrook Health Sc...,Drug:neoadjuvant chemothe...,placebo,Target:HER2 (ERBB2), Search all connections
Abstract A single-arm phase 2 study of peri-operative immune checkpoint inhibition and cryoablation in women with hormone receptor-negative, HER2-negative, early-stage/resectable breast cancer. Clinical trial:IIT2018-01-McArthur-...,Organization:University of Texas ...,Memorial Sloan Kette...,CLION-CAM Group, Search all connections
Abstract Neoadjuvant HER2-targeted therapy +/- immunotherapy with pembrolizumab (neoHIP): An open label randomized phase II trial. Clinical trial:IIT2018-04-MCARTHUR-...,Organization:University of Texas ...,Clion - CAM Group,Cedars-Sinai Medical..., Search all connections
Abstract A phase II study of concurrent WOKVAC vaccination with neoadjuvant chemotherapy and HER2-targeted monoclonal antibody therapy. Clinical trial:RG1005296,Organization:University of Washin...,Cancer Vaccine Insti...,University of Washin...,Drug:Trastuzumab,pertuzumab,WOKVAC,Target:HER2 (ERBB2), Search all connections
Abstract Phase 1 dose-escalation, dose-expansion trial of intratumoral HER2- and HER3-primed dendritic cells injections for the treatment of early-stage TNBC and HR low positive breast cancer: DecipHER trial. Clinical trial:MCC-20897,Organization:H. Lee Moffitt Cance...,H. Lee Moffit Cancer...,Drug:KEYNOTE 522,Target:PD-L1,PD-1,Congress:ASCO 2023, Search all connections
Abstract ORACLE-RIPA study: A phase II, randomized, open-label, parallel-group study comparing the immune modulation effect of neoadjuvant ribociclib, palbociclib, and abemaciclib in early ER+/HER2- breast cancer. Organization:National Taiwan Univ...,National Taiwan Univ...,Drug:ribociclib,palbociclib,abemaciclib,Target:CDK6,CDK4 & 6,Congress:ASCO 2023, Search all connections
Abstract A randomized phase 2 non-inferiority trial of (Z)-endoxifen and exemestane + goserelin as neoadjuvant treatment for premenopausal women with ER+/HER2- breast cancer (EVANGELINE). Clinical trial:ATOS-Z-201,Organization:Mayo Clinic,Rochester, MN,Phoenix, AZ, Search all connections
Abstract Metformin with neoadjuvant chemotherapy in localized triple negative and HER2neu-positive breast cancer: A prospective phase 2 open label randomised controlled trial (McBETH). Organization:All India Institute ...,Dr. Brairch,NCI AIIMS,Drug:Metformin,Target:IGF-2,mTORC1,IGF-1R, Search all connections
Abstract NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery (BCS) of stage 1, HR+, HER2-, RS ≤18 breast cancer. Clinical trial:NRG-BR007,Organization:University of Kansas...,NRG Oncology SDMC,The University of Pi..., Search all connections
Abstract DIRECT2: A randomized phase III trial with a fasting mimicking diet program to improve chemotherapy in patients with hormone receptor positive, HER2-negative breast cancer—A Dutch Breast Cancer Research Group study (BOOG). Organization:Leiden University Me...,Psychosocial Researc...,Netherlands Cancer I..., Search all connections
Abstract A phase II single-arm, open-label trial of T-DM1 (ado-trastuzumab emtansine) and neratinib for HER2-positive breast cancer with molecular residual disease (KAN-HER2 MRD). Organization:Division of Medical ...,Department of Medici...,Princess Margaret Ca..., Search all connections
Abstract LESS: Single-arm study to de-escalate adjuvant endocrine therapy duration in post-menopausal women with HR+ HER2- early-stage breast cancer at very low risk of metastasis. Clinical trial:UC-BCG-2103,Organization:Centre Hospitalier U...,Office of Biostatist...,Groupe Hospitalier M..., Search all connections
Abstract Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in breast cancer patients with residual disease or high-risk PCR after both neoadjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01. Clinical trial:GLSI-21-01,Organization:Greenwich LifeScienc...,Stafford, TX,Lester and Sue Smith...,Drug:GP2, Search all connections
Abstract lidERA Breast Cancer (BC): Phase III adjuvant study of giredestrant vs. physician’s choice of endocrine therapy (PCET) in patients (pts) with estrogen receptor-positive, HER2-negative early BC (ER+, HER2– eBC). Clinical trial:GO42784,Organization:NSABP Foundation and...,Massachusetts Genera...,Breast Center, Depar..., Search all connections
Abstract Ribociclib (RIB) vs. palbociclib (PAL) in patients (pts) with hormone receptor-positive/HER2-negative/HER2-enriched (HR+/HER2-/HER2-E) advanced breast cancer (ABC): A head-to-head phase III study—HARMONIA SOLTI-2101/AFT-58. Clinical trial:SOLTI-2101,Organization:SOLTI Cancer Researc...,Ohio State Universit...,Novartis Pharmaceuti..., Search all connections
Abstract A phase 1b/2 dose escalation and expansion study of OP-1250 in combination with ribociclib or alpelisib in patients with advanced and/or metastatic estrogen receptor–positive (ER+)/HER2-negative (HER2-) breast cancer. Clinical trial:OP-1250-003,Organization:University of Colora...,Breast Cancer Resear...,Dana-Farber Cancer I...,Drug:Palazestrant,ribociclib, Search all connections
Abstract Harnessing olaparib, palbociclib, and endocrine therapy: A phase I/II trial of olaparib, palbociclib and fulvestrant in patients with BRCA mutation-associated, hormone receptor-positive, human epidermal growth factor receptor 2 (HER2)-negative metastatic breast cancer (HOPE). Clinical trial:UPCC 21118,Organization:University of Pennsy...,Philadelphia, PA,University of Pennsy..., Search all connections
Abstract INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–) PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC). Organization:Massachusetts Genera...,Harvard Medical Scho...,Winship Cancer Cente..., Search all connections
Abstract UCLA B-13: A phase 1b trial evaluating the safety of ribociclib, tucatinib, and trastuzumab in patients with metastatic, HER2+ breast cancer and a multicenter, randomized, open-label, phase 2 study of preoperative treatment with ribociclib, trastuzumab, tucatinib, with or without fulvestrant versus docetaxel, carboplatin, trastuzumab, and pertuzumab in HR+/HR-, HER2+ breast cancer. Organization:David Geffen School ...,Congress:ASCO 2023, Search all connections
Abstract EPIK-B6: A phase 2, open-label, 2-part, multicenter study of alpelisib in combination with fulvestrant for men and postmenopausal women with PIK3CA mutation HR–positive, HER2-negative, advanced breast cancer, which progressed on/after aromatase inhibitor treatment in Japan. Organization:Novartis Pharmaceuti...,Novartis Pharma K.K.,Drug:Alpelisib,fulvestrant,Target:Estrogen Receptor (E...,PIK3CA,Congress:ASCO 2023, Search all connections
Abstract CAPTOR-BC: Comprehensive analysis of spatial, temporal and molecular biomarkers predicting response and resistance to first-line treatment with ribociclib + ET in HR+, HER2- advanced breast cancer. Clinical trial:IFG-01-2022,Organization:Erlangen University ...,Department of Gyneco...,Comprehensive Cancer..., Search all connections
Abstract evERA Breast Cancer (BC): Phase III study of giredestrant + everolimus vs exemestane + everolimus in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced or metastatic BC (ER+, HER2– LA/mBC). Clinical trial:ML43171,Organization:Dana-Farber Cancer I...,UPMC Hillman Cancer ...,University of Pittsb..., Search all connections
Abstract A phase 3 study of gedatolisib plus fulvestrant with and without palbociclib in patients with HR+/ HER2- advanced breast cancer previously treated with a CDK4/6 inhibitor plus a nonsteroidal aromatase inhibitor (VIKTORIA-1). Clinical trial:CELC-G-301,Organization:David Geffen School ...,University of Califo...,Jonsson Comprehensiv..., Search all connections
Abstract VERITAC-2: A global, randomized phase 3 study of ARV-471, a proteolysis targeting chimera (PROTAC) estrogen receptor (ER) degrader, vs fulvestrant in ER+/human epidermal growth factor receptor 2 (HER2)- advanced breast cancer. Clinical trial:C4891001,Organization:Institut de Cancérol...,Washington Universit...,Istituto Nazionale T..., Search all connections
Abstract A phase 1, first-in-human, open label, escalation and expansion study of ORM-5029, a highly potent GSPT1 degrader targeting HER2, in patients with HER2-expressing advanced solid tumors. Organization:Sarah Cannon Researc...,Tennessee Oncology, ...,NEXT Oncology - Virg..., Search all connections
Abstract Phase I study of adoptive T cell therapy following HER2-pulsed dendritic cell vaccine and pepinemab/trastuzumab in patients with metastatic HER2-positive breast cancer (MBC). Clinical trial:MCC-21378,Organization:H. Lee Moffitt Cance...,Vaccinex, Inc.,Drug:Trastuzumab,pepinemab,Target:HER2 (ERBB2),SEMA4D,Congress:ASCO 2023, Search all connections
Abstract The proliferation biomarker SPAG5 expression in HER2 low and HER2 overexpression early breast cancer (BC) predicting tumour response to neoadjuvant chemotherapy (NACT) with and without trastuzumab. Organization:Nottingham Univ City...,Van Geest Cancer res...,School of Science an..., Search all connections
Abstract Palbociclib (P) plus tamoxifen (TAM) ± goserelin in women with hormone receptor-positive (HR+)/HER2-negative (HER2−) advanced breast cancer (ABC): Primary results of NCCH1607/PATHWAY, an Asian international double-blind randomized phase 3 trial. Clinical trial:NCCH1607,Organization:National Cancer Cent...,National Cancer Cent...,Kanagawa Cancer Cent..., Search all connections
Abstract Whole-genome sequencing based assessment of HER2 focal amplification for precision oncology of breast cancers. Organization:Genome Insight Inc.,Samsung Medical Cent...,Division of Breast S...,Drug:docetaxel, Search all connections
Abstract Randomised open-label phase II study of induction standard of care fulvestrant and CDK4/6 inhibition with addition of ipatasertib in metastatic ER+/HER2- breast cancer patients without circulating tumour (ct) DNA suppression (FAIM). Clinical trial:CCR5214,Organization:The Royal Marsden NH...,University Hospitals...,The Beatson Cancer C..., Search all connections
Abstract Phase IIa study of αDC1 vaccines targeting HER2/HER3 combined with pembrolizumab in patients with asymptomatic brain metastasis from triple negative breast cancer or HER2+ breast cancer. Clinical trial:I-19-04120,Organization:Roswell Park Compreh...,Buffalo, IL,Nykode Therapeutics, Search all connections
Abstract A prospective, phase II, neoadjuvant clinical study based on chemotherapy sensitivity in hormone receptor–positive, HER2-negative breast cancer: FINEST study. Clinical trial:SCHBCC0N026,Organization:Fudan University Sha...,Shanghai Cancer Cent...,Department of Breast...,Drug:Abraxane,carboplatin, Search all connections
Abstract Association of HER2/CEP17 ratio with pCR after HER2-directed neoadjuvant treatments in the phase III NeoALTTO trial. Organization:Comprehensive Cancer...,Medical University o...,Dept of OB/GYN, Karl..., Search all connections
Abstract Artificial intelligence (AI) –based machine learning models (ML) for predicting pathological complete response (pCR) in patients with hormone receptor (HoR) –positive/HER2-negative early breast cancer (EBC) undergoing neoadjuvant chemotherapy (NCT): A retrospective cohort study. Organization:Medical Oncology, Co...,Drug:anthracyclines,taxanes,Target:Topoisomerase II,taxanes,Congress:ASCO 2023, Search all connections
Abstract Neoadjuvant giredestrant + palbociclib (P) vs. anastrozole (A) + P in postmenopausal women with estrogen receptor-positive, HER2-negative, untreated early breast cancer (ER+, HER2– eBC): Patient (pt)-reported outcomes (PROs) in the randomized, open-label, international phase II coopERA BC study. Clinical trial:WO42133,Organization:Samsung Medical Cent...,GEICAM Spanish Breas...,University Hospital ..., Search all connections
Abstract Exploring HER2-low disease: Does it impact breast cancer survival? Organization:Medical Oncology Dep...,Catalan Institute of...,B-ARGO (Badalona App..., Search all connections
Abstract Neoadjuvant therapy of HER2 directed conventional dendritic cell (DC1) intratumoral (IT) therapy plus weekly paclitaxel, trastuzumab, and pertuzumab in patients with HER-2 positive breast cancer: NATASHA trial. Clinical trial:MCC-20915,Organization:H. Lee Moffitt Cance...,H. Lee Moffit Cancer...,Drug:IT DC1,Trastuzumab,pertuzumab,Target:HER2 (ERBB2), Search all connections
Abstract Do HER2 low tumors have a distinct clinicopathologic phenotype? Organization:Breast Service, Depa...,Congress:ASCO 2023, Search all connections
Abstract Outcomes in premenopausal patients with HR+/HER2- breast cancer and lymph node micro-metastasis based on the 21-gene recurrence score. Organization:Icahn School of Medi...,Icahn School of Medi...,Drug:chemoendocrine thera...,endocrine monotherap...,Target:HER2 (ERBB2),Hormone receptor pos...,Hormone receptors,Congress:ASCO 2023, Search all connections
Abstract ERBB2 mRNA expression to distinguish HER2-low/neg breast cancer prognosis. Organization:The Fourth Hospital ...,Fudan University Sha...,Shanghai Medical Col...,Drug:trastuzumab deruxtec...,Target:HER2 (ERBB2), Search all connections
Abstract Impact of HER2 low expression in the Oncotype DX RS in patients with operable hormone receptor positive early stage breast cancer. Organization:Weill Cornell Medici...,New York Oncology He...,Weill Cornell Medici...,Drug:Oncotype DX RS,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Impact of race on BluePrint genomic subtyping in HER2+ breast cancer. Organization:Vanderbilt-Ingram Ca...,Vanderbilt Universit...,Division of Epidemio..., Search all connections
Abstract Decision value of the circulating tumor DNA on the adjuvant anti-Her2 regimens in patients with Her2-positive breast cancer treated with neoadjuvant therapy. Organization:National Taiwan Univ...,National Taiwan Univ...,Drug:T-DM1,Trastuzumab,pertuzumab,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract State-of-the-art management of HER2-negative early breast cancer: Treatment patterns among healthcare professionals and concordance with expert recommendations. Organization:Clinical Care Option...,Reston, VA,Department of Hemato..., Search all connections
Abstract Prognostic role of HER2 expression in patients with ER-positive/HER2-negative breast cancer: Results from a population-based cancer registry study. Organization:Gruppo Oncologico It...,University Hospital ...,University of Parma,Congress:ASCO 2023, Search all connections
Abstract Prognostic impact of adjuvant endocrine therapy for estrogen receptor-positive and HER2-negative T1a/bN0M0 breast cancer. Organization:Department of Breast...,Department of Surgic...,Department of Breast..., Search all connections
Abstract Additional prognostic value of the BCT score in patients with ER+HER2- breast cancer receiving 21-gene assay–guided adjuvant treatments. Organization:Gangnam Severance Ho...,Yonesi University Co...,Seoul National Unive..., Search all connections
Abstract Disease-free survival (DFS) as a surrogate for overall survival (OS) in patients (pts) with HR+/HER2− early breast cancer (EBC): A correlation analysis. Organization:Helios Klinikum Berl...,Dana-Farber Cancer I...,International Breast..., Search all connections
Abstract Real-world outcomes with adjuvant nonsteroidal aromatase inhibitors (NSAIs) vs tamoxifen (TAM) in patients with hormone receptor−positive/human epidermal growth factor receptor 2−negative (HR+/HER2−) early breast cancer (EBC): A US database analysis. Organization:Lifespan Cancer Inst...,Department of Medica...,Dana-Farber Cancer I..., Search all connections
Abstract The worldwide impact of HER2-targeted treatments in women with breast cancer: An epidemiological modeling study. Organization:Genentech Inc.,F. Hoffmann-La Roche...,Drug:Trastuzumab,pertuzumab,T-DM1,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Real-world impact of TAILORx on chemotherapy use and SOFT/TEXT on ovarian function suppression uptake in a population based-cohort of women 40 years and under with HR-positive, HER2-negative, axillary lymph node negative breast cancer. Organization:Schulich School of M...,Department of Intern...,Western University,Drug:Cisplatin,Target:cell division, Search all connections
Abstract Phase II study of pembrolizumab plus mifepristone in patients with advanced HER2-negative breast cancer. Clinical trial:IRB17-0721,Organization:University of Chicag...,University of Chicag...,Northshore Universit...,Drug:pembrolizumab, Search all connections
Abstract Distribution and outcomes of HER2-low and HER2-zero metastatic breast cancer in Black and younger women. Organization:UNC Lineberger Compr...,University of North ...,Department of Medici...,Drug:CDK4/6i,etoposide,Cisplatin, Search all connections
Abstract Biomarker analysis of phase II pembrolizumab maintenance treatment after chemotherapy response in patients with HER2-negative inflammatory breast cancer and triple-negative breast cancer. Clinical trial:2014-0533,Organization:The University of Te...,Department of Breast...,St. Luke's Internati..., Search all connections
Abstract Phase II study of trifluridine/tipiracil (FTD/TPI) in HER2-negative metastatic breast cancers with or without prior exposure to fluoropyrimidines. Organization:Department of Haemat...,National University ...,National University ...,Drug:FTD/TPI,trifluridine/tipirac...,tipiracil, Search all connections
Abstract Prognostic value of HER2-low status in breast cancer: A systematic review and meta-analysis. Organization:Università degli Stu...,Humanitas Research H...,Université Libre de ..., Search all connections
Abstract Phase Ib study of talimogene laherparepvec (T-VEC) in combination with chemotherapy (CT) or endocrine therapy (ET) in patients with metastatic, unresectable, or locoregionally recurrent HER2-negative breast cancer (BC). Organization:University of Califo...,University of Califo...,UCSF Medical Center,Drug:talimogene laherpare...,FF-10832, Search all connections
Abstract Efficacy of oral selective estrogen receptor degraders (SERD)s in the treatment of estrogen receptor positive (ER+), HER2-negative metastatic breast cancer (MBC): A stratified analysis of the ESR1 wild type (wt) and mutant (mt) subgroups. Drug:fulvestrant,Elacestrant,Target:Estrogen Receptor 1 ...,Organization:Yong Loo Lin School ...,National University ...,Department of Haemat..., Search all connections
Abstract Discovery of CDK4/6 bifunctional degraders for ER+/HER2- breast cancer. Organization:San Diego, CA,BioTheryX,Drug:palbociclib,ribociclib,CDK4/6 bifunctional ...,Target:CDK6,CDK4 & 6,Congress:ASCO 2023, Search all connections
Abstract Trop-2 mRNA expression and association with clinical outcomes with sacituzumab govitecan (SG) in patients with HR+/HER2– metastatic breast cancer (mBC): Biomarker results from the phase 3 TROPiCS-02 study. Clinical trial:IMMU-132-09,Organization:Medical Oncology Gro...,Massachusetts Genera...,Harvard Medical Scho..., Search all connections
Abstract A phase I trial of palbociclib (palbo) and bosutinib (bos) with fulvestrant (fulv) in patients (pts) with hormone receptor–positive, HER2-negative (HR+/HER2-) metastatic breast cancer (MBC) refractory to an aromatase inhibitor (AI) and a CDK4/6 inhibitor (CDK4/6i). Clinical trial:STUDY00000057,Organization:Medstar Georgetown U...,Department of Biosta...,Dana-Farber Cancer I...,Drug:bosutinib, Search all connections
Abstract Clinical outcomes and correlation with longitudinal circulating tumor (ct)DNA dynamics of a phase I/II study of GSK525762 combined with fulvestrant in patients with hormone receptor-positive/HER2-negative (HR+/HER2−) advanced or metastatic breast cancer. Clinical trial:201973,Organization:Princess Margaret Ca...,University Health Ne...,University of Toront..., Search all connections
Abstract A multicenter, single-arm, open-label trial of birociclib, a CDK4/6 inhibitor, as a single agent, in patients with refractory HR+/HER2- metastatic breast cancer. Organization:National Cancer Cent...,Harbin Medical Unive...,Cancer Hospital of C..., Search all connections
Abstract Indirect treatment comparison of first-line CDK4/6-inhibitors in post-menopausal patients with HR+/HER2- metastatic breast cancer. Organization:Yong Loo Lin School ...,National University ...,Department of Radiat..., Search all connections
Abstract Oral elacestrant vs standard-of-care in estrogen receptor-positive, HER2-negative (ER+/HER2-) advanced or metastatic breast cancer (mBC) without detectable ESR1 mutation (EMERALD): Subgroup analysis by prior duration of CDK4/6i plus endocrine therapy (ET). Clinical trial:RAD1901-308,Organization:UT Health San Antoni...,Institut Curie, Sain...,Universitaire Zieken..., Search all connections
Abstract Impact of pathogenic germline BRCA1/2 and PALB2 mutations and tumor aneuploidy in patients with HR+/HER2- metastatic breast cancer treated with CDK4/6 inhibitors. Organization:Division of Medical ...,Princess Margaret Ca...,University Health Ne..., Search all connections
Abstract Outcomes with first-line (1L) ribociclib (RIB) + endocrine therapy (ET) vs physician’s choice combination chemotherapy (combo CT) by age in pre/perimenopausal patients (pts) with aggressive HR+/HER2− advanced breast cancer (ABC): A subgroup analysis of the RIGHT Choice trial. Clinical trial:CLEE011A3201C,Organization:American University ...,National Cancer Cent...,Acıbadem Research In..., Search all connections
Abstract Capivasertib (C) and fulvestrant (F) for patients (pts) with aromatase inhibitor (AI)-resistant HR+/HER2– advanced breast cancer (ABC): Characterization and management of common adverse events (AEs) from the phase 3 CAPItello-291 trial. Clinical trial:D3615C00001,Drug:Filgrastim,lenalidomide,Varlilumab,Target:AKT1,Organization:University of Califo...,Vall d'Hebron Univer...,The University of Ma..., Search all connections
Abstract Endocrine therapy resistance (ETR) in hormone receptor-positive, HER2-negative metastatic breast cancer (HR+, HER2– mBC): Prevalence, biomarker characteristics, and outcomes. Organization:Dana-Farber Cancer I...,Genentech,F. Hoffmann-La Roche...,Drug:fulvestrant,CDK4/6 inhibitors, Search all connections
Abstract Efficacy analysis of CDK4/6 inhibitors (CDKi) + endocrine therapy (ET) treatment in hormone receptor-positive/HER2-negative (HR+/HER2-) advanced breast cancer (aBC): Biomarker analysis including chemoendocrine score (CES) by CDKi type in SOLTI-1801_CDK-PREDICT study. Organization:Medical Oncology Dep...,Hospital 12 de Octub...,Hospital Clínic de B..., Search all connections
Abstract Exploratory biomarker analysis of acelERA breast cancer (BC): Phase II study of giredestrant vs. physician’s choice of endocrine therapy (PCET) for previously treated, estrogen receptor-positive, HER2-negative advanced BC (ER+, HER2– aBC). Clinical trial:WO42312,Organization:Genentech,The University of Te...,Massachusetts Genera...,Drug:giredestrant,PCET, Search all connections
Abstract Interim analyses (IA) of the giredestrant (G), G + abemaciclib (A), and G + ribociclib (R) arms in MORPHEUS Breast Cancer (BC): A phase I/II study of G treatment (tx) combinations in patients (pts) with estrogen receptor-positive, HER2-negative locally advanced/metastatic BC (ER+, HER2– LA/mBC). Organization:Vall d’Hebron Univer...,Tel Aviv Sourasky Me...,University of Califo..., Search all connections
Abstract Artificial intelligence–powered tumor-infiltrating lymphocytes analyzer to reveal distinct immune landscapes in breast cancer by molecular subtype and HER2 score. Organization:Oncology Therapeutic...,Lunit Inc.,Samsung Medical Cent..., Search all connections
Abstract Metastatic patterns and outcomes by HER2 and hormone receptor (HR) status in patients (pts) with metastatic breast cancer (mBC). Organization:Flatiron Health, San...,Drug:trastuzumab deruxuta...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Real-world patient characteristics and treatment patterns associated with tucatinib therapy in patients with HER2+ metastatic breast cancer. Organization:Duke University Canc...,Seagen, Inc.,Genesis Research,Drug:Tucatinib,Trastuzumab,CAPOX, Search all connections
Abstract Real-world treatment patterns in patients with HER2+ unresectable or metastatic breast cancer: Interim results from HER2 REAL Asia cohort. Organization:National University ...,National Cheng Kung ...,Queen Elizabeth Hosp...,Drug:trastuzumab emtansin..., Search all connections
Abstract PLEASURABLE: Results and biomarkers analysis from the phase II study of dalpiciclib combined with pyrotinib and endocrine therapy (ET) in women with dual-receptor positive (ER+/HER2+) metastatic breast cancer (MBC). Organization:Fudan University Sha...,Department of Breast...,Hubei Cancer Hospita..., Search all connections
Abstract Anti-HER2 antibody inetetamab plus camrelizumab and utidelone for pretreated HER2-positive metastatic breast cancer: Final results from the phase 2 ICU trial. Organization:Department of Breast...,Henan Breast Cancer ...,The Affiliated Cance..., Search all connections
Abstract Preclinical and early clinical data of ZN-1041, a best-in-class BBB penetrable HER2 inhibitor to treat breast cancer with CNS metastases. Clinical trial:ZN-A-1041-101-US,Organization:National Cancer Cent...,Cancer Institute and...,Sun Yat-sen Memorial..., Search all connections
Abstract Lasofoxifene (LAS) plus abemaciclib (Abema) for treating ESR1-mutated ER+/HER2- metastatic breast cancer (mBC) after progression on prior therapies: ELAINE 2 study update. Clinical trial:SMX 20-001,Organization:University of Texas ...,Cleveland Clinic Fou...,St. Joseph Heritage ...,Drug:Lasofoxifene, Search all connections
Abstract Updated results from a phase 2 study on dalpiciclib and pyrotinib, a dual-oral chemotherapy-free regimen in HER2-positive advanced breast cancer (DAP-HER-01). Organization:Department of Breast...,Henan Breast Cancer ...,Jiangsu Hengrui Phar...,Drug:dalpiciclib,pyrotinib,Target:CDK4/6,HER2 (ERBB2), Search all connections
Abstract Pyrotinib plus capecitabine for patients with HER2-positive metastatic breast cancer and brain metastases: 3-year follow-up results from the phase 2 PERMEATE trial. Clinical trial:HR-MBC-HN001,Organization:Department of Breast...,The Affiliated Cance...,Department of Breast..., Search all connections
Abstract Cardiac function of long-responders to dual anti-HER2 antibodies amongst patients with HER2 positive advanced breast cancer. Organization:Department of Clinic...,Queen Elizabeth Hosp...,Hong Kong Sanatorium...,Drug:pertuzumab,Trastuzumab,taxane,Target:HER2 (ERBB2),taxanes, Search all connections
Abstract Zanidatamab (zani), a HER2-targeted bispecific antibody, in combination with docetaxel as first-line therapy (1L) for patients (pts) with advanced HER2-positive breast cancer (BC): Updated results from a phase 1b/2 study. Clinical trial:BGB-A317-ZW25-101,Organization:BeiGene (Shanghai) C...,The Fifth Medical Ce...,Drug:zanidatamab,ZW25,docetaxel,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract Association of C-MYC, MYC target gene, and unfolded protein response (UPR) expression with clinical benefit from the oral aurora kinase A (AURKA) inhibitor, alisertib (A), in combination with paclitaxel (P) compared with P alone in patients (Pts) with HER2-negative metastatic breast cancer (MBC). Organization:Integrated Cancer Ge...,Translational Genomi...,Phoenix, AZ, Search all connections
Abstract Clinical features, genomic landscapes, and survival outcomes of HER2-low breast cancer. Organization:Fudan University (Xi...,Shanghai Cancer Cent...,Shanghai Medical Col...,Drug:trastuzumab deruxtec...,adotrastuzumab emtan...,Target:HER2 (ERBB2),Congress:ASCO 2023, Search all connections
Abstract KEYNOTE-859 study of pembrolizumab plus chemotherapy for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Outcomes in the protocol-specified PD-L1–selected populations. Clinical trial:3475-859,Organization:Yonsei Cancer Center...,Maria Sklodowska-Cur...,James Lind Cancer Re..., Search all connections
Abstract Tissue-agnostic efficacy of trastuzumab deruxtecan (T-DXd) in advanced solid tumors with HER2 amplification identified by plasma cell-free DNA (cfDNA) testing: Results from a phase 2 basket trial (HERALD/EPOC1806). Organization:Guardant Health, Inc...,Department of Molecu...,Department of Biosta...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2023, Search all connections
Abstract First-in-human phase 1/2a study of a potent and novel CDK2-selective inhibitor PF-07104091 in patients (pts) with advanced solid tumors, enriched for CDK4/6 inhibitor resistant HR+/HER2- breast cancer. Clinical trial:C4161001,Organization:Department of Invest...,Drug:PF-07104091,fulvestrant,Target:CDK2,Estrogen Receptor (E...,Congress:ASCO 2023, Search all connections
Abstract First-in-human first-in-class phase 1/2a study of the next generation CDK4-selective inhibitor PF-07220060 in patients (pts) with advanced solid tumors, enriched for HR+ HER2- mBC who progressed on prior CDK4/6 inhibitors and endocrine therapy. Clinical trial:C4391001,Organization:Department of Invest...,Dana-Farber Cancer I...,Sarah Cannon Researc...,Drug:PF-07220060, Search all connections
Abstract The immune microenvironment in hormone positive, HER2 negative breast cancer: A focus on tumour infiltrating lymphocytes, spatial phenotypes and tertiary lymphoid structures. Organization:St Vincents Universi...,RCSI & UCD Malaysia ...,UCD School of Biomol..., Search all connections
Abstract A phase I/II trial investigating safety and efficacy of autologous TAC01-HER2 in relapsed or refractory solid tumors. Clinical trial:TAC01-HER2-03,Organization:DFCI/BWH Cancer Cent...,University of Chicag...,Comprehensive Cancer..., Search all connections
Abstract Outcomes according to treatment received for small node-negative HER2+ breast tumors in the Surveillance, Epidemiology, and End Results (SEER) database, 2010-2019. Organization:Dana-Farber Cancer I...,Unidad Oncologica de...,Cooperative Oncologi...,Drug:Cisplatin,Target:HER2 (ERBB2),Congress:ASCO 2023,ASCO 2019, Search all connections
Abstract Gene expression signatures, stromal tumor infiltrating lymphocytes (sTILs), and change in tumor cellularity to predict pathological complete response (pCR) after 12 week de-escalated neoadjuvant endocrine therapy (ET) vs paclitaxel + dual HER2 blockade in the WSG-TP-II trial. Organization:West German Study Gr...,Moenchengladbach, Ge...,Klinikum Dortmund gG...,Clinical trial:PH002-TP-II,Drug:Tiragolumab,Trastuzumab,pertuzumab, Search all connections
Abstract MammaPrint Index as a predictive biomarker for neoadjuvant chemotherapy response and outcome in patients with HR+HER2- breast cancer in NBRST. Organization:Dallas Surgical Grou...,Bon Secours Cancer I...,Yale University, Search all connections
Abstract Primary efficacy analyses of NeoRHEA, neoadjuvant biomarker research study of palbociclib combined with endocrine therapy in estrogen receptor positive/HER2 negative breast cancer. Clinical trial:IJB-BC-NEORHEA-2016,Organization:Université Libre de ...,Hôpital Universitair...,Institut Jules Borde..., Search all connections
Abstract Efficacy of tucatinib+trastuzumab+capecitabine (TTC) after trastuzumab-deruxtecan (T-DXd) exposure in Her2-positive metastatic breast cancer: A French multicentre retrospective study. Organization:Institut de Cancerol...,Gustave Roussy Cance...,ICO Institut de Canc..., Search all connections
Abstract LEONARDA-1: Phase III randomized study of lerociclib plus fulvestrant in patients with HR+, HER2- locally advanced or metastatic breast cancer that has progressed on prior endocrine therapy. Organization:National Cancer Cent...,Harbin Medical Unive...,Genor Biopharma Co.,...,Drug:lerociclib,fulvestrant,LHRH agonist,Target:CDK6, Search all connections
Abstract The frequency of HER2-low breast cancer among BRCA1, BRCA2, and PALB2 mutation carriers. Organization:Hospital of Universi...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Clinical significance of HER2 expression between primary tumors and metastatic lymph nodes in patients with extramammary Paget's disease. Drug:Disitamab Vedotin (R...,Organization:Sun Yat-sen Universi...,State Key Laboratory...,Collaborative Innova..., Search all connections
Abstract Community oncology preparedness and perceptions of challenges in care with HER2/HER3 therapy for NSCLC. Organization:Needham, MA,Congress:ASCO 2024, Search all connections
Abstract Spectrum of HER2 alterations in NSCLC: Comparative analysis of tissue and liquid biopsies in lung cancer. Organization:Care Hospital,Congress:ASCO 2024, Search all connections
Abstract Exposure-response (ER) analyses of efficacy and safety of trastuzumab deruxtecan (T-DXd) to inform dosing recommendation in HER2-mutant non-small cell lung cancer (NSCLC). Organization:Syndax Pharmaceutica...,Target:HER2 (ERBB2),Clinical trial:DS8201-A-U204,Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract Population pharmacokinetics of trastuzumab deruxtecan (T-DXd) in subjects with HER2-mutant and HER2-overexpressing non-small cell lung cancer (NSCLC). Drug:deruxtecan,trastuzumab-deruxtec...,Organization:Syndax Pharmaceutial...,Tariffville, CT,Target:HER2 (ERBB2),Clinical trial:DS8201-A-U206,Congress:ASCO 2024, Search all connections
Abstract Phase Ia/Ib trial of zongertinib (BI 1810631), a HER2-specific tyrosine kinase inhibitor (TKI), in patients (pts) with HER2 aberration-positive solid tumors: Updated Phase Ia data from Beamion LUNG-1, including progression-free survival (PFS) data. Drug:zongertinib,Organization:Mary Crowley Cancer ...,Guangdong Lung Cance...,Valkyrie Clinical Tr...,Target:HER2 (ERBB2), Search all connections
Abstract The tumor immune profile of bladder cancer (BC) with HER2 over-expression and the investigation into RC48-ADC versus BCG in high-risk non-muscle invasive BC with HER2 over-expression. Drug:bacillus Calmette-Gu...,Disitamab vedotin,RC48-ADC,Target:innate immunity,adaptive immunity,Organization:Department of Urolog...,Institute of Urology, Search all connections
Abstract Preliminary results from a phase II study to evaluate the efficacy and safety of perioperative disitamab vedotin (RC48-ADC) plus cadonilimab (AK104, PD-1/CTLA-4 bispecific antibody) for HER2-expressing muscle-invasive bladder cancer (MIBC). Drug:Cisplatin,RC48-ADC,PD-1/CTLA-4 antibody,Target:CTLA-4,PD-1,Organization:Department of Urolog..., Search all connections
Abstract Preliminary results from a multi-center phase Ib/II study of RC48-ADC combined with tislelizumab as neoadjuvant treatment in patients with HER2 positive locally advanced muscle-invasive urothelial bladder cancer (Hope-03). Drug:RC48-ADC,tislelizumab,Target:PD-1,HER2 (ERBB2),Organization:West China Hospital,Sichuan University,Department of Urolog..., Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) combined with camrelizumab and S-1 for neoadjuvant therapy of locally advanced gastric cancer with HER2 overexpression: Preliminary results of a prospective, single-arm, phase II study. Drug:Disitamab vedotin,RC48,camrelizumab,Target:PD-1,Organization:Department of Gastro...,Shandong Cancer Hosp...,Shandong First Medic..., Search all connections
Abstract Influence of neoadjuvant regimen on the prognosis of locally advanced gastric and gastroesophageal junction cancer with HER2 overexpression. Drug:anti-PD-1 immunother...,anti-HER2 agents,Target:PD-1,HER2 (ERBB2),Organization:Cancer Hospital Affi...,Henan Cancer Hosptal,Congress:ASCO 2024, Search all connections
Abstract Triple combination treatment of trastuzumab, chemotherapy and immune checkpoint inhibitor in HER2 positive unresectable, locally advanced, metastatic gastric and esophageal adenocarcinoma: A systematic review and meta-analysis. Drug:Trastuzumab,Organization:Quezon City,Philippines,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Exploration of different immunogenomic TMEs in gastric cancer based on HER2 and PD-L1 expression. Organization:Samsung Advanced Ins...,Congress:ASCO 2024, Search all connections
Abstract Effectiveness and safety analysis of serplulimab-based regimens in patients with HER2-negative advanced gastric cancer from a real-world retrospective study. Drug:serplulimab,platinum-based chemo...,taxanes,Target:Platinum-based chemo...,PD-1,Thymidylate synthase..., Search all connections
Abstract The role of determining HER2neu status in patients with gastric cancer. Organization:CENTEast,Kazakh National Medi...,Kazakhstan Cancer So...,Congress:ASCO 2024, Search all connections
Abstract Immune checkpoint inhibitor plus chemotherapy versus chemotherapy alone in HER2-negative advanced gastric or gastroesophageal junction cancer: A systematic review and meta-analysis of randomized controlled trials. Drug:immune checkpoint in...,PD-1 inhibitors,PD-L1 inhibitors,Target:PD-1,PD-L1,Organization:Federal Univerity of...,DASA Oncologia, Search all connections
Abstract Efficacy and safety of SOX regimen combined with inetetamab as first-line treatment for HER2-positive advanced gastric cancer. Drug:Inetetamab,Trastuzumab,Organization:The Second Affiliate...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract The effect of HER2-targeted inhibitors as second-line or later-line regimens in the treatment of HER2-positive advanced colorectal cancer: A systematic review and meta-analysis. Organization:Fujian Medical Unive...,Congress:ASCO 2024, Search all connections
Abstract Final results of a phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC (MOUNTAINEER). Drug:Tucatinib,Trastuzumab,Organization:Keck Medical Center ...,Target:HER2 (ERBB2),Clinical trial:SGNTUC-017,Congress:ASCO 2024, Search all connections
Abstract Multicenter study evaluating the utility of AI-aided HER2 scoring in the clinically relevant categories. Organization:Pathgroup Labs,Alverno Laboratories,Ibex Medical Analyti...,Congress:ASCO 2024, Search all connections
Abstract Peony exploratory analyses of biomarker changes: From baseline to surgical samples in patients with HER2+ breast cancer. Drug:pertuzumab,Trastuzumab,docetaxel,Organization:Roche (China) Holdin...,Product Development ...,Target:HER2 (ERBB2),Clinical trial:YO28762,Congress:ASCO 2024, Search all connections
Abstract FS-1502 in patients with HER2 high expression, locally advanced or metastatic gastric or gastroesophageal junction adenocarcinoma: An open-label, multicenter, phase II study. Drug:FS-1502,Monomethylauristatin...,Organization:Meizhou People's Hos...,Meizhou Academy of M...,Meizhou Hospital Aff...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Phase 1 study of ZV0203, a first in class pertuzumab ADC, in patients with HER2 positive advanced solid tumors. Drug:ZV0203,DUO5,Trastuzumab,Target:tubulin,HER2 (ERBB2),Organization:Hangzhou Adcoris Bio..., Search all connections
Abstract Disitamab vedotin combined with fruquintinib in patients with HER2-expressing or HER2 mutation/amplified metastatic colorectal cancer refractory to at least two standard regimens: A prospective, exploratory, single-arm study. Drug:Disitamab vedotin,fruquintinib,Organization:Department of Abdomi...,Target:HER2 (ERBB2),Clinical trial:HCCSC C03,Congress:ASCO 2024, Search all connections
Abstract Association between stromal tumor-infiltrating lymphocytes (TILs) and pathologic complete response (pCR) in patients with early breast cancer (BC) treated with neoadjuvant chemotherapy and HER2-directed therapies in NSABP B-41. Drug:Trastuzumab,lapatinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:NSABP/NRG Oncology a...,Congress:ASCO 2024, Search all connections
Abstract Tucatinib-trastuzumab-capecitabine for treatment of leptomeningeal metastasis in HER2+ breast cancer: TBCRC049 phase 2 study results. Drug:Tucatinib,Trastuzumab,capecitabine,Organization:Berry Consultants, L...,Seagen,Cleveland Clinic Tau..., Search all connections
Abstract Evaluation of recurrence rate in Canadian patients with stage II/III HR+/HER2- early breast cancer in the real-world setting. Organization:Centre Hospitalier d...,Hopital St-Sacrement,Center of Oncology L...,Congress:ASCO 2024, Search all connections
Abstract Clinicopathological characteristics and outcomes of patients with HER2-low breast cancer: 6-year ambispective cohort study from India. Drug:trastuzumab deruxtec...,trastuzumab deruxtec...,Organization:Kasturba Medical Col...,Manipal Academy of H...,Kasturba Medical Col...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Targeted interventions to address local challenges in HR+/HER2- and HER2+ breast cancer treatment in community-based settings. Organization:Miami Cancer Institu...,Baptist Health South...,Sarah Cannon Researc...,Congress:ASCO 2024, Search all connections
Abstract Understanding breast cancer (BC) from the patient (pt) perspective: A qualitative study of symptoms, impacts and health-related quality of life (HRQoL) in hormone receptor-positive, HER2-negative (HR+, HER2–) BC. Organization:Roche Global Breast ...,Europa Donna Sloveni...,Congress:ASCO 2024, Search all connections
Abstract Disparities in patients with HER2-positive breast cancer receiving optimal treatment: Analysis of the real-world ASCO CancerLinQ dataset. Organization:Brigham and Women's ...,Boston, MA,Dana-Farber Cancer I...,Congress:ASCO 2024, Search all connections
Abstract Unraveling the impact of social determinants of health on HER2+ early breast cancer screening and treatment in a county oncology setting in China. Organization:The People's Hospita...,Inner Mongolia Fores...,Guiping People's Hos..., Search all connections
Abstract Treatment patterns among HCPs and concordance with expert recommendations in HER2-negative early breast cancer: Analysis of an interactive online treatment decision support tool. Organization:Cancer Center Stanfo...,Congress:ASCO 2024, Search all connections
Abstract Landscape of HER2-low breast cancer: Insights from a six-year study on incidence and clinicopathological characteristics. Drug:HER2 CAR-T,Organization:Saint Joseph Univers...,Hotel-Dieu de France,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Evaluation and treatment response in patients with hormone receptor-positive, HER2 low metastatic breast cancer: A single center retrospective analysis. Drug:aromatase inhibitor,CDK 4/6 inhibitor,Target:Cyclin dependent kin...,aromatase,Cyclin Dependent Kin...,Organization:Henry Ford Hospital,Detroit, MI,Congress:ASCO 2024, Search all connections
Abstract A meta-analysis of the difference in response to trastuzumab-deruxtecan (T-DXd) based on HER2 immunohistochemistry (IHC) in HER2 low metastatic breast cancer (mBC). Organization:SUNY Upstate Univers...,SUNY Upstate Medical...,SUNY Upstate Medical...,Target:HER2 (ERBB2),Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract A phase Ia/b trial of ARX788 combined with toripalimab for HER2-low advanced breast cancer (ABC) and other HER2-expressing solid tumors. Drug:ARX788,Toripalimab (Loqtorz...,capecitabine,Target:PD-1,Organization:Department of Breast...,Cancer Hospital of t...,Center of Hepato-Pan..., Search all connections
Abstract Frequency of HER2-Low in breast cancer biopsies in Chile. Organization:Clínica Santa María,Universidad Finis Te...,Congress:ASCO 2024, Search all connections
Abstract A phase II trial of anlotinib combined chemotherapy as second-line and above therapy in HER2-negative advanced breast cancer. Drug:Anlotinib,Target:VEGFR-1,FGFRa,PDGFR-α,Organization:Jiangsu Cancer Hospi...,Nanjing Yoko Biomedi...,Jiangsu HengRui Medi..., Search all connections
Abstract Prevalence of “HER2 ultra-low” among patients with advanced breast cancer with historical IHC0 status. Drug:trastuzumab deruxtec...,Organization:nference Inc.,AstraZeneca LLC,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of eribulin plus gemcitabine in second-line or beyond for patients with HER2-negative metastatic breast cancer (MBC): A multicenter, open-label, single-arm, phase II study. Drug:eribulin,Gemcitabine,paclitaxel,Target:Gemcitabine,eribulin,paclitaxel,Organization:The Cancer Center of...,The First People's H..., Search all connections
Abstract Antibody-drug conjugates (ADC) in patients with advanced/metastatic HER2-low expressing breast cancer: A systematic review and meta-analysis. Drug:trastuzumab deruxtec...,Sacituzumab goviteca...,MRG002,Organization:Catholic University ...,Pelotas, Brazil,Universidade Estadua..., Search all connections
Abstract Real-world data comparison of time to next treatment for patients with HER2 low metastatic treated with either chemotherapy or fam-trastuzumab deruxtecan-nxki following chemotherapy in the metastatic setting. Drug:TDxd,paclitaxel,capecitabine,Target:capecitabine,DNA,Gemcitabine, Search all connections
Abstract Biologic and prognostic significance of HER2-low and ER-low expressions in de novo metastatic breast cancer. Organization:Hebei Cangzhou Hospi...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of abemaciclib in combination with endocrine therapy for HR+/HER2- advanced or metastatic breast cancer: A systematic review and meta-analysis. Drug:abemaciclib,fulvestrant,Target:CDK6,CDK4 & 6,Fulvestrant,Organization:Services Institute o...,Congress:ASCO 2024, Search all connections
Abstract Frequency of dose reductions of abemaciclib in metastatic and early-stage hormone positive, HER2 negative breast cancer. Drug:abemaciclib,Target:CDK6,CDK4 & 6,Organization:Scripps Clinic/Green...,La Jolla, CA,Congress:ASCO 2024, Search all connections
Abstract Overall survival analysis of first line CDK4/6 inhibitors in a large real-world cohort of patients with hormone receptor-positive (HR+)/HER2-negative metastatic breast cancer. Drug:palbociclib,abemaciclib,ribociclib,Target:CDK6,CDK4 & 6,Organization:Memorial Sloan Kette...,Weill Cornell Medica...,Congress:ASCO 2024, Search all connections
Abstract Co-occurrence of ESR1 and PIK3CA mutations in HR+/HER2- metastatic breast cancer: Incidence and outcomes with targeted therapy. Organization:Plantation,Fort Lauderdale,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of sacituzumab govitecan in HR+/HER2– advanced breast cancer: A comprehensive systematic review and meta-analysis. Drug:Sacituzumab goviteca...,Target:Trop-2,Organization:The Frank H. Netter ...,Samaritan Medical Ce...,BronxCare Health Sys...,Congress:ASCO 2024, Search all connections
Abstract Fulvestrant and elacestrant utilization on prognostic outcome of patients with HR+ve/HER2-ve MBC. Organization:Mediclinic City Hosp...,TriNetX Europe,Congress:ASCO 2024, Search all connections
Abstract Early tumor response in first‐line palbociclib plus AI in Chinese women with HR+/HER2- advanced breast cancer: Primary analysis of a multicenter, prospective real-world study. Drug:CDK4/6 inhibitors,aromatase inhibitors,palbociclib,Target:CDK6,CDK4 & 6,Organization:The Affiliated Peopl...,Medical School of Zh...,Congress:ASCO 2024, Search all connections
Abstract Employing semi-quantitative methods to classify breast cancer markers (ER, PR, HER2, Ki67) expression, using the RT-qPCR based APIS Breast Cancer Subtyping Kit. Organization:APIS Assay Technolog...,MVZ Prof. Dr. Med. A...,Congress:ASCO 2024, Search all connections
Abstract Real-world treatment patterns and clinical outcomes among patients with HR+/HER2- advanced/metastatic breast cancer receiving palbociclib in Brazil: IRIS study. Organization:Cerner Enviza,Congress:ASCO 2024, Search all connections
Abstract The impact of vitamin D levels on the progression-free survival of women with hormone receptor-positive, HER2-negative metastatic breast cancer treated with CDK4/6 inhibitors. Drug:CDK4/6 inhibitors,palbociclib,ribociclib,Target:cyclin-dependent kin...,CDK6,Cyclin-dependent kin..., Search all connections
Abstract The association of hormone receptor expression level and clinical efficacy of CDK4/6 inhibitor in hormone receptor-positive, HER2-negative metastatic breast cancer. Drug:palbociclib,ribociclib,abemaciclib,Target:CDK6,CDK4 & 6,Organization:Department of Clinic...,Queen Elizabeth Hosp...,Hong Kong Sanatorium..., Search all connections
Abstract Dalpiciclib and chidamide in patients with HR+/HER2- advanced breast cancer and resistance to CDK4/6 inhibitors: A phase Ib trial. Drug:dalpiciclib,Chidamide,Tucidinostat,Target:HDAC,histone deacetylase ...,Organization:Department of Oncolo...,The Fifth Medical Ce...,Beijing, China, Search all connections
Abstract Clinical outcomes with alpelisib (ALP) plus fulvestrant (FUL) in patients with HR-positive (HR+)/HER2-negative (HER2-) advanced breast cancer (ABC) with PIK3CA mutations (m) in routine practice at several Russian centers. Drug:Alpelisib,fulvestrant,chemotherapy,Target:Histamine-1 receptor,metformin,PIK3CA, Search all connections
Abstract The association between age, toxicity and outcomes of abemaciclib treatment in HR+/HER2- metastatic breast cancer. Drug:abemaciclib,Target:CDK6,CDK4 & 6,Organization:Faculty of Medicine,...,Congress:ASCO 2024, Search all connections
Abstract Clinical utility of an ultra-sensitive ctDNA NGS assay for the detection and monitoring in HR-positive, HER2-negative breast cancer. Organization:Huidu Shanghai Medic...,Congress:ASCO 2024, Search all connections
Abstract A phase II trial of anlotinib and fulvestrant in patients with HR-positive and HER2-negative, secondary aromatase inhibitor–resistant, metastatic breast cancer. Drug:fulvestrant,Anlotinib,Target:Estrogen Receptors (...,tyrosine kinase rece...,Organization:The Third Hospital o...,Nanchang People's Ho...,Congress:ASCO 2024, Search all connections
Abstract Defining low-HER2 cancers using RNA quantification by next generation sequencing. Drug:trastuzumab-deruxtec...,Target:HER2 (ERBB2),Organization:John Theurer Cancer ...,Hackensack Medical C...,NJ, Search all connections
Abstract Efficacy and safety of dalpiciclib, fulvestrant, and pyrotinib in HR+ HER2-low advanced breast cancer following cyclin-dependent kinases 4 and 6 (CDK4/6) inhibitors and aromatase inhibitors (AIs): A Bayesian optimal phase II trial. Drug:pyrotinib,abemaciclib,palbociclib,Target:Estrogen Receptor (E...,CDK6,CDK4 & 6, Search all connections
Abstract Real-world experience with CDK4/6 inhibitors in the first-line palliative setting for HR+/HER2- advanced breast cancer. Organization:Windsor, ON, Canada,Congress:ASCO 2024, Search all connections
Abstract Results of a retrospective study on the efficacy and safety of alpelisib in patients with HR+/HER2- metastatic breast cancer in real-world clinical practice. Organization:Republican Clinical ...,Russian Medical Acad...,Republican Clinical ...,Congress:ASCO 2024, Search all connections
Abstract Risk predictors as companion diagnostics for ER positive, HER2 negative early staged breast cancers from India. Organization:Cancer Institute (WI...,Congress:ASCO 2024, Search all connections
Abstract Effectiveness and safety of disitamab vedotin (RC48) in pretreated HER2-positive advanced breast cancer: A real-world experience in China. Drug:anti-microtubule che...,RC48,Trastuzumab,Target:microtubules,Organization:National Cancer Cent...,Internal Medicine-On...,The Second Affiliate..., Search all connections
Abstract Real-world data comparison of time to next treatment for patients with HER2 positive metastatic breast cancer treated in the second line of therapy with fam-trastuzumab deruxtecan-nxki or ado-trastuzumab emtansine. Drug:fam-trastuzumab ders...,ado-tratztozuri emtd...,tritzlizagal danov-t..., Search all connections
Abstract Interim safety analysis of phase IB trial of HER2 inhibitor tucatinib combined with PI3Kα inhibitor alpelisib in HER2+ PIK3CA-mutated metastatic breast cancer. Drug:Tucatinib,Alpelisib,Trastuzumab,Target:Estrogen Receptors (..., Search all connections
Abstract Trastuzumab-induced cardiotoxicity in patients with metastatic HER2-positive breast cancer treated at a reference hospital in Mexico. Drug:Trastuzumab,anthracyclines,Organization:Hospital de Oncologi...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Is HER2-negative breast cancer really negative? Clinical implication of novel assessment method using inPROBE technology. Organization:Institute of Health ...,The John Paul II Cat...,Congress:ASCO 2024, Search all connections
Abstract Outcome with pertuzumab, docetaxel, and trastuzumab (PTH) regimen in patients with HER2 positive metastatic breast cancer: Real-world data from a single center in India. Drug:pertuzumab,docetaxel,Trastuzumab,Target:microtubules,HER2 (ERBB2),Organization:Associate Consultant,Congress:ASCO 2024, Search all connections
Abstract Safety and preliminary efficacy of GQ1001, a next generation HER2-targeting ADC, combined with pyrotinib in pretreated patients with HER2-positive metastatic breast cancer: A phase 1b clinical trial. Drug:GQ1001,Trastuzumab,DM1,Organization:Department of Medica...,Fudan University Sha..., Search all connections
Abstract Is early inclusion of neratinib with HER blockers possible in the treatment of stage 4 HER2 positive cancer? Drug:Trastuzumab,pertuzumab,neratinib,Target:tubulin,thymidylate synthase, Search all connections
Abstract Enhancing HER2 evaluation: Correlation of APIS Breast Cancer Subtyping Kit and IHC/ISH with accurate HER2 quantification. Organization:APIS Assay Technolog...,MVZ Prof. Dr. Med. A...,Congress:ASCO 2024, Search all connections
Abstract The efficacy and safety of trastuzumab biosimilar HLX02 compared with reference trastuzumab plus pertuzumab in combination with chemotherapy as the first-line treatment for HER2 positive metastatic breast cancer: A real-world study in China. Drug:Trastuzumab,pertuzumab,HLX02,Target:paclitaxel, Search all connections
Abstract Treatment of HER2 positive stage 4 breast cancer: When to stop anti-HER2 agents. Organization:Nahanishi Clinic, Na...,Naha, Japan,Congress:ASCO 2024, Search all connections
Abstract Evaluation of AI-assisted HER2 scoring in breast carcinoma-stained whole-slide images. Organization:DiaDeep,IHP Group,Pathology Department,Congress:ASCO 2024, Search all connections
Abstract Effect of HER2-low expression on the efficacy of CDK4/6 inhibitors in breast cancer: A meta-analysis. Organization:The Second Affiliate...,Guangdong Provincial...,The Second Clinical ...,Congress:ASCO 2024, Search all connections
Abstract Use of multimodal circulating tumor cell assay to detect HER2-ultralow and ER co-expression matched with single-cell chromosomal instability in metastatic breast cancer. Organization:Epic Sciences, Inc.,San Diego State Univ...,La Jolla, CA,Congress:ASCO 2024, Search all connections
Abstract T-DM1 in Chinese patients with Her2-positive metastatic breast cancer: A multi-center, retrospective, real world study. Drug:T-DM1,pyrotinib,lapatinib,Target:EGFR-TKI sensitizing...,HER2 (ERBB2),Organization:National Cancer Cent...,Shougang Beijing Uni..., Search all connections
Abstract Clinical efficacy of pyrotinib combined with stereotactic radiosurgery in HER2-positive breast cancer brain metastases. Drug:pyrotinib,Organization:Guanghzou, China,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Real-world analysis of inetetamab combined with pyrotinib plus chemotherapy for the treatment of HER2-positive advanced breast cancer: A multi-center retrospective study. Drug:inetetamab,tyrosine kinase inhi...,pyrotinib,Organization:The First Hospital o...,Zhangjiakou First Ho..., Search all connections
Abstract Innovative fiber optic–based approach of HER2 expression quantitative assessment using inPROBE technology. Organization:SDS Optic Inc.,Congress:ASCO 2024, Search all connections
Abstract Evaluating the correlation between expression levels of carboxyl terminal modulator protein (CTMP) and the efficacy of trastuzumab in Syrian patients with HER2+ metastatic breast cancer. Target:CTMP,HER2 (ERBB2),Drug:Trastuzumab,docetaxel,vinorelbine,Organization:Damascus University,Syrian Arab Republic,Congress:ASCO 2024, Search all connections
Abstract Comparing the mutation profiles of primary HER2-positive breast cancers in patients with and without brain metastases. Organization:Sun Yat-sen Universi...,Guangzhou, China,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of HER2-ADC SHR-A1811 in HER2-positive breast cancer with brain metastases. Drug:SHR-A1811,pyrotinib,bevacizumab,Target:VEGF and c-MET pathw...,HER2 (ERBB2),Organization:Affiliated Cancer Ho...,Clinical trial:HNCH-MBC12,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of inetetamab-containing regimens in patients with HER2-positive metastatic breast cancer in first-line/second-line setting. Organization:Department of Medica...,Department of Oncolo...,Department of Medica...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of pyrotinib combined with trastuzumab emtansine (T-DM1) for patients with advanced HER2-positive breast cancer (BC): A single-arm phase II trial. Drug:Tucatinib,lapatinib,T-DM1,Organization:Tianjin Cancer Hospi..., Search all connections
Abstract Novel oleanolic acid derivative ZQL-4c as a target for SCD to modulate lipid metabolism reprogramming to overcome trastuzumab resistance in HER2 positive breast cancer. Organization:College of Pharmaceu...,Dalian University of...,Shenyang, Liaoning, ...,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of disitamab vedotin (RC48) in HER2-expressing breast cancer: A multicenter retrospective study. Drug:RC48,Organization:Guizhou University o...,Affiliated Hospital ...,Department of Oncolo...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Real-world efficacy and safety of inetetamab-based therapy in patients with HER2-positive metastatic breast cancer with prior trastuzumab exposure: A multi-center retrospective study. Organization:Department of Breast...,Breast Cancer Center...,Cancer Center of Fir...,Congress:ASCO 2024, Search all connections
Abstract Heterogeneity of immune status in patient-derived malignant pleural effusion and ascites: Relationship to the ex-vivo efficacy of a HER2-targeted tri-specific antibody and a novel cytokine fusion protein. Drug:IAMA-004,IAMA-005,anti-PD1,Target:Herceptin,PD-1, Search all connections
Abstract Efficacy, safety, and predictive biomarkers of dalpiciclib combined with letrozole, pertuzumab and trastuzumab as neoadjuvant therapy in HR+/HER2+ breast cancer: A phase II study. Drug:tranduzumab,Trastuzumab,pertuzumab,Target:Cyclin dependent kin...,HER2 (ERBB2), Search all connections
Abstract Trastuzumab, pertuzumab and nab-paclitaxel plus pyrotinib or not in neoadjuvant treatment of HER2-positive breast cancer: A multi-center, randomized, open-label, phase II study. Drug:Trastuzumab,pertuzumab,pyrotinib,Target:microtubules,HER2 (ERBB2),Organization:Shangyu People's Hos...,Shaoxing, China, Search all connections
Abstract A prospective, open-label, single-arm phase II clinical study of inetetamab in combination with pyrotinib and albumin-bound paclitaxel for the neoadjuvant treatment of patients with HER2+ early and locally advanced breast cancer. Drug:Inetetamab,pyrotinib,albumin-bound paclit..., Search all connections
Abstract Unveiling the relationship between the UGT2B gene family and neoadjuvant treatment response in patients with HER2-positive breast cancer. Drug:taxanes,anthracyclines,Trastuzumab,Organization:Instituto Biomedicin...,Institute of Biomedi...,Andalusian - Roche N...,Congress:ASCO 2024, Search all connections
Abstract A retrospective, single-center study comparing two neoadjuvant protocols for patients with HER2-positive breast cancer. Drug:Trastuzumab,docetaxel,carboplatin,Organization:Sheba Medical Center...,Sheba Medical Center...,Congress:ASCO 2024, Search all connections
Abstract Predictors of response and surgical approach after neoadjuvant chemotherapy in receptor-positive/HER2-negative stage II-III breast cancer patients treated in two private cancer care centers in Lima, Peru: Real-world data. Organization:Clinica Internaciona...,Universidad Peruana ...,ALIADA Centro Oncolo...,Congress:ASCO 2024, Search all connections
Abstract Prognostic significance of ctDNA mutation analysis in patients with HER2-positive breast cancer undergoing neoadjuvant chemotherapy. Organization:Kyungpook National U...,Kyungpook National U...,Predicine, Inc., Search all connections
Abstract Efficacy and safety of recombinant humanized anti-HER2 antibody-MMAE conjugate (RC48) in neoadjuvant for HER2-positive breast cancer: A single-arm phase II study. Drug:RC48,EC,Trastuzumab,Organization:Air Force Medical Un...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Long-term outcomes of neoadjuvant treatment in older patients with HER2-positive breast cancer: Evidence from a single center in Mexico. Organization:Instituto Nacional d...,Congress:ASCO 2024, Search all connections
Abstract Role of NEDD9 expression in non-metastatic HER2-positive breast cancer. Organization:Sonic Healthcare USA,WVU Health Sciences ...,West Virginia Univer...,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant dalpiciclib combined with aromatase inhibitors in stage I-III HER2 negative luminal B breast cancer (DANCER): Preliminary findings from an ongoing phase II study. Drug:dalpiciclib,anastrozole,letrozole,Target:CDK6,aromatase,CDK4 & 6,Organization:Genecast Precision M...,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant pyrotinib and inetetamab in combination with chemotherapy for locally advanced HER2-positive breast cancer (NeoPICD study): A prospective, multicenter, open-label, single-arm study. Target:DNA,Drug:inetetamab,pyrotinib,carboplatin,Organization:Department of Thyroi...,Department of Breast..., Search all connections
Abstract Pathological complete response rate to anthracycline versus non−anthracycline based chemotherapy regimens in localized and regional HER2 neu positive breast cancer. Organization:Johns Hopkins Aramco...,Dhahran,Congress:ASCO 2024, Search all connections
Abstract Clinical significance of circulating tumor DNA in neoadjuvant-treated HER2-negative luminal B breast cancer. Drug:neoadjuvant chemothe...,CDK4/6 inhibitors,neoadjuvant endocrin...,Target:CDK4/6,CDK4 & 6,CDK6,Organization:Genecast Biotechnolo..., Search all connections
Abstract A propensity-matched analysis of the efficacy and safety of neoadjuvant inetetamab and pertuzumab with paclitaxel and carboplatin (TCbIP) on locally advanced HER2-positive breast cancer. Drug:Inetetamab,Trastuzumab,pertuzumab,Target:paclitaxel,DNA,Organization:National Cancer Cent..., Search all connections
Abstract Efficacy and safety of neoadjuvant trastuzumab, pyrotinib, and dalpiciclib without chemotherapy in early-stage HR-negative/HER2-positive breast cancer: An open-label, single-arm phase II trial. Drug:dalpiciclib,Trastuzumab,pyrotinib,Target:CDK6,CDK4 & 6,Organization:The First People's H...,Xiangtan,ShaoYang Central Hos..., Search all connections
Abstract The predictive role of Ki67 in pathological complete response (pCR) and invasive disease-free survival (IDFS) in HER2-positive breast cancer: A retrospective study of 246 cases. Organization:University Carl Gust...,Congress:ASCO 2024, Search all connections
Abstract Effect of neratinib on HER2 mRNA stability via hsa-miR-23a-5p and efficacy of CDK4/6 inhibitors in HER2-low breast cancer. Drug:CDK4/6 inhibitors,neratinib,actinomycin D,Target:CDK6,CDK4 & 6,HER2 (ERBB2),Organization:The Second Clinical ...,Congress:ASCO 2024, Search all connections
Abstract Spatial transcriptomic and proteomic insight into Trop-2, HER2, and AR expression: A pathway to tailored therapies in triple-negative breast cancer. Organization:University Hospital ...,Laboratoire d’Anatom...,Congress:ASCO 2024, Search all connections
Abstract Overall survival in patients with HER2-low breast cancer at a reference hospital in Mexico. Organization:Instituto Mexicano d...,Instituo Mexicano de...,Instituto Mexicano d...,Congress:ASCO 2024, Search all connections
Abstract Coping with inter-observer variability when assessing AI for scoring of HER2-stained whole slides. Organization:IHP Paris,Congress:ASCO 2024, Search all connections
Abstract Prediction of pathological response to neo-adjuvant chemotherapy using texture parameters of initial 18-FDG PET/CT in estrogen receptor positive/Her2 negative (ER+/HER2-) early breast cancer (eBC). Organization:Institut de Cancérol...,Institut de Cancérol...,Institut de Cancérol...,Congress:ASCO 2024, Search all connections
Abstract Immune subtyping of ER-positive, PR-negative and HER2-negative breast cancers by immunohistochemistry: Molecular basis and clinical relevance. Organization:The First Affiliated...,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant pertuzumab, docetaxel, carboplatin, and trastuzumab (PTCH) regimen in patients with HER2 positive early, locally advanced, and oligometastatic breast cancer: Real-world Indian experience. Organization:Dr. BRA-IRCH,Institute of Rotary ...,Congress:ASCO 2024, Search all connections
Abstract The correlation between Ki 67 and Oncotype Dx on HR+, HER2- early breast cancer management: Insights of molecular testing. Organization:University of Miami ...,Ecua-american Labora...,Hospital de los Vall...,Congress:ASCO 2024, Search all connections
Abstract Factors associated with benefit of adjuvant chemotherapy in patients with T1b/T1c HR-positive/HER2-negative breast cancer and high multigene recurrence score. Organization:Maroone Cancer Cente...,Cleveland Clinic Flo...,Weston, FL,Congress:ASCO 2024, Search all connections
Abstract Clinical factors associated with response to neoadjuvant chemotherapy in women of Hispanic origin diagnosed with early-stage TNBC or HER2+ breast cancer in the United States. Organization:Maroone Cancer Cente...,Cleveland Clinic Flo...,Congress:ASCO 2024, Search all connections
Abstract Real-world (RW) risk of recurrence among patients (pts) diagnosed with stage II-III HR+/HER2− early breast cancer (EBC) treated with endocrine therapy (ET) in the US. Organization:RTI International,Congress:ASCO 2024, Search all connections
Abstract Optimal neoadjuvant treatment and prognostic factors in patients with HR-positive/HER2-positive early or locally advanced breast cancer: A national real-world study in China. Drug:Trastuzumab,pertuzumab,platinum-based chemo...,Target:DNA topoisomerase II,DNA,Organization:Department of Breast..., Search all connections
Abstract Trends in the management of small HER2-positive breast cancers. Organization:Outcomes Research Co...,Department of Anesth...,Integrated Surgical ...,Congress:ASCO 2024, Search all connections
Abstract Real-world safety and discontinuation rates of fam-trastuzumab deruxtecan in advanced HER2-positive and HER2-low cancer. Drug:Enhertu,Organization:University of Kansas...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract HR+/HER2- early breast cancer with a high risk of recurrence: The impact of online education on clinician knowledge, competence, and confidence in utilization of clinical practice guidelines to enhance patient care. Organization:Medscape Oncology,Carrollton, TX,Medscape LLC,Congress:ASCO 2024, Search all connections
Abstract Association between PIK3CA mutations and disease-free survival in patients with HR+, HER2- tumors treated with adjuvant hormonal therapy: A real-world study in Croatia. Organization:University Hospital ...,University of Split,University Hospital ..., Search all connections
Abstract Baseline (BL) characteristics and efficacy endpoints for patients (pts) with node-negative (N0) HR+/HER2− early breast cancer (EBC): NATALEE trial. Target:Gonadotropin-releasi...,aromatase,Cyclin-dependent kin...,Drug:ribociclib,non-steroidal aromat...,letrozole, Search all connections
Abstract Exosome-delivered microRNAs confer adriamycin-resistance through modulating the immune and metabolism-related gene PTEN in HER2-negative breast cancer. Organization:The First Affiliated...,The Affiliated Chang...,Dalian Medical Unive...,Congress:ASCO 2024, Search all connections
Abstract ACE-Breast-02: A pivotal phase II/III trial of ARX788, a novel anti-HER2 antibody-drug conjugate (ADC), versus lapatinib plus capecitabine for HER2+ advanced breast cancer (ABC). Drug:ARX788,Amberstatin 269,Trastuzumab,Target:tubulin,Organization:Hospital of Xinjiang..., Search all connections
Abstract H3B-6545 in women with locally advanced/metastatic estrogen receptor-positive (ER+), HER2 negative (–) breast cancer (BC). Drug:H3B-6545,Target:ERα,Organization:Sarah Cannon Researc...,Saint Luke's Cancer ...,Florida Cancer Speci..., Search all connections
Abstract Association of MammaPrint index and 3-year outcome of patients with HR+HER2- early-stage breast cancer treated with chemotherapy with or without anthracycline. Organization:Comprehensive Breast...,Congress:ASCO 2024, Search all connections
Abstract Comparison of antitumor efficacy of first-line palbociclib, ribociclib, or abemaciclib in patients with HR+/HER2- aBC: Results of the multicenter, real-world, Italian study PALMARES-2. Drug:palbociclib,ribociclib,abemaciclib,Target:Cyclin Dependent Kin...,CDK6,Cyclin Dependent Kin...,Organization:IRCCS Policlinico S...., Search all connections
Abstract Racial differences in genomic profiles and targeted treatment use in ER+ HER2- metastatic breast cancer. Organization:Robert H. Lurie Comp...,Dipartimento di Onco...,Congress:ASCO 2024, Search all connections
Abstract HOPE: Harnessing olaparib, palbociclib, and endocrine therapy for BRCA1/2-associated HR+, HER2- metastatic breast cancer. Drug:olaparib,fulvestrant,palbociclib,Target:Estrogen Receptor (E...,BRCA2,CDK6, Search all connections
Abstract Clinical and economic benefit of genomic testing strategies to guide the treatment of patients with HR+/HER2- breast cancer in the US. Organization:Putnam Associates,Congress:ASCO 2024, Search all connections
Abstract Beamion LUNG-2: A phase III randomized controlled trial of zongertinib (BI 1810631) versus standard of care (SoC) in patients with locally advanced/metastatic non-squamous non-small cell lung cancer (NSCLC) harboring HER2 tyrosine kinase domain (TKD) mutations. Drug:zongertinib,pemetrexed,Cisplatin,Target:Programmed death-1 (...,Glycinamide Ribonucl...,Dihydrofolate reduct..., Search all connections
Abstract Safety and anti-tumor activity of BAY 2927088 in patients with HER2-mutant NSCLC: Results from an expansion cohort of the SOHO-01 phase I/II study. Drug:BAY 2927088,Target:EGFR-TKI sensitizing...,Organization:Shanghai Lung Cancer...,Department I of Thor...,Nanjing Drum Tower H..., Search all connections
Abstract Efficacy of immunotherapy in first-line treatment for non-small cell lung cancer with HER2 mutation: Results from LC-SCRUM-Asia. Drug:ICIs,platinum-based chemo...,Target:Immune checkpoints,DNA,Organization:Japanese Red Cross M...,Sendai Kousei Hospit...,Yamaguchi-Ube Medica..., Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients with HER2-mutant metastatic non–small cell lung cancer (mNSCLC): Final analysis results of DESTINY-Lung02. Target:HER2 (ERBB2),Organization:Nantes University Ho...,Azienda Ospedaliero-...,Clinical trial:DS8201-A-U206,Drug:trastuzumab-deruxtec...,Congress:ASCO 2024, Search all connections
Abstract Characterization of HER2 alterations in lung adenocarcinoma. Drug:trastuzumab deruxtec...,Organization:Temple University Ho...,Target:HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract Pyrotinib in HER2-altered advanced salivary gland carcinomas: Analysis of two cohorts from an exploratory study. Drug:pyrotinib,Target:HER1,HER4,HER2 (ERBB2),Organization:Department of Oral a...,Shanghai Ninth Peopl...,Congress:ASCO 2024, Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing head and neck tumors: Outcomes from DESTINY-PanTumor02 (DP-02). Drug:trastuzumab deruxtec...,Organization:Hadassah Medical Mos...,Srinagarind Hospital,Chris O’Brien Lifeho...,Target:HER2 (ERBB2),Clinical trial:D967VC00001,Congress:ASCO 2024, Search all connections
Abstract Phase II/III study of paclitaxel/carboplatin alone or combined with either trastuzumab and hyaluronidase-oysk or pertuzumab, trastuzumab, and hyaluronidase-zzxf in HER2 positive, stage I-IV endometrial serous carcinoma or carcinosarcoma (NRG-GY026). Drug:Trastuzumab,hyaluronidase-oysk,pertuzumab,Target:pertuzumab,tubulin, Search all connections
Abstract Evaluation of the effectiveness and safety of disitamab vedotin in HER2-expressing 2L recurrent or metastatic cervical cancer (r/mCC): Interim results of RC48-C018. Drug:Disitamab vedotin,Organization:Union Hospital Tong ...,Qilu Hospital of Sha...,The First Affiliated..., Search all connections
Abstract Adjuvant or rescue disitamab vedotin (RC48-ADC) for high-risk non-muscle invasive bladder cancer with HER2 overexpression: A phase II multi-center study. Drug:Bacillus Calmette-Gu...,Disitamab vedotin,Organization:The First Affiliated...,Target:HER2 (ERBB2),Clinical trial:2023(24),Congress:ASCO 2024, Search all connections
Abstract Phase 3 study of disitamab vedotin with pembrolizumab vs chemotherapy in patients with previously untreated locally advanced or metastatic urothelial carcinoma that expresses HER2 (DV-001). Drug:Enfortumab vedotin,pembrolizumab,Disitamab vedotin,Target:Programmed cell deat...,Nectin-4, Search all connections
Abstract Preliminary efficacy and safety results from RC48-C017: A phase II study of neoadjuvant treatment with disitamab vedotin plus toripalimab in patients with muscle invasive bladder cancer (MIBC) with HER2 expression. Drug:Disitamab vedotin,Toripalimab (Loqtorz...,Target:PD-1,HER2 (ERBB2),Organization:School of Life Scien...,Clinical trial:RC48-C017,Congress:ASCO 2024, Search all connections
Abstract Efficacy and safety of trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing solid tumors: Results from the bladder cohort of the DESTINY-PanTumor02 (DP-02) study. Drug:trastuzumab deruxtec...,Organization:Jagiellonian Univers...,Kraków,N.N Blokhin National..., Search all connections
Abstract Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2-expressing biliary tract cancer (BTC) and pancreatic cancer (PC): Outcomes from DESTINY-PanTumor02 (DP-02). Drug:trastuzumab deruxtec...,DS-8201a,trastuzumab deruxtec...,Organization:Maria Skłodowska-Cur...,Hôtel-Dieu de Québec,Clinical Hospital “R...,Target:HER2 (ERBB2), Search all connections
Abstract Zanidatamab in previously-treated HER2-positive (HER2+) biliary tract cancer (BTC): Overall survival (OS) and longer follow-up from the phase 2b HERIZON-BTC-01 study. Drug:zanidatamab,Gemcitabine,Target:ribonucleotide reduc...,deoxycytidine kinase,Organization:Zhongshan Hospital o...,Seoul National Unive...,Yonsei Cancer Center..., Search all connections
Abstract Phase II randomized study of maintenance therapy with regorafenib (REGO) versus placebo after first-line platinum and fluoropyrimidines-based chemotherapy in HER2 negative locally advanced/metastatic gastric (GC) or gastroesophageal junction (GEJ) cancer: Results of a-MANTRA study (GOIRC-05-2016). Drug:Regorafenib,Target:VEGFR-1,EGFR-TKI sensitizing...,Organization:Reggio Emilia,Potenza,Italy - Reggio Emili..., Search all connections
Abstract Safety and efficacy results from the phase I/IIa study of FG-M108 plus CAPOX as first-line (1L) treatment for patients with CLDN18.2+/HER2- locally advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma. Drug:FG-M108,CAPOX,Target:CLDN18.2,Organization:FutureGen Biopharmac...,Futuregen Biopharmac...,FutureGen Biopharmac...,Congress:ASCO 2024, Search all connections
Abstract Pembrolizumab (pembro) + chemotherapy (chemo) for advanced HER2-negative gastric or gastroesophageal junction (G/GEJ) cancer: Updated results from the KEYNOTE-859 study. Drug:pembrolizumab,5-FU,Cisplatin,Target:DNA,thymidylate synthase,PD-L1 cell densities, Search all connections
Abstract Final overall survival results from phase 3 SPOTLIGHT study evaluating zolbetuximab + mFOLFOX6 as first-line (1L) treatment for patients (pts) with claudin 18 isoform 2 (CLDN18.2)+, HER2−, locally advanced (LA) unresectable or metastatic gastric or gastroesophageal junction (mG/GEJ) adenocarcinoma. Drug:zolbetuximab,folinic acid,5-FU,Target:5-FU,oxaliplatin,CLDN18.2, Search all connections
Abstract Association of ERBB2 extrachromosomal DNA (ecDNA) with first-line HER2-targeted treatment outcomes in advanced esophagogastric adenocarcinoma (EGC). Drug:HER2-targeted agents,Target:ERBB2,Organization:Weill Cornell Medica...,Department of Epidem...,Congress:ASCO 2024, Search all connections
Abstract Deciphering tumor microenvironment dynamics in HER2-amplified refractory metastatic colorectal cancer in the TRIUMPH trial. Drug:Trastuzumab,pertuzumab,pertuzumab,Organization:Hiroshima University...,Department of Surger...,Department of Gastro..., Search all connections
Abstract IAM1363-01: A phase 1/1b study of a selective and brain-penetrant HER2 inhibitor for HER2-driven solid tumors. Drug:IAM1363,Trastuzumab,Organization:Iambic Clinical Advi...,Target:HER2 (ERBB2),Clinical trial:IAM1363-01,Congress:ASCO 2024, Search all connections
Abstract Phase II study to evaluate safety and efficacy of neratinib, an irreversible pan-HER tyrosine kinase inhibitor, and trastuzumab biosimilar in patients with HER2 mutated advanced solid tumors (KCSG AL20-17). Drug:neratinib,Trastuzumab,Organization:Division of Hematolo...,Target:HER2 (ERBB2),Clinical trial:AL20-17,Congress:ASCO 2024, Search all connections
Abstract First-in-human phase 1/2a study of the first-in-class, next-generation CDK4-selective inhibitor PF-07220060 + endocrine therapy (ET): Updated safety data in patients with HR+/HER2− mBC. Drug:PF-07220060,letrozole,fulvestrant,Target:Aromatase inhibitors,Estrogen Receptor (E...,CDK4 & 6,Organization:Centro Oncologico In...,Clinical trial:C4391001, Search all connections
Abstract Characterization of BTX-9341, a bifunctional degrader of CDK4 and CDK6 for HR+/HER2- breast cancer and glioblastoma multiforme. Drug:CDK4/6 inhibitors,BTX-9341,palbociclib,Target:Estrogen Receptor (E...,Cyclin E,CDK6, Search all connections
Abstract Phase Ib trial of tasurgratinib (E7090) with or without endocrine therapies for patients (pts) with ER+, HER2− recurrent/metastatic breast cancer (BC) after receiving a CDK4/6 inhibitor. Drug:E7090,fulvestrant,exemestane,Target:FGFR3,FGFR1,Estrogen Receptor (E...,Organization:Cancer Institute Hos..., Search all connections
Abstract Focus on human epidermal growth factor receptor 2 (HER2) positive metastatic colorectal cancer (HER2+ mCRC): A real world retrospective analysis. Organization:Fondazione Policlini...,'Tor Vergata' Clinic...,University of Rome, Search all connections
Abstract Characterization of molecular response and progression in patients with metastatic HR+/HER2- breast cancer receiving endocrine therapy and CDK4/6 inhibitors using a high-sensitivity tumor-informed assay. Drug:palbociclib,ribociclib,abemaciclib,Target:CDK6,CDK4 & 6,Organization:Division of Medical ...,Congress:ASCO 2024, Search all connections
Abstract Classification of HER2 status across multiple cancers using epigenomic profiles from a novel liquid biopsy assay. Organization:Precede Biosciences,Boston Pharmaceutica...,MaaT Pharma, Search all connections
Abstract Phase Ia/Ib trial on the safety and efficacy of mobocertinib in combination with T-DM1 for patients with HER2-mutant solid tumors (WJOG16022M). Drug:Mobocertinib,T-DM1,Organization:Division of Medical ...,Department of Oncolo...,Department of Clinic...,Target:HER2 (ERBB2), Search all connections
Abstract The design, preclinical study and phase I dose escalation plan of a HER2 targeted immunoliposome (HF-K1) for HER2 low solid tumor treatment. Drug:doxorubicin,PEG-coated liposomes,immunoliposomes,Organization:Hangzhou HighField B..., Search all connections
Abstract A phase 1, first-in-human study of autologous monocytes engineered to express an anti-HER2 chimeric antigen receptor (CAR) in participants with HER2-overexpressing solid tumors. Drug:CT-0508,pembrolizumab,CT-0525,Target:Programmed cell deat...,Granulocyte colony-s...,HER2 (ERBB2),Organization:Division of Hematolo..., Search all connections
Abstract Binary oncolytic adenovirus in combination with HER2-specific autologous CAR VST for treatment of advanced HER2-positive solid tumors (VISTA). Organization:Cell and Gene Therap...,Baylor College of Me...,Baylor College of Me...,Clinical trial:H-43405 VISTA,Congress:ASCO 2024, Search all connections
Abstract A first-in-human phase 1 trial of dose escalating intrathecal (IT) dendritic cells (cDC1s) primed against HER2/HER3 in patients (pts) with leptomeningeal disease (LMD) from triple-negative (TNBC) or HER2+ breast cancer (BC). Drug:cDC1,Target:HER3,Organization:H. Lee Moffitt Cance...,Tampa, FL,Roswell Park Compreh..., Search all connections
Abstract Evaluating Ki67 and Oncotype DX Breast Recurrence Score during neoadjuvant treatment with letrozole/abemaciclib or chemotherapy in patients with highly proliferative HR+/HER2- breast cancer participating in the GEICAM CARABELA trial. Drug:letrozole,abemaciclib,chemotherapy,Target:CDK6,Recurrence Score,Estrogen Receptor 1 ..., Search all connections
Abstract Activating HR+/HER2- and triple-negative breast cancer care teams and their patients in shared decision-making. Organization:PRIME Education, LLC,Miami Cancer Institu...,Baptist Health South...,Congress:ASCO 2024, Search all connections
Abstract Unveiling the cost-effectiveness of CDK4/6 inhibitors in treating patients with HR+/HER2- metastatic breast cancer: A closer look at nonmedication expenses. Organization:UVA Comprehensive Ca...,University of Virgin...,Duke University Medi...,Drug:CDK4/6i,etoposide,Target:CDK6,CDK4 & 6,Congress:ASCO 2024, Search all connections
Abstract Neoadjuvant dynamic marker-adjusted personalized therapy comparing trastuzumab-deruxtecan versus pacli-/docetaxel + carboplatin + trastuzumab + pertuzumab in HER2+ early breast cancer: WSG-ADAPT-HER2-IV. Organization:LMU University Hospi...,Interdisciplinary Br...,Rotkreuz-Clinics Mun..., Search all connections
Abstract Neoadjuvant targeted therapy in early resectable HER2-mutant lobular breast cancer. Organization:Vanderbilt-Ingram Ca...,University of Texas ...,UT Southwestern Simm...,Drug:neratinib,endocrine therapy,Target:ERBB2,HER2 (ERBB2),Congress:ASCO 2024, Search all connections
Abstract A window-of-opportunity (WOO) trial of giredestrant +/- LHRHa vs anastrozole+LHRHa in premenopausal women with ER+/HER2- early breast cancer (EBC; IBCSG 67-22; PREcoopERA). Organization:European Institute o...,Dana-Farber Cancer I...,Peter MacCallum Canc..., Search all connections
Abstract Neoadjuvant dalpiciclib, exemestane, and goserelin in premenopausal women with HR-positive, HER2-negative breast cancer: A prospective, multicenter, randomized two-group, non-controlled phase 2 clinical trial. Organization:Tianjin Medical Univ...,National Clinical Re...,Tianjin Hemay Pharma...,Drug:dalpiciclib, Search all connections
Abstract NRG-BR007: A phase III trial evaluating de-escalation of breast radiation (DEBRA) following breast-conserving surgery of stage 1, HR+, HER2-, RS ≤18 breast cancer. Organization:University of Kansas...,Department of Biosta...,St. Luke’s Universit..., Search all connections
Abstract Phase III study to evaluate the efficacy and safety of GLSI-100 (GP2 + GM-CSF) in patients with breast cancer with residual disease or high-risk PCR after both neo-adjuvant and postoperative adjuvant anti-HER2 therapy: Flamingo-01. Organization:Greenwich LifeScienc...,Stafford, TX,Lester and Sue Smith...,Drug:GLSI-100,Trastuzumab, Search all connections
Abstract Interim FDG-PET/CT for predicting response of HER2-positive breast cancer to neoadjuvant therapy: ECOG-ACRIN EA1211/DIRECT trial. Organization:Cancer Research @UCC,Brown University - E...,Dana-Farber Cancer I..., Search all connections
Abstract A phase III randomized trial of radiotherapy optimization for low-risk HER2-positive breast cancer (HERO): NRG-BR008. Organization:Memorial Sloan Kette...,The University of Te...,NRG Oncology Statist..., Search all connections
Abstract A phase III trial evaluating addition of adjuvant chemotherapy to ovarian function suppression + endocrine therapy in premenopausal women with pN0-1, HR+/HER2- breast cancer (BC) and oncotype recurrence score (RS) ≤25 (OFSET): NRG-BR009. Organization:Georgetown Lombardi ...,Georgetown Universit...,MedStar Health, Search all connections
Abstract Phase II study of a PARP inhibitor, talazoparib, in HER2- metastatic breast cancer (MBC) with a somatic BRCA1/2 mutation identified in a cell-free DNA or tumor tissue genotyping assay. Organization:Massachusetts Genera...,Harvard Medical Scho...,The University of Te..., Search all connections
Abstract INAVO121: Phase III study of inavolisib (INAVO) + fulvestrant (FUL) vs. alpelisib (ALP) + FUL in patients (pts) with hormone receptor-positive, HER2-negative (HR+, HER2–), PIK3CA‑mutated (mut) locally advanced or metastatic breast cancer (LA/mBC). Organization:Massachusetts Genera...,Harvard Medical Scho...,Winship Cancer Insti..., Search all connections
Abstract OPERA-01: A randomized, open-label, phase 3 study of palazestrant (OP-1250) vs standard-of-care for ER+, HER2- advanced or metastatic breast cancer patients after endocrine therapy and CDK4/6 inhibitors. Organization:Gustave Roussy Cance...,Vall d’Hebron Univer...,Vall d’Hebron Instit..., Search all connections
Abstract Innovation of the first-line strategy optimized as abemaciclib with endocrine therapy based on the ESR1 mutation of ctDNA for patients with HR-positive HER2-negative advanced metastatic breast cancer (JBCRG-M08; AMBER study). Organization:Osaka University Hos...,Department of Surgic...,Research Institute f..., Search all connections